Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA single cell type specificity"	"RNA single cell type distribution"	"RNA single cell type specificity score"	"RNA single cell type specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"CCD Protein"	"CCD Transcript"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - GAMG [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - hTERT-RPE1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - JURKAT [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - OE19 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - SuSa [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"	"Single Cell Type RNA - Alveolar cells type 1 [NX]"	"Single Cell Type RNA - Alveolar cells type 2 [NX]"	"Single Cell Type RNA - B-cells [NX]"	"Single Cell Type RNA - Basal glandular cells [NX]"	"Single Cell Type RNA - Basal keratinocytes [NX]"	"Single Cell Type RNA - Bipolar cells [NX]"	"Single Cell Type RNA - Cardiomyocytes [NX]"	"Single Cell Type RNA - Cholangiocytes [NX]"	"Single Cell Type RNA - Ciliated cells [NX]"	"Single Cell Type RNA - Club cells [NX]"	"Single Cell Type RNA - Collecting duct cells [NX]"	"Single Cell Type RNA - Cone photoreceptor cells [NX]"	"Single Cell Type RNA - Cytotrophoblasts [NX]"	"Single Cell Type RNA - Distal tubular cells [NX]"	"Single Cell Type RNA - Ductal cells [NX]"	"Single Cell Type RNA - Early spermatids [NX]"	"Single Cell Type RNA - Endothelial cells [NX]"	"Single Cell Type RNA - Enterocytes [NX]"	"Single Cell Type RNA - Erythroid cells [NX]"	"Single Cell Type RNA - Exocrine glandular cells [NX]"	"Single Cell Type RNA - Extravillous trophoblasts [NX]"	"Single Cell Type RNA - Fibroblasts [NX]"	"Single Cell Type RNA - Glandular cells [NX]"	"Single Cell Type RNA - granulocytes [NX]"	"Single Cell Type RNA - Hepatocytes [NX]"	"Single Cell Type RNA - Hofbauer cells [NX]"	"Single Cell Type RNA - Horizontal cells [NX]"	"Single Cell Type RNA - Intestinal endocrine cells [NX]"	"Single Cell Type RNA - Ito cells [NX]"	"Single Cell Type RNA - Kupffer cells [NX]"	"Single Cell Type RNA - Late spermatids [NX]"	"Single Cell Type RNA - Leydig cells [NX]"	"Single Cell Type RNA - Macrophages [NX]"	"Single Cell Type RNA - Melanocytes [NX]"	"Single Cell Type RNA - monocytes [NX]"	"Single Cell Type RNA - Mucus-secreting cells [NX]"	"Single Cell Type RNA - Muller glia cells [NX]"	"Single Cell Type RNA - Pancreatic endocrine cells [NX]"	"Single Cell Type RNA - Paneth cells [NX]"	"Single Cell Type RNA - Peritubular cells [NX]"	"Single Cell Type RNA - Proximal tubular cells [NX]"	"Single Cell Type RNA - Rod photoreceptor cells [NX]"	"Single Cell Type RNA - Sertoli cells [NX]"	"Single Cell Type RNA - Smooth muscle cells [NX]"	"Single Cell Type RNA - Spermatocytes [NX]"	"Single Cell Type RNA - Spermatogonia [NX]"	"Single Cell Type RNA - Suprabasal keratinocytes [NX]"	"Single Cell Type RNA - Syncytiotrophoblasts [NX]"	"Single Cell Type RNA - T-cells [NX]"	"Single Cell Type RNA - Undifferentiated cells [NX]"	"Single Cell Type RNA - Urothelial cells [NX]"
ACE	"ACE1, CD143, DCP1"	ENSG00000159640	"Angiotensin I converting enzyme"	P12821	17	63477061-63498380	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Carboxypeptidase, Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"intestine: 205.6"	"Group enriched"	"Detected in many"	25	"Early spermatids: 470.5;Late spermatids: 1015.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 3.7"	"Group enriched"	"Detected in many"	23	"B-cells: 3.7;monocytes: 2.0;T-cells: 1.9"	"Group enriched"	"Detected in some"	4	"ASC TERT1: 36.7;HUVEC TERT2: 18.7"									"CAB002426, CAB002921, HPA029298, HPA069790"	Enhanced		Approved	Vesicles	"Secreted to blood"	NA	NA	104000000	92000000	Vesicles		"CAB002426: AB_442052, CAB002921: , HPA029298: AB_10960255, HPA069790: AB_2686197"	"unprognostic (4.72e-2)"	"unprognostic (4.16e-1)"	"unprognostic (1.93e-3)"	"unprognostic (6.06e-2)"	"unprognostic (2.78e-1)"	"unprognostic (1.35e-2)"	"unprognostic (4.37e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.25e-2)"	"unprognostic (3.13e-2)"	"unprognostic (2.38e-1)"	"unprognostic (7.66e-2)"	"unprognostic (9.07e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.76e-2)"	6.8	2.0	0.5	2.4	4.2	0.0	2.9	0.5	1.1	5.3	83.2	0.7	37.7	46.4	4.5	5.1	1.7	1.5	4.4	4.7	0.6	0.7	2.6	1.4	16.3	2.2	0.4	0.7	1.4	3.0	3.6	3.6	3.6	0.8	3.4	1.4	1.7	2.5	20.1	3.6	1.3	205.6	2.4	0.6	1.4	1.9	32.6	1.3	0.5	6.9	3.1	2.2	1.7	1.6	3.7	0.1	0.0	2.0	0.0	1.9	0.4	0.0	0.0	0.0	0.0	1.5	36.7	0.4	1.3	2.7	0.0	0.0	0.5	3.2	0.7	1.1	6.2	0.0	0.0	1.7	0.0	0.0	0.0	0.7	3.5	0.0	0.0	0.8	0.0	0.0	2.4	0.0	0.0	0.0	0.6	18.7	0.0	3.1	0.0	0.0	0.6	0.0	0.8	0.3	6.3	0.4	0.1	0.2	0.5	0.0	0.0	4.6	3.2	0.0	0.0	0.0	0.7	1.6	0.2	0.0	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.4	0.6	0.9	3.7	1.9	1.4	0.1	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.4	0.5	4.2	0.5	1.1	0.6	0.7	0.4	0.7	0.8	1.3	0.0	3.5	0.0	1.5	1.3	3.1	1.4	0.0	0.0	1.2	0.0	0.0	0.1	0.0	3.4	470.5	13.5	29.6	0.0	0.4	0.1	1.0	6.0	6.9	0.0	4.4	0.0	17.3	2.5	18.5	1015.1	4.0	5.1	3.3	0.0	8.7	1.9	0.7	10.2	2.5	10.7	1.0	0.0	0.9	8.1	3.4	0.1	0.1	0.9	8.6	2.1
ACE2		ENSG00000130234	"Angiotensin I converting enzyme 2"	Q9BYF1	X	15561033-15602148	"Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"	"Host-virus interaction"	"Carboxypeptidase, Host cell receptor for virus entry, Hydrolase, Metalloprotease, Protease, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"intestine: 122.0"	"Cell type enhanced"	"Detected in many"	13	"Cholangiocytes: 61.1;Enterocytes: 38.8;Proximal tubular cells: 45.6;Sertoli cells: 19.4"	"Cancer enhanced"	"Detected in many"		"renal cancer: 26.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 2.4;HaCaT: 4.1;Hep G2: 2.5;NB-4: 2.2;RPMI-8226: 2.1;RT4: 2.5;SH-SY5Y: 2.8;SuSa: 1.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"HPA000288, CAB026174, CAB026213, CAB080024, CAB080025, CAB080027, CAB080028"	Enhanced				"Secreted to blood"	NA	NA		85000			"CAB026174: , CAB026213: , CAB080024: AB_10864415, CAB080025: AB_2809589, CAB080027: AB_2665870, CAB080028: AB_2665871, HPA000288: AB_1078160"	"unprognostic (1.40e-1)"	"unprognostic (7.26e-2)"	"unprognostic (2.76e-2)"	"unprognostic (5.71e-2)"	"unprognostic (2.51e-1)"	"unprognostic (5.26e-2)"	"prognostic favorable (4.21e-4)"	"unprognostic (2.34e-2)"	"unprognostic (6.74e-3)"	"unprognostic (2.54e-3)"	"unprognostic (1.00e-1)"	"unprognostic (1.74e-1)"	"prognostic favorable (2.12e-5)"	"unprognostic (1.94e-1)"	"unprognostic (9.62e-2)"	"unprognostic (2.11e-1)"	"unprognostic (7.10e-2)"	4.5	0.4	0.2	0.8	0.2	0.0	2.3	0.2	0.2	0.4	49.1	0.2	2.3	46.0	0.4	2.7	1.2	0.6	16.4	10.5	0.2	0.1	23.2	1.2	0.8	0.6	0.2	0.2	1.3	1.6	0.0	0.2	1.0	0.2	0.5	1.3	0.2	1.1	1.2	0.7	0.2	122.0	0.3	0.2	0.2	0.5	17.9	0.2	0.2	4.5	0.5	0.2	0.4	0.9	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.2	0.0	0.4	0.0	0.7	0.0	2.4	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.7	0.0	0.4	4.1	0.2	0.1	0.0	0.1	0.1	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.1	0.2	0.2	0.0	0.0	2.1	0.4	2.5	0.6	2.8	0.1	0.3	0.2	1.9	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.0	0.3	2.2	0.5	0.1	0.0	9.8	61.1	0.0	0.0	0.0	0.0	2.9	3.3	0.5	0.4	0.0	38.8	0.0	0.7	0.2	0.0	0.4	0.0	0.8	0.7	0.0	6.9	0.0	0.0	1.1	7.8	0.0	0.0	0.0	1.2	0.0	0.9	4.2	5.6	45.6	0.0	19.4	0.0	1.1	0.7	0.1	10.6	0.0	3.3	1.6
AMY2A	AMY2	ENSG00000243480	"Amylase, alpha 2A (pancreatic)"	P04746	1	103616811-103625780	"Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Carbohydrate metabolism"	"Glycosidase, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	31	"pancreas: 1849.4"	"Cell type enriched"	"Detected in some"	68	"Exocrine glandular cells: 849.6"	"Cancer enriched"	"Detected in single"	2010	"pancreatic cancer: 200.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"THP-1: 1.0;U-2 OS: 1.3"									"HPA045394, HPA045399, CAB045960, HPA046980"	Enhanced				"Secreted to digestive system"	NA	NA		77000000			"CAB045960: AB_2226891, HPA045394: AB_2679311, HPA045399: AB_2679313, HPA046980: AB_2679889"					"unprognostic (3.27e-1)"					"unprognostic (1.78e-3)"	"unprognostic (3.24e-2)"			"unprognostic (1.29e-1)"		"unprognostic (2.13e-2)"		0.2	0.0	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.9	1849.4	0.0	0.2	0.2	0.2	0.2	0.0	0.2	59.9	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.3	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	0.3	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.8	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.9	1.5	0.0	0.0	0.0	849.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.2	0.0	0.0	12.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.4
ANXA1	"ANX1, LPC1"	ENSG00000135046	"Annexin A1"	P04083	9	73151757-73170393	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	"Adaptive immunity, Immunity, Inflammatory response, Innate immunity"	"Phospholipase A2 inhibitor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 432.6;tongue: 235.4"	"Cell type enhanced"	"Detected in many"	10	"granulocytes: 2387.0;Syncytiotrophoblasts: 5914.0;Urothelial cells: 4139.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA011271, HPA011272, CAB013023, CAB035987, CAB058693"	Enhanced		Enhanced	"Nucleoplasm,Plasma membrane,Cytosol"	"Secreted to blood"	NA	Yes		77000000	"Plasma membrane, Cytosol"	Nucleoplasm	"CAB013023: AB_2533983, CAB035987: , CAB058693: AB_2665585, HPA011271: AB_1844883, HPA011272: AB_1844884"	"unprognostic (2.53e-2)"	"unprognostic (1.31e-1)"	"unprognostic (9.08e-2)"	"prognostic favorable (5.71e-5)"	"unprognostic (1.53e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.82e-2)"	"unprognostic (1.30e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.54e-3)"	"unprognostic (1.47e-1)"	"unprognostic (9.82e-3)"	"unprognostic (1.13e-1)"	"unprognostic (8.55e-2)"	"prognostic favorable (4.57e-5)"	"prognostic unfavorable (6.19e-6)"	52.7	3.5	2.7	11.5	3.3	81.4	45.9	0.9	2.5	61.5	8.5	3.6	5.5	2.4	6.9	11.2	432.6	11.9	14.9	8.9	3.2	2.5	9.1	2.1	37.3	7.6	4.3	1.9	11.7	2.4	0.5	6.3	149.5	13.5	12.9	4.4	6.4	93.0	7.2	7.9	11.6	6.4	12.3	6.5	5.9	5.9	5.6	3.1	3.9	21.7	235.4	153.3	18.0	83.1	0.7	98.9	146.2	79.1	27.3	52.5	102.8	66.2	104.7	4.7	4.9	66.8	63.6	0.3	114.8	71.8	47.5	32.2	3.0	59.9	0.1	38.0	100.1	105.0	81.6	10.1	69.5	37.7	37.5	0.7	5.1	31.1	0.1	53.3	11.0	2.5	36.6	57.6	48.0	94.4	44.0	67.3	6.0	21.0	2.8	58.5	0.2	19.5	6.0	5.9	26.5	42.6	0.0	26.7	0.2	106.8	14.0	0.0	0.0	39.5	1.0	26.5	65.5	0.2	1.7	83.1	55.7	35.1	76.5	58.9	0.4	0.1	0.2	128.7	10.3	83.8	146.2	79.1	141.1	52.2	21.5	52.5	0.7	47.0	45.9	98.9	0.2	13.7	25.4	8.6	27.3	19.3	3.5	8.3	102.8	2.7	3.3	0.9	2.5	3.2	2.5	4.3	1.9	13.5	3.1	541.9	512.9	7.3	2232.0	752.1	0.0	11.9	17.8	1060.0	889.5	59.3	0.0	1215.0	0.0	156.6	6.3	398.1	0.8	0.0	20.0	1352.9	735.1	1709.3	2387.0	2.5	570.9	0.0	5.1	113.5	449.6	2.3	206.0	1058.5	291.8	475.3	1.8	0.2	431.7	0.0	8.9	3.1	0.0	64.7	275.6	0.7	2.9	522.6	5914.0	282.4	0.5	4139.3
AOC3	"HPAO, VAP-1, VAP1"	ENSG00000131471	"Amine oxidase, copper containing 3"	Q16853	17	42851184-42858130	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"	Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	19	"Peritubular cells: 70.4;Sertoli cells: 116.4;Smooth muscle cells: 56.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	13	"neutrophil: 1.2"	"Lineage enriched"	"Detected in single"	13	"granulocytes: 1.2"	"Cell line enriched"	"Detected in some"	18	"ASC diff: 85.5"	"Low region specificity"	"Detected in many"							"HPA000980, CAB025797"	Enhanced		Approved	"Golgi apparatus,Cytosol"	"Secreted - unknown location"	NA	NA		240000000	Cytosol	"Golgi apparatus"	"CAB025797: , HPA000980: AB_1078170"	"unprognostic (2.20e-1)"	"unprognostic (4.49e-2)"	"prognostic unfavorable (3.68e-4)"	"unprognostic (2.97e-2)"	"unprognostic (1.17e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.22e-1)"	"unprognostic (2.15e-2)"	"unprognostic (1.48e-1)"	"unprognostic (4.00e-2)"	"unprognostic (2.95e-1)"	"unprognostic (9.02e-2)"	"prognostic unfavorable (1.79e-5)"	"unprognostic (5.61e-2)"	"unprognostic (1.67e-1)"	"unprognostic (8.39e-2)"	"prognostic unfavorable (6.98e-4)"	97.0	11.5	0.4	18.7	1.0	0.0	67.7	0.5	1.3	26.9	44.3	1.0	16.3	3.6	44.7	34.8	36.1	18.5	50.9	12.1	0.4	0.4	5.8	8.3	48.0	7.9	0.5	1.2	23.8	2.4	2.2	1.3	10.8	2.0	36.5	9.4	32.1	8.0	24.7	7.7	5.5	15.0	79.2	0.6	7.5	17.7	16.2	0.3	1.0	6.6	11.6	2.6	75.9	20.9	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.2	85.5	0.1	1.3	0.0	0.0	0.0	0.2	0.2	0.0	0.1	0.2	0.0	0.0	0.1	0.2	0.0	0.2	0.3	1.5	0.1	0.1	4.7	0.2	0.0	0.2	0.9	0.2	0.1	0.2	0.0	0.0	0.5	0.0	0.4	0.1	0.0	0.0	0.3	0.1	0.0	0.1	0.2	0.2	0.7	0.0	0.5	0.0	0.1	0.0	0.0	0.5	0.6	0.0	0.0	0.0	0.0	0.7	0.3	0.1	1.2	1.4	0.1	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.4	1.0	0.5	1.3	0.4	0.4	0.5	1.2	2.0	0.3	3.0	8.9	0.8	0.0	2.6	0.0	3.2	0.0	1.4	3.4	0.0	0.0	0.1	0.0	0.1	3.8	4.7	0.0	0.0	0.2	0.1	2.6	0.2	1.1	0.0	1.1	0.0	0.0	22.7	3.0	2.1	3.1	0.5	3.3	0.0	0.0	0.4	0.1	0.0	70.4	0.7	0.5	116.4	56.5	0.9	0.7	1.6	0.2	0.0	0.0	0.3
BCHE	"CHE1, CHE2, E1"	ENSG00000114200	Butyrylcholinesterase	P06276	3	165772904-165837472	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Serine esterase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"liver: 145.4"	"Cell type enriched"	"Detected in many"	10	"Hepatocytes: 360.7"	"Group enriched"	"Detected in many"	6	"glioma: 24.0;liver cancer: 13.7;melanoma: 18.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	9	"Karpas-707: 131.7"	"Low region specificity"	"Detected in all"							HPA001560	Approved				"Secreted to blood"	NA	NA		13000000000			"HPA001560: AB_1078271"	"unprognostic (4.74e-2)"	"unprognostic (2.00e-1)"	"unprognostic (9.21e-4)"	"unprognostic (8.19e-8)"	"unprognostic (2.66e-2)"	"prognostic unfavorable (1.06e-4)"	"unprognostic (1.44e-1)"	"unprognostic (5.04e-2)"	"unprognostic (6.15e-2)"	"unprognostic (9.59e-2)"	"unprognostic (5.15e-2)"	"unprognostic (3.65e-2)"	"unprognostic (3.18e-3)"	"unprognostic (4.46e-5)"	"unprognostic (2.17e-2)"	"unprognostic (5.92e-2)"	"unprognostic (4.26e-4)"	14.0	3.9	6.7	6.2	4.3	0.4	1.9	3.6	9.1	24.4	15.5	4.7	8.3	1.8	20.2	13.4	20.0	18.0	2.2	7.8	6.1	4.4	2.8	145.4	3.7	0.7	5.5	2.7	10.3	1.1	0.4	1.2	0.5	4.7	4.7	5.3	0.7	1.0	10.5	1.1	2.8	6.4	13.9	3.4	3.7	1.9	1.8	6.1	1.0	0.8	0.4	0.5	9.7	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	14.3	0.0	0.0	0.0	0.0	0.0	0.2	0.1	1.2	0.0	0.0	0.0	5.4	0.0	0.0	0.1	0.9	0.0	1.0	0.0	0.1	0.0	0.0	0.0	1.1	0.0	0.0	4.2	0.2	0.0	1.4	4.4	0.6	5.2	0.0	131.7	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	4.8	10.9	0.1	0.0	0.0	0.1	0.0	0.0	7.5	0.0	5.8	0.0	0.0	3.2	0.0	0.0	1.3	0.5	0.0	0.2	1.3	0.0	14.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	4.3	3.6	4.3	6.1	4.4	5.5	2.7	4.7	6.1	0.0	0.0	0.0	0.3	4.8	0.9	4.3	12.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.1	1.5	0.0	0.0	0.0	0.0	2.2	0.2	0.0	360.7	0.1	1.6	0.0	6.2	5.3	5.5	2.0	0.0	18.6	0.0	0.0	34.4	0.0	0.0	0.0	2.9	1.0	0.0	4.6	0.3	0.1	3.0	0.0	0.0	0.0	0.1
BGLAP	OCN	ENSG00000242252	"Bone gamma-carboxyglutamate protein"	P02818	1	156241962-156243321	"FDA approved drug targets, Predicted secreted proteins"	Biomineralization		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 11.0"	"Cell type enhanced"	"Detected in some"	13	"Melanocytes: 3.3;Sertoli cells: 6.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	16	"NK-cell: 2.2;plasmacytoid DC: 4.2"	"Group enriched"	"Detected in many"	16	"dendritic cells: 4.2;NK-cells: 2.2"	"Cell line enhanced"	"Detected in some"		"hTERT-RPE1: 7.5;U-87 MG: 6.4"														"Secreted to blood"	NA	NA	15500000	430000				"unprognostic (2.50e-2)"	"unprognostic (4.49e-2)"	"unprognostic (3.82e-4)"	"unprognostic (1.13e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.44e-5)"	"unprognostic (2.63e-2)"	"unprognostic (6.54e-2)"	"unprognostic (5.64e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.53e-3)"	"unprognostic (4.70e-2)"	"unprognostic (9.67e-6)"	"unprognostic (3.02e-2)"	"unprognostic (1.72e-1)"	"unprognostic (4.34e-2)"	"unprognostic (8.64e-3)"	1.6	0.7	6.0	6.7	6.9	2.2	1.4	5.2	11.0	1.1	9.3	6.2	0.0	3.2	4.8	1.4	0.8	2.3	1.7	0.7	4.3	2.9	1.2	1.6	1.4	2.3	6.2	6.8	3.4	0.8	1.5	1.3	3.1	9.7	2.1	3.4	0.0	3.6	2.8	2.2	6.8	6.4	3.9	8.4	2.1	2.3	0.3	4.1	0.6	1.6	0.0	1.2	0.7	1.2	0.0	4.2	0.2	0.0	2.2	0.1	0.1	0.3	0.7	1.6	0.5	0.0	0.5	1.2	0.0	0.0	0.0	0.2	0.0	1.2	0.0	0.4	0.0	0.7	0.6	0.0	0.4	0.0	1.8	0.9	0.0	2.0	1.1	0.5	0.0	0.4	0.0	0.6	0.6	0.6	7.5	0.6	1.5	0.5	2.2	0.0	1.9	0.0	1.4	0.8	0.1	0.3	0.9	0.1	1.4	0.6	0.0	0.2	1.8	0.6	0.3	0.7	0.3	1.1	0.0	0.0	0.0	0.4	0.4	0.4	2.7	2.5	1.4	6.4	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	2.2	0.0	4.2	0.0	0.1	6.0	6.9	5.2	11.0	4.3	2.9	6.2	6.8	9.7	4.1	0.0	0.0	0.0	0.9	1.3	0.2	0.0	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.1	0.1	0.7	0.0	0.0	0.2	0.2	1.1	0.6	0.0	0.0	0.2	0.0	0.0	1.3	0.0	0.0	1.4	0.0	3.3	0.0	0.1	0.3	0.0	0.0	0.4	1.1	0.5	6.5	0.0	0.5	0.9	1.1	0.3	0.0	0.6	0.7
C1R		ENSG00000159403	"Complement C1r"	P00736	12	7080209-7092607	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Complement pathway, Immunity, Innate immunity"	"Hydrolase, Protease, Serine protease"	"Disease mutation, Ehlers-Danlos syndrome, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 370.2"	"Group enriched"	"Detected in many"	5	"Fibroblasts: 462.9;Hepatocytes: 1385.8;Leydig cells: 1057.9;Peritubular cells: 364.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"eosinophil: 2.0;gdT-cell: 1.6;MAIT T-cell: 2.0;memory CD4 T-cell: 1.4;memory CD8 T-cell: 3.4;naive CD4 T-cell: 2.8;naive CD8 T-cell: 2.9;neutrophil: 2.5;NK-cell: 3.2;T-reg: 1.4"	"Group enriched"	"Detected in many"	6	"granulocytes: 2.5;NK-cells: 3.2;T-cells: 3.4"	"Cell line enhanced"	"Detected in many"		"ASC diff: 181.7;ASC TERT1: 92.7;BJ hTERT+: 80.0;BJ hTERT+ SV40 Large T+ RasG12V: 49.3;HSkMC: 107.4"					"Low region specificity"	"Detected in all"			"HPA001251, HPA001551"	Uncertain		Uncertain	Nucleoplasm,Cytosol	"Secreted to blood"	NA	NA		14000000000	"Nucleoplasm, Cytosol"		"HPA001251: AB_2666252, HPA001551: AB_10754818"	"unprognostic (1.55e-2)"	"unprognostic (8.97e-2)"	"unprognostic (3.46e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.47e-2)"	"unprognostic (2.66e-2)"	"unprognostic (1.94e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.50e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.21e-1)"	"unprognostic (4.16e-2)"	"prognostic unfavorable (1.94e-14)"	"unprognostic (3.54e-2)"	"unprognostic (2.25e-2)"	"unprognostic (6.13e-2)"	"unprognostic (2.59e-2)"	45.8	17.4	2.6	18.1	3.8	0.0	82.0	1.4	2.8	36.7	24.5	2.4	11.2	5.0	27.2	66.8	38.1	33.3	46.7	49.5	1.9	1.8	27.5	370.2	25.3	46.8	3.5	2.0	103.5	11.4	1.4	6.3	10.3	4.6	47.8	15.3	17.7	12.8	13.2	16.0	10.7	14.4	53.2	6.2	35.1	19.8	39.3	1.9	2.3	30.6	20.7	15.1	46.8	83.8	0.4	0.0	2.5	0.4	3.2	3.4	0.8	0.1	1.5	0.1	1.3	181.7	92.7	0.1	20.4	80.0	24.2	49.3	0.2	0.3	0.0	0.6	15.9	1.6	0.3	1.7	0.8	3.4	1.9	0.1	0.0	0.6	0.6	34.9	0.1	0.2	107.4	0.5	11.0	0.8	18.4	0.4	0.1	0.0	2.5	3.1	0.0	0.9	0.1	0.8	0.0	0.1	1.1	0.5	0.1	0.1	0.9	0.0	0.3	14.7	0.4	0.4	0.2	0.0	0.0	0.0	5.8	0.9	26.7	0.1	0.1	0.4	0.0	8.3	0.1	0.8	0.0	0.4	2.0	1.6	0.1	2.0	0.0	1.4	3.4	0.0	0.4	2.8	2.9	2.5	3.2	0.0	0.0	1.4	0.8	2.6	3.8	1.4	2.8	1.9	1.8	3.5	2.0	4.6	1.9	20.8	84.7	28.4	53.6	48.5	0.2	14.6	168.2	6.7	34.2	17.4	2.0	2.9	3.3	164.2	3.5	51.3	0.3	23.3	39.1	4.8	462.9	14.1	9.3	1385.8	10.3	0.0	0.0	128.9	25.4	9.4	1057.9	10.1	50.6	2.8	0.6	15.1	74.1	0.6	364.9	5.0	0.9	168.1	97.8	5.7	4.1	35.0	4.3	13.1	0.7	9.8
C1S		ENSG00000182326	"Complement C1s"	P09871	12	6988259-7071032	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Complement pathway, Immunity, Innate immunity"	"Hydrolase, Protease, Serine protease"	"Disease mutation, Ehlers-Danlos syndrome, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 351.6"	"Cell type enhanced"	"Detected in many"	21	"Hepatocytes: 2464.3;Leydig cells: 1104.9;Peritubular cells: 601.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	10	"neutrophil: 6.2"	"Lineage enriched"	"Detected in single"	17	"granulocytes: 6.2"	"Cell line enhanced"	"Detected in many"		"ASC diff: 99.3;ASC TERT1: 132.1;BJ hTERT+: 42.1;HSkMC: 70.1"					"Low region specificity"	"Detected in all"			"CAB016722, HPA018852"	Supported		Approved	Nucleoplasm,Cytosol	"Secreted to blood"	NA	NA	93000000000	13000000000	Nucleoplasm	Cytosol	"CAB016722: , HPA018852: AB_1847112"	"unprognostic (2.72e-3)"	"unprognostic (7.31e-2)"	"unprognostic (9.37e-2)"	"unprognostic (1.39e-2)"	"unprognostic (1.05e-2)"	"unprognostic (9.63e-2)"	"prognostic favorable (7.73e-4)"	"unprognostic (6.38e-2)"	"unprognostic (1.16e-1)"	"unprognostic (6.14e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.85e-2)"	"prognostic unfavorable (7.44e-15)"	"unprognostic (2.02e-2)"	"unprognostic (5.68e-3)"	"unprognostic (1.19e-2)"	"unprognostic (5.39e-2)"	48.7	16.6	3.3	18.7	4.1	0.0	55.7	1.9	3.1	35.3	31.1	2.9	12.7	6.8	32.2	50.0	38.3	46.4	47.2	34.4	2.5	1.1	18.0	351.6	31.4	21.1	6.3	3.2	98.8	15.5	1.9	6.0	8.5	6.5	52.1	18.6	26.1	14.6	12.4	18.2	14.7	19.2	47.6	8.8	32.5	24.6	37.2	2.3	3.2	30.5	22.7	18.8	48.6	73.0	0.2	0.1	6.2	0.3	0.2	0.1	0.0	0.0	2.2	0.1	1.3	99.3	132.1	0.4	17.9	42.1	9.5	17.4	0.0	0.2	0.0	2.4	22.2	2.5	0.1	0.0	0.2	0.8	0.0	0.0	0.0	0.6	4.7	29.9	0.2	0.1	70.1	0.3	7.7	0.5	11.9	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.1	1.2	0.0	0.0	0.0	0.1	0.1	0.3	0.3	0.0	0.1	10.9	0.2	0.2	2.1	0.0	0.0	0.0	4.4	0.3	16.9	0.0	0.0	0.0	0.1	9.5	0.1	0.2	0.6	0.3	0.2	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.2	0.1	0.1	6.2	0.2	0.1	0.1	0.0	0.0	3.3	4.1	1.9	3.1	2.5	1.1	6.3	3.2	6.5	2.3	14.9	34.2	18.3	17.5	67.8	0.6	21.4	152.8	6.7	20.5	3.5	0.0	2.9	1.7	170.0	5.7	37.8	0.0	46.7	37.9	3.5	388.0	7.4	4.7	2464.3	7.1	4.8	0.0	105.6	49.3	8.8	1104.9	9.4	84.4	1.8	0.0	15.1	43.6	0.0	601.8	4.1	0.9	135.8	123.7	5.0	4.1	47.0	2.2	4.3	0.0	3.0
C3	"ARMD9, C3a, C3b, CPAMD1"	ENSG00000125730	"Complement C3"	P01024	19	6677704-6730562	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Complement alternate pathway, Complement pathway, Fatty acid metabolism, Immunity, Inflammatory response, Innate immunity, Lipid metabolism"		"Age-related macular degeneration, Disease mutation, FDA approved drug targets, Hemolytic uremic syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	10	"liver: 611.7"	"Cell type enriched"	"Detected in many"	5	"Hepatocytes: 4080.2"	"Cancer enhanced"	"Detected in all"		"liver cancer: 1213.6"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 13.3"	"Group enriched"	"Detected in many"	4	"granulocytes: 4.2;monocytes: 13.3"	"Group enriched"	"Detected in many"	7	"BJ hTERT+: 48.5;EFO-21: 102.2;Hep G2: 105.6;HSkMC: 75.4;SiHa: 28.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003563, CAB004209, HPA020432"	Enhanced				"Secreted to blood"	NA	NA	1260000000000	250000000000			"CAB004209: AB_627277, HPA003563: AB_1847117, HPA020432: AB_1847118"	"unprognostic (3.26e-3)"	"unprognostic (3.91e-1)"	"unprognostic (3.92e-1)"	"unprognostic (5.98e-3)"	"unprognostic (3.31e-1)"	"unprognostic (1.04e-1)"	"prognostic favorable (8.11e-4)"	"unprognostic (1.99e-1)"	"unprognostic (9.26e-2)"	"unprognostic (5.80e-2)"	"unprognostic (8.12e-3)"	"unprognostic (5.48e-2)"	"prognostic unfavorable (1.09e-5)"	"unprognostic (2.63e-2)"	"unprognostic (2.49e-2)"	"unprognostic (6.03e-3)"	"unprognostic (3.88e-1)"	59.7	34.1	9.3	20.0	19.6	1.0	47.3	0.7	10.2	28.3	17.8	13.9	3.7	3.2	9.1	19.9	17.9	38.8	37.9	57.6	7.0	4.1	21.6	611.7	22.6	25.2	12.3	2.2	42.4	22.2	3.1	3.0	2.7	12.8	12.7	9.6	3.9	18.7	7.6	6.8	5.8	15.1	19.1	29.6	1.6	12.6	11.2	10.7	0.1	10.3	3.2	14.1	25.2	38.2	1.2	0.8	4.2	13.3	2.0	0.4	0.8	8.4	3.0	0.0	0.0	1.5	5.1	10.3	0.7	48.5	0.9	1.7	0.5	6.7	0.2	102.2	0.0	7.5	6.3	0.0	5.8	0.9	3.1	0.0	0.4	4.5	105.6	2.3	0.8	1.2	75.4	1.7	8.4	3.8	1.3	0.0	0.0	0.2	0.1	0.0	0.1	0.0	0.2	0.2	0.0	0.0	0.0	0.7	0.0	4.4	0.8	0.0	0.0	28.2	0.0	0.0	0.0	2.3	1.1	0.4	0.8	1.0	0.6	0.4	0.2	0.5	0.5	10.4	0.6	0.0	1.7	1.5	0.9	0.4	2.7	0.3	0.7	0.3	0.2	0.8	1.2	0.4	0.4	4.2	2.0	13.3	0.7	0.2	0.8	9.3	19.6	0.7	10.2	7.0	4.1	12.3	2.2	12.8	10.7	71.5	405.7	102.4	11.5	24.5	0.0	13.3	822.9	29.4	84.2	15.7	0.0	1.2	5.0	273.3	34.0	21.5	0.3	70.0	114.7	2.1	60.9	11.5	4.7	4080.2	36.1	0.0	0.0	120.9	123.3	75.5	209.4	25.1	33.7	25.2	0.6	0.5	589.9	0.0	10.3	39.2	3.7	6.5	22.8	3.2	7.9	19.2	2.3	24.5	0.4	12.3
C4A	"C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG"	ENSG00000244731	"Complement C4A (Rodgers blood group)"	P0C0L4	6	31982024-32002681	"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Complement pathway, Immunity, Inflammatory response, Innate immunity"	"Blood group antigen"	"Disease mutation, FDA approved drug targets, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 49.5"	"Cell type enhanced"	"Detected in some"	21	"Alveolar cells type 1: 8.9;Alveolar cells type 2: 36.1;Ciliated cells: 8.1;Club cells: 25.0"	"Cancer enhanced"	"Detected in many"		"liver cancer: 27.8"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 25.4;HSkMC: 36.1;U-266/70: 8.4;U-266/84: 16.0"									"CAB009811, CAB032603, HPA046356, HPA048287, HPA050103"	Supported				"Secreted to blood"	NA	NA	342000000	98000000000			"CAB009811: AB_2066891, CAB032603: AB_2290613, HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016"	"unprognostic (2.13e-1)"	"unprognostic (3.02e-2)"	"unprognostic (3.74e-2)"	"unprognostic (3.10e-1)"	"unprognostic (5.29e-2)"	"unprognostic (3.09e-2)"	"unprognostic (2.48e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.00e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.70e-1)"	"unprognostic (3.15e-1)"	"unprognostic (4.47e-2)"	"unprognostic (3.20e-2)"	"unprognostic (5.20e-2)"	"unprognostic (3.97e-2)"	"unprognostic (8.63e-2)"	2.7	17.5	1.3	4.3	1.1	0.0	3.3	0.0	0.1	0.4	3.0			2.9	1.6	5.8	0.7	3.5	0.8	2.7	0.7	0.9	12.8	49.5	6.7	1.4	0.9		8.0	2.6	0.0	2.2	0.0		1.5	1.7		1.3	0.0	0.0	0.1	1.2	0.0	0.7	2.9	4.1	0.3			8.1		1.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.2	0.0	25.4	0.2	0.0	0.0	0.4	0.0	0.0	0.0	36.1	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.1	8.4	16.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											8.9	36.1	0.0	0.0	0.0	0.0	4.7	0.0	8.1	25.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	4.7	0.0	0.0	0.0	0.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C4B	"C4B1, C4B3, C4F, CH, CO4, CPAMD3"	ENSG00000224389	"Complement C4B (Chido blood group)"	P0C0L5	6	32014762-32035418	"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Complement pathway, Immunity, Inflammatory response, Innate immunity"	"Blood group antigen"	"FDA approved drug targets, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"adrenal gland: 30.7;liver: 52.4"	"Group enriched"	"Detected in some"	4	"Alveolar cells type 2: 95.9;Cardiomyocytes: 44.1;Club cells: 42.1"	"Cancer enhanced"	"Detected in many"		"liver cancer: 33.8"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"Karpas-707: 53.7"									"HPA046356, HPA048287, HPA050103"	Approved				"Secreted to blood"	NA	NA		97000000000			"HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016"	"unprognostic (1.29e-1)"	"unprognostic (2.99e-2)"	"unprognostic (5.50e-3)"	"unprognostic (1.30e-1)"	"unprognostic (8.09e-2)"	"unprognostic (6.24e-2)"	"unprognostic (6.09e-2)"	"unprognostic (1.05e-1)"	"unprognostic (4.81e-2)"	"unprognostic (1.12e-1)"	"unprognostic (6.24e-2)"	"unprognostic (6.86e-2)"	"unprognostic (1.04e-1)"	"unprognostic (3.12e-2)"	"unprognostic (1.30e-1)"	"unprognostic (3.99e-3)"	"unprognostic (1.11e-2)"	3.7	30.7	0.9	0.0	0.7	0.0	1.3	0.0	0.9	0.7	2.3			0.9	1.4	0.0	0.0	4.7	2.4	2.6	0.4	0.9	7.2	52.4	2.0	0.7	0.7		7.2	2.7	1.0	1.8	0.5		0.5	2.7		2.0	0.4	0.0	0.0	1.0	3.8	0.6	1.4	0.8	0.7			5.7		1.6	2.5	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.8	3.3	0.2	0.0	10.5	0.0	0.0	0.0	1.2	0.0	0.0	0.0	53.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											3.0	95.9	0.0	0.0	0.0	0.0	44.1	0.0	14.7	42.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	1.1	3.4	0.0	0.0	0.0	0.0	0.3	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C5	"C5a, C5b, CPAMD4"	ENSG00000106804	"Complement C5"	P01031	9	120952335-121050276	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Inflammatory response, Innate immunity"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	55	"liver: 259.9"	"Cell type enriched"	"Detected in many"	12	"Hepatocytes: 458.7"	"Cancer enriched"	"Detected in many"	17	"liver cancer: 73.0"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A549: 20.5;Hep G2: 21.6"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			HPA029339	Supported				"Secreted to blood"	NA	NA	113000000000	46000000000			"HPA029339: AB_10601125"	"unprognostic (2.51e-1)"	"unprognostic (5.88e-3)"	"unprognostic (2.50e-3)"	"unprognostic (1.57e-2)"	"unprognostic (5.05e-2)"	"unprognostic (9.52e-3)"	"prognostic favorable (9.43e-4)"	"unprognostic (1.83e-1)"	"unprognostic (3.19e-2)"	"unprognostic (1.55e-1)"	"unprognostic (2.35e-2)"	"unprognostic (4.41e-2)"	"unprognostic (1.46e-5)"	"unprognostic (5.91e-2)"	"unprognostic (1.20e-1)"	"unprognostic (3.67e-2)"	"unprognostic (2.75e-1)"	0.5	0.3	0.4	0.3	0.5	0.3	0.4	0.3	0.3	0.4	1.1	0.3	0.3	0.7	0.5	0.7	0.3	0.6	0.4	0.3	0.4	0.3	1.1	259.9	2.3	0.3	0.4	0.3	0.7	4.7	0.8	0.7	0.3	0.4	0.6	0.2	0.3	0.3	0.4	0.3	0.7	3.2	0.3	0.5	0.3	1.2	0.4	0.3	0.3	0.3	0.3	0.3	0.5	0.4	1.8	2.1	1.8	1.6	0.1	1.2	0.5	1.1	20.5	4.7	8.3	6.1	7.1	0.2	2.5	2.6	0.7	1.5	0.6	2.0	3.0	0.1	1.3	2.8	8.1	0.2	0.2	1.1	0.6	0.0	1.2	1.0	21.6	1.1	0.7	0.5	3.1	0.4	1.5	2.7	1.3	0.7	1.2	0.5	2.8	1.6	4.0	0.3	0.1	1.2	5.0	8.0	1.8	2.1	0.3	1.3	0.6	1.2	4.9	1.1	0.0	2.0	3.4	1.6	2.7	0.9	2.1	0.1	5.5	2.4	1.7	1.2	1.2	1.6	2.8	5.0	0.0	1.6	1.8	0.3	0.4	1.2	1.8	0.6	0.5	2.1	1.0	0.5	0.3	0.1	0.1	0.1	0.1	0.1	0.5	0.4	0.5	0.3	0.3	0.4	0.3	0.4	0.3	0.4	0.3	6.0	25.8	2.2	1.0	0.9	4.5	0.6	38.2	5.3	12.5	1.8	0.0	0.1	1.7	0.1	1.3	0.5	0.0	0.0	0.4	0.0	0.8	0.7	0.0	458.7	1.5	6.4	0.0	8.0	12.9	1.7	2.8	3.1	0.0	1.8	0.4	3.9	1.1	0.0	8.5	7.8	2.5	0.0	1.2	1.8	2.3	1.1	0.0	0.7	0.9	0.1
CARTPT	CART	ENSG00000164326	"CART prepropeptide"	Q16568	5	71719163-71721048	"FDA approved drug targets, Predicted secreted proteins"		"Neuropeptide, Neurotransmitter"	"FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	10	"adrenal gland: 67.5;brain: 101.4"	"Cell type enhanced"	"Detected in some"	12	"Bipolar cells: 5.8;Cone photoreceptor cells: 7.9;Early spermatids: 12.3;Glandular cells: 4.8;Intestinal endocrine cells: 6.8;Rod photoreceptor cells: 7.6"	"Cancer enriched"	"Detected in many"	9	"breast cancer: 117.7"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"NB-4: 1.1;SH-SY5Y: 3.5"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"hippocampal formation: 179.9"	"CAB025515, HPA046278, CAB079776"	Enhanced	Supported			"Secreted to blood"	NA	NA					"CAB025515: , CAB079776: , HPA046278: AB_10961570"			"unprognostic (1.37e-1)"		"unprognostic (1.43e-1)"					"unprognostic (2.27e-1)"	"unprognostic (3.45e-2)"	"unprognostic (6.67e-2)"		"prognostic unfavorable (4.36e-4)"		"unprognostic (1.14e-1)"		1.6	67.5	8.0	2.8	22.3	0.5	5.8	0.1	29.0	0.5	3.4	2.1	0.0	3.5	0.6	0.9	3.5	0.7	0.6	0.5	31.1	101.4	0.5	0.5	0.5	0.5	1.0	4.5	0.5	5.3	0.5	1.7	0.5	54.1	3.3	3.1	1.6	0.5	0.5	0.5	0.5	1.4	8.1	8.6	0.5	3.4	1.9	9.7	0.0	3.4	0.0	0.5	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.0	22.3	0.1	29.0	31.1	101.4	1.0	4.5	54.1	9.7	0.0	0.0	0.0	0.3	0.0	5.8	0.0	0.0	0.0	0.0	0.0	7.9	0.0	0.0	0.0	12.3	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	6.8	0.0	0.0	2.7	0.6	0.0	0.0	0.0	0.0	2.3	0.0	0.0	1.1	0.0	7.6	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.0	0.1
CCL2	"GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF"	ENSG00000108691	"C-C motif chemokine ligand 2"	P13500	17	34255218-34257203	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	14	"Ductal cells: 3138.5;Pancreatic endocrine cells: 1040.3;Smooth muscle cells: 1844.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"classical monocyte: 10.3;eosinophil: 3.9"	"Group enriched"	"Detected in many"	6	"granulocytes: 3.9;monocytes: 10.3"	"Group enriched"	"Detected in many"	4	"BJ hTERT+: 163.0;HMC-1: 212.4"					"Low region specificity"	"Detected in many"			"CAB013676, HPA019163"	Approved		Approved	"Golgi apparatus,Vesicles"	"Secreted to blood"	NA	NA	323000		"Golgi apparatus"	Vesicles	"CAB013676: , HPA019163: AB_1846179"	"unprognostic (6.43e-2)"	"unprognostic (4.14e-2)"	"unprognostic (4.78e-2)"	"unprognostic (5.57e-2)"	"unprognostic (2.37e-3)"	"unprognostic (8.64e-2)"	"unprognostic (2.78e-2)"	"unprognostic (7.53e-2)"	"unprognostic (2.90e-1)"	"unprognostic (1.19e-1)"	"unprognostic (9.33e-2)"	"unprognostic (2.65e-1)"	"prognostic unfavorable (4.51e-4)"	"unprognostic (1.33e-1)"	"unprognostic (2.50e-2)"	"unprognostic (1.81e-1)"	"unprognostic (4.92e-2)"	78.1	31.2	10.3	52.3	50.6	19.1	19.0	1.5	23.3	9.7	41.9	28.6	3.0	9.4	7.2	7.6	14.4	25.8	62.0	76.9	45.1	6.7	32.5	38.4	105.2	16.9	16.0	2.0	28.6	32.8	15.2	17.3	22.8	63.6	42.0	25.3	22.3	13.5	13.4	17.8	10.5	16.7	34.6	85.4	16.1	30.2	4.6	8.6	4.8	20.8	21.6	19.1	27.2	9.0	0.0	1.1	3.9	10.3	0.0	0.1	2.3	0.0	1.3	3.5	0.0	9.8	8.4	0.0	9.9	163.0	21.2	45.5	0.6	0.0	0.0	7.9	2.3	0.3	5.5	0.3	0.0	10.8	0.0	0.0	0.0	1.2	0.0	0.3	0.0	212.4	9.4	0.0	4.4	0.2	14.2	9.6	0.0	0.5	1.7	0.0	0.0	0.0	1.6	0.5	0.0	0.0	0.0	0.2	1.7	30.3	0.0	0.0	0.7	0.0	0.5	0.2	9.9	0.4	0.2	0.5	11.3	0.5	0.3	0.0	0.1	0.0	0.0	6.6	3.1	7.2	0.0	10.3	3.9	0.0	0.3	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.1	0.7	0.0	0.0	0.3	0.0	2.3	10.3	50.6	1.5	23.3	45.1	6.7	16.0	2.0	63.6	8.6	169.7	145.0	2.7	681.4	505.1	0.0	10.8	91.7	41.5	131.9	130.9	0.0	2.4	0.0	3138.5	0.0	322.6	0.0	0.0	773.5	3.2	475.0	113.8	329.6	0.0	387.1	0.0	0.0	58.3	3.5	0.0	11.2	253.5	202.4	63.1	0.0	6.0	1040.3	0.0	1.4	11.5	0.2	129.4	1844.0	0.0	0.1	194.7	3.8	4.3	0.0	39.4
CD44	"CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1"	ENSG00000026508	"CD44 molecule (Indian blood group)"	P16070	11	35138870-35232402	"Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion"	"Blood group antigen, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	4	"Basal keratinocytes: 888.0;Ductal cells: 858.7;Suprabasal keratinocytes: 895.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 139.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000112, CAB000316, HPA005785"	Enhanced		Supported	"Golgi apparatus,Plasma membrane"	"Secreted - unknown location"	NA	NA		2400000000	"Plasma membrane"	"Golgi apparatus"	"CAB000112: , CAB000316: AB_2076596, HPA005785: AB_1078467"	"unprognostic (5.33e-2)"	"unprognostic (1.85e-1)"	"unprognostic (4.97e-2)"	"unprognostic (9.90e-3)"	"unprognostic (3.50e-3)"	"unprognostic (1.46e-2)"	"unprognostic (1.56e-2)"	"unprognostic (8.12e-2)"	"unprognostic (1.57e-1)"	"unprognostic (4.18e-2)"	"unprognostic (1.51e-3)"	"unprognostic (4.63e-2)"	"prognostic unfavorable (1.78e-8)"	"unprognostic (6.41e-2)"	"unprognostic (4.14e-2)"	"unprognostic (3.93e-2)"	"unprognostic (7.98e-2)"	45.5	9.0	10.5	42.5	21.7	53.0	35.6	4.7	13.4	43.2	19.5	26.3	8.3	10.6	80.5	20.3	66.5	18.6	48.0	11.7	14.9	9.3	12.4	9.1	43.4	48.4	31.5	6.1	12.8	83.9	0.8	3.8	19.4	40.7	30.1	24.5	30.2	148.2	22.4	15.9	107.7	18.9	44.5	100.5	30.9	19.9	7.2	20.3	17.9	20.6	53.9	53.7	55.0	54.2	22.7	41.0	19.1	65.2	54.6	53.1	59.9	39.7	35.9	0.3	0.0	21.7	60.0	0.1	77.9	60.9	43.4	24.2	2.4	12.5	0.0	10.4	110.3	89.3	68.5	0.8	84.7	59.6	8.5	0.4	1.4	17.7	0.0	21.4	20.2	93.5	27.0	66.8	58.3	47.4	139.4	15.1	0.0	0.3	13.0	41.6	0.2	1.8	13.3	0.7	0.7	10.6	0.1	7.4	0.6	63.6	11.5	0.1	0.1	14.7	0.4	35.2	3.4	2.1	1.2	43.5	54.1	9.8	66.3	80.0	22.5	24.3	0.2	82.1	11.4	78.6	19.1	65.2	6.0	26.2	45.7	37.0	22.7	39.8	34.9	41.0	16.2	34.5	28.7	16.4	54.6	59.3	14.2	53.1	59.9	10.5	21.7	4.7	13.4	14.9	9.3	31.5	6.1	40.7	20.3	89.3	339.9	168.9	263.7	888.0	0.0	4.0	25.5	18.7	135.4	19.2	2.0	4.0	1.7	858.7	30.1	53.0	5.0	23.3	741.5	3.7	143.9	293.1	733.4	2.5	234.7	0.0	96.2	20.3	427.0	13.8	20.8	611.7	573.6	514.0	84.8	26.6	787.6	8.6	0.4	0.6	1.6	155.2	254.2	0.4	0.4	895.8	15.0	244.8	66.1	304.0
COL1A1	OI4	ENSG00000108821	"Collagen type I alpha 1 chain"	P02452	17	50183289-50201632	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation, Dwarfism, Ehlers-Danlos syndrome, FDA approved drug targets, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 415.7"	"Cell type enhanced"	"Detected in many"	22	"Fibroblasts: 2038.6;Ito cells: 615.0;Leydig cells: 514.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	5	"naive CD8 T-cell: 1.1"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.1"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 91.8;BJ: 176.2;fHDF/TERT166: 266.1;HHSteC: 71.8;HSkMC: 134.8;U-138 MG: 143.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"HPA011795, HPA012111"	Approved		Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to extracellular matrix"	NA	NA		58000000	"Endoplasmic reticulum, Vesicles"		"HPA011795: AB_1847088, HPA012111: "	"unprognostic (1.61e-1)"	"unprognostic (3.60e-3)"	"unprognostic (8.29e-2)"	"unprognostic (5.52e-2)"	"unprognostic (7.74e-2)"	"unprognostic (2.22e-1)"	"unprognostic (6.01e-2)"	"prognostic unfavorable (4.43e-4)"	"unprognostic (1.23e-2)"	"unprognostic (2.55e-2)"	"unprognostic (8.53e-2)"	"unprognostic (9.90e-2)"	"prognostic unfavorable (7.19e-12)"	"unprognostic (2.74e-2)"	"unprognostic (4.73e-2)"	"unprognostic (7.26e-2)"	"unprognostic (3.87e-3)"	30.2	5.7	0.7	28.2	4.0	0.1	31.7	0.6	0.9	415.7	25.7	1.6	23.9	3.0	121.8	70.9	17.4	33.0	110.3	43.9	0.7	0.1	7.5	4.6	18.8	38.5	0.7	1.2	73.6	10.5	1.0	10.7	89.1	2.2	31.5	4.0	9.2	9.1	21.0	11.0	35.5	10.6	88.0	1.3	13.7	15.0	44.6	0.7	7.7	6.7	15.5	8.7	67.3	49.7	0.2	0.0	0.0	0.0	0.0	1.1	0.0	0.3	0.2	0.9	0.1	37.7	91.8	1.6	176.2	47.9	43.9	27.6	3.5	0.8	0.0	0.4	266.1	0.3	0.5	0.4	0.1	7.9	0.2	0.3	0.0	4.4	0.2	71.8	0.0	0.0	134.8	2.6	53.7	0.2	7.3	0.0	0.2	0.1	0.0	22.1	0.4	0.0	0.0	0.9	0.6	0.5	0.3	0.1	0.1	0.2	0.0	0.1	0.5	0.3	0.2	0.0	13.7	2.2	0.0	0.0	143.2	31.3	21.4	0.8	0.1	0.3	0.0	10.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	4.0	0.6	0.9	0.7	0.1	0.7	1.2	2.2	0.7	8.9	14.4	0.5	11.0	166.9	0.0	4.8	0.0	5.3	12.5	7.0	0.0	29.5	0.0	11.2	0.9	5.1	0.0	0.0	3.7	26.1	2038.6	12.1	2.3	1.9	59.9	0.0	2.9	615.0	0.8	4.5	514.8	7.7	178.8	0.0	2.2	2.8	25.7	0.0	252.1	0.5	0.1	77.6	273.4	4.2	1.7	142.9	93.5	0.5	1.3	7.5
CPB2	"CPU, PCPB, TAFI"	ENSG00000080618	"Carboxypeptidase B2"	Q96IY4	13	46053195-46105033	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis"	"Carboxypeptidase, Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	82	"liver: 246.8"	"Cell type enriched"	"Detected in some"	8	"Hepatocytes: 1070.7"	"Cancer enriched"	"Detected in some"	112	"liver cancer: 268.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	76	"Hep G2: 62.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA004146	Approved				"Secreted to blood"	NA	NA		14000000000			"HPA004146: AB_1078397"	"unprognostic (3.44e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.94e-2)"	"unprognostic (1.89e-2)"	"unprognostic (7.69e-2)"	"unprognostic (1.17e-2)"	"prognostic favorable (2.06e-4)"	"unprognostic (1.89e-1)"	"unprognostic (2.74e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.17e-2)"	"unprognostic (4.83e-2)"	"unprognostic (3.20e-3)"	"unprognostic (1.34e-1)"	"unprognostic (7.10e-2)"	"unprognostic (3.34e-2)"	"unprognostic (9.61e-2)"	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.7	0.0	0.0	0.0	0.0	246.8	3.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.5	0.5	0.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	62.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.3	0.0	0.6	0.0	0.0	0.4	0.2	0.1	0.0	0.0	0.4	0.2	0.5	0.4	0.5	0.2	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	24.8	0.0	0.0	0.0	0.0	0.0	127.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1070.7	0.1	0.0	0.0	16.0	15.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0
CSF2RA	"alphaGMR, CD116, CSF2R"	ENSG00000198223	"Colony stimulating factor 2 receptor alpha subunit"	P15509	X	1268800-1310381	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 60.2;placenta: 79.5"	"Cell type enhanced"	"Detected in many"	26	"Cytotrophoblasts: 215.8;monocytes: 954.0;Syncytiotrophoblasts: 261.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 30.0;eosinophil: 36.0;intermediate monocyte: 17.7;myeloid DC: 31.9;neutrophil: 60.2;plasmacytoid DC: 30.5"	"Group enriched"	"Detected in many"	28	"dendritic cells: 31.9;granulocytes: 60.2;monocytes: 30.0"	"Group enriched"	"Detected in some"	7	"BEWO: 60.4;HMC-1: 18.2;SK-MEL-30: 42.3"									CAB016148	Uncertain				"Secreted to blood"	NA	NA		9400000			"CAB016148: AB_626868"	"unprognostic (4.19e-2)"	"prognostic favorable (2.38e-5)"	"unprognostic (5.47e-2)"	"unprognostic (4.33e-2)"	"unprognostic (4.88e-2)"	"prognostic favorable (2.81e-4)"	"unprognostic (8.24e-2)"	"unprognostic (2.17e-1)"	"unprognostic (5.55e-2)"	"unprognostic (8.48e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.80e-1)"	"unprognostic (2.89e-2)"	"unprognostic (8.91e-3)"	"prognostic unfavorable (5.53e-4)"	"unprognostic (3.60e-1)"	"unprognostic (9.44e-2)"	8.7	2.3	11.8	11.1	11.1	8.9	17.7	3.4	9.6	3.1	2.2	0.6	0.6	2.2	4.4	0.6	2.1	2.2	5.7	3.7	15.0	4.7	2.4	1.7	11.2	8.3	18.8	6.5	3.5	1.0	0.2	2.1	79.5	13.2	1.5	3.3	0.6	3.1	1.0	0.6	1.8	3.3	2.9	25.5	12.6	1.7	0.6	16.3	0.6	2.5	0.6	10.4	4.2	1.5	0.3	31.9	60.2	30.0	1.4	0.2	10.1	0.1	3.5	0.2	0.0	0.0	0.0	60.4	0.0	0.1	0.1	0.0	1.2	0.3	0.0	3.9	0.0	3.3	0.0	0.0	0.0	0.0	1.1	0.0	0.0	2.4	0.0	0.0	1.3	18.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.1	5.6	0.5	0.5	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.1	1.0	0.0	42.3	5.0	2.8	5.0	0.0	0.0	1.7	0.3	0.0	0.1	0.1	0.1	0.0	5.5	0.0	2.4	30.0	36.0	0.0	17.7	0.2	0.3	0.0	0.0	31.9	0.1	0.0	0.0	60.2	1.4	8.4	30.5	0.1	10.1	11.8	11.1	3.4	9.6	15.0	4.7	18.8	6.5	13.2	16.3	0.0	8.2	11.1	1.0	6.9	0.6	1.1	5.1	4.0	5.7	1.8	0.0	215.8	0.0	0.2	0.5	1.4	0.0	0.0	1.5	101.6	5.3	0.5	9.3	0.0	66.0	0.0	0.0	1.3	66.8	0.0	0.9	146.7	8.5	954.0	0.0	0.5	0.3	0.0	0.4	0.0	1.1	6.5	2.1	0.2	0.4	4.5	261.3	0.0	0.0	2.1
DPP4	"ADCP2, CD26, DPPIV"	ENSG00000197635	"Dipeptidyl peptidase 4"	P27487	2	161992241-162074542	"CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion"	"Aminopeptidase, Hydrolase, Protease, Receptor, Serine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 133.1;parathyroid gland: 75.5"	"Cell type enhanced"	"Detected in many"	9	"Cytotrophoblasts: 134.1;Proximal tubular cells: 80.1;Syncytiotrophoblasts: 143.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 26.7"	"Lineage enriched"	"Detected in many"	10	"T-cells: 26.7"	"Cell line enhanced"	"Detected in many"		"ASC diff: 42.8;ASC TERT1: 43.4;BJ hTERT+: 39.8;RPTEC TERT1: 58.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"CAB045970, HPA068778, HPA071236"	Enhanced				"Secreted in other tissues"	NA	NA		170000000			"CAB045970: AB_11140529, HPA068778: , HPA071236: "	"unprognostic (4.47e-2)"	"unprognostic (4.47e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.36e-1)"	"unprognostic (7.25e-2)"	"unprognostic (5.40e-2)"	"unprognostic (2.78e-1)"	"unprognostic (3.54e-2)"	"unprognostic (3.58e-1)"	"unprognostic (4.73e-1)"	"unprognostic (2.36e-1)"	"prognostic unfavorable (1.98e-4)"	"prognostic favorable (1.35e-6)"	"unprognostic (4.68e-2)"	"unprognostic (6.33e-2)"	"prognostic favorable (4.99e-4)"	"unprognostic (1.21e-2)"	9.5	2.9	0.3	3.2	0.5	0.0	5.0	0.3	1.4	2.2	50.0	0.2	36.9	19.1	2.2	3.5	1.2	1.2	5.2	2.1	0.4	0.3	29.1	12.2	5.4	2.1	0.4	0.2	2.7	1.8	75.5	0.3	24.0	0.2	21.1	2.8	0.6	46.9	38.8	2.4	4.4	133.1	0.9	0.8	5.0	1.2	0.6	0.1	6.2	1.0	1.4	1.1	1.0	2.6	0.1	2.1	0.3	0.0	2.6	26.7	2.5	0.0	0.0	0.1	0.0	42.8	43.4	0.1	7.9	39.8	2.2	7.7	8.0	0.2	0.0	3.0	13.7	7.4	0.2	0.1	0.0	1.3	2.5	0.1	0.0	0.0	11.9	17.4	0.0	0.0	4.9	0.0	13.4	0.1	2.0	1.3	0.1	0.0	0.0	0.7	0.0	0.7	0.1	0.4	0.3	16.4	0.0	0.0	0.1	58.0	0.0	0.0	0.1	0.0	0.0	0.0	0.9	0.0	0.0	7.1	4.6	0.2	0.2	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	3.2	0.0	26.7	0.1	8.3	5.2	0.6	0.0	8.3	3.3	0.3	2.6	0.0	2.1	0.9	2.5	0.3	0.5	0.3	1.4	0.4	0.3	0.4	0.2	0.2	0.1	6.0	17.5	0.0	0.3	3.7	1.7	4.0	12.7	4.0	4.5	14.0	9.8	134.1	1.7	3.1	13.0	3.9	21.3	0.0	0.0	52.7	45.7	38.3	12.8	39.9	12.7	0.0	53.0	12.3	1.6	6.2	0.0	4.6	5.0	1.0	11.0	0.0	0.9	11.4	0.0	80.1	0.0	0.0	1.0	2.1	0.8	3.6	143.8	11.4	12.8	0.3
EGFR	"ERBB, ERBB1"	ENSG00000146648	"Epidermal growth factor receptor"	P00533	7	55019021-55211628	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Host-virus interaction"	"Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 102.3"	"Cell type enhanced"	"Detected in many"	8	"Cytotrophoblasts: 207.2;Syncytiotrophoblasts: 315.1"	"Cancer enhanced"	"Detected in all"		"glioma: 136.0"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	12	"A-431: 345.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000035, HPA001200, HPA018530, CAB068186, CAB073534"	Enhanced		Enhanced	"Plasma membrane,Cell Junctions"	"Secreted to blood"	NA	NA	4740000	93000000	"Plasma membrane, Cell Junctions"		"CAB000035: , CAB068186: AB_2665679, CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044"	"unprognostic (2.62e-2)"	"unprognostic (9.56e-3)"	"unprognostic (1.59e-1)"	"unprognostic (7.51e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.27e-2)"	"unprognostic (6.11e-2)"	"unprognostic (4.88e-2)"	"unprognostic (2.85e-2)"	"unprognostic (3.30e-3)"	"unprognostic (1.78e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.93e-3)"	"unprognostic (6.98e-3)"	"unprognostic (1.72e-1)"	"unprognostic (6.62e-2)"	"prognostic unfavorable (2.04e-5)"	16.2	8.4	4.9	7.5	6.8	0.1	39.8	5.1	8.5	13.8	7.8	3.3	10.7	3.6	8.2	11.7	15.6	8.8	8.5	4.8	6.8	2.7	7.6	23.5	14.2	2.3	4.1	3.9	10.4	10.1	1.8	2.1	102.3	5.6	10.9	6.7	9.2	15.4	12.9	10.7	32.5	6.3	15.5	3.5	3.3	7.8	5.5	5.9	3.2	12.8	15.5	8.0	10.2	28.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	345.9	4.4	1.1	1.5	7.1	4.4	1.2	3.4	4.6	2.1	1.6	0.8	3.7	0.2	0.8	2.9	9.0	13.9	0.0	15.3	2.5	0.1	0.2	0.0	1.9	0.2	1.8	0.0	0.0	2.1	14.0	5.3	28.6	3.1	0.2	0.0	0.0	0.0	4.5	0.2	0.0	0.0	0.3	1.3	2.2	0.0	0.6	0.0	2.6	3.7	0.0	1.3	2.9	3.5	0.7	1.2	0.3	0.8	1.0	1.9	0.5	14.9	3.2	0.0	0.3	0.2	2.6	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	6.8	5.1	6.6	6.8	2.7	4.1	3.9	5.6	5.9	89.3	37.5	4.2	67.7	76.2	1.5	7.3	53.5	16.0	59.1	21.0	5.9	207.2	0.0	30.6	4.6	10.9	15.9	23.3	21.0	36.6	45.3	37.8	0.0	77.4	24.2	0.0	4.1	6.7	7.0	2.2	118.8	1.3	16.9	2.8	25.3	106.1	41.7	17.3	125.5	14.0	2.3	77.6	23.1	1.6	2.7	78.5	315.1	0.0	20.0	46.4
ELANE	"ELA2, HLE, HNE, NE"	ENSG00000197561	"Elastase, neutrophil expressed"	P08246	19	851014-856247	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"bone marrow: 244.3"	"Cell type enhanced"	"Detected in some"	9	"Basal keratinocytes: 7.7;Fibroblasts: 5.7;Kupffer cells: 5.6;Leydig cells: 5.8;Melanocytes: 6.8;Suprabasal keratinocytes: 6.5"	"Group enriched"	"Detected in some"	7	"pancreatic cancer: 3.5;stomach cancer: 3.7"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"classical monocyte: 3.2;neutrophil: 6.9"	"Group enriched"	"Detected in many"	9	"granulocytes: 6.9;monocytes: 3.2"	"Cell line enriched"	"Detected in some"	65	"THP-1: 197.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"CAB015409, HPA066836"	Enhanced				"Secreted to blood"	NA	NA		59000			"CAB015409: AB_831596, HPA066836: AB_2685733"	"unprognostic (3.46e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.42e-3)"	"unprognostic (2.09e-2)"	"unprognostic (1.80e-3)"	"unprognostic (3.43e-2)"	"unprognostic (3.92e-1)"	"unprognostic (6.38e-3)"	"unprognostic (5.80e-1)"	"unprognostic (2.54e-2)"	"unprognostic (4.06e-2)"	"unprognostic (3.48e-2)"	"unprognostic (1.19e-10)"	"unprognostic (6.27e-3)"	"unprognostic (4.00e-2)"	"unprognostic (2.76e-2)"	"unprognostic (4.75e-3)"	1.5	0.3	0.1	0.3	0.1	244.3	1.6	0.2	0.6	0.3	0.6	0.7	0.0	0.3	0.3	0.7	0.5	0.6	0.8	31.2	0.0	0.0	0.3	1.5	17.8	1.6	0.0	0.0	0.3	1.8	0.3	0.4	4.7	0.5	1.4	0.3	1.0	0.7	0.3	1.1	2.1	0.5	0.5	0.0	22.5	0.5	0.3	0.0	23.0	2.3	0.9	0.3	1.0	0.2	0.0	0.0	6.9	3.2	0.0	0.5	11.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	197.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	3.2	0.0	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	0.0	11.2	0.1	0.1	0.2	0.6	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	7.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	5.7	0.0	0.0	0.5	0.2	0.0	0.0	0.0	5.6	0.0	5.8	0.0	6.8	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	1.7	0.2	0.0	6.5	0.0	0.0	0.0	0.0
F10		ENSG00000126218	"Coagulation factor X"	P00742	13	113122814-113149529	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"liver: 116.7"	"Cell type enhanced"	"Detected in many"	12	"Hepatocytes: 174.9;Leydig cells: 199.9;Peritubular cells: 222.0"	"Cancer enriched"	"Detected in many"	11	"liver cancer: 95.4"	"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in single"		"MAIT T-cell: 1.0"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"BJ: 8.5;BJ hTERT+: 6.8;CACO-2: 7.2;fHDF/TERT166: 7.6;Hep G2: 33.5;HHSteC: 7.0;SH-SY5Y: 16.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"								"Secreted to blood"	NA	NA		16000000000				"unprognostic (4.18e-2)"	"unprognostic (1.07e-1)"	"unprognostic (7.62e-2)"	"unprognostic (9.88e-2)"	"unprognostic (9.44e-2)"	"unprognostic (1.15e-2)"	"unprognostic (4.90e-2)"	"unprognostic (1.02e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.24e-1)"	"prognostic favorable (1.82e-5)"	"unprognostic (6.39e-2)"	"prognostic unfavorable (5.14e-5)"	"unprognostic (6.60e-2)"	"unprognostic (1.21e-1)"	"unprognostic (3.87e-2)"	"unprognostic (2.23e-3)"	8.1	3.7	0.3	2.9	0.7	0.0	5.4	0.4	0.8	20.3	5.9	0.6	7.6	4.5	12.6	21.4	4.5	9.9	10.0	18.4	0.5	0.5	2.3	116.7	4.9	1.6	0.5	0.7	18.2	3.0	0.0	1.7	3.6	1.0	18.1	0.7	6.9	2.0	6.1	2.6	7.8	7.6	11.7	0.6	1.3	3.2	9.5	0.6	0.6	3.1	5.6	1.8	7.8	10.3	0.0	0.0	0.0	0.0	0.9	1.0	0.3	0.0	0.0	1.5	0.2	4.9	5.0	0.0	8.5	6.8	0.5	0.2	7.2	0.0	0.0	0.3	7.6	0.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	33.5	7.0	0.0	0.2	4.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.8	0.1	0.0	0.1	0.0	0.7	0.1	0.1	0.0	0.0	0.0	0.1	0.6	16.6	0.0	0.3	0.0	0.3	0.3	0.1	0.0	0.0	0.4	0.1	0.0	0.1	0.0	0.0	0.1	0.1	0.3	0.0	0.0	0.0	0.2	0.0	1.0	0.0	0.1	0.0	0.0	0.0	0.1	0.3	0.0	0.9	0.0	0.0	0.0	0.3	0.3	0.7	0.4	0.8	0.5	0.5	0.5	0.7	1.0	0.6	0.0	0.0	0.0	0.0	14.0	1.0	4.8	7.6	0.0	0.0	1.8	0.0	0.6	0.0	0.0	2.6	2.1	0.3	0.0	0.0	0.6	66.0	0.1	1.1	174.9	1.2	6.4	17.1	9.8	4.5	5.6	199.9	0.3	18.6	1.0	1.4	3.8	0.5	2.9	222.0	5.6	1.1	51.8	54.2	2.1	1.1	13.4	0.9	2.5	0.9	0.2
F11	FXI	ENSG00000088926	"Coagulation factor XI"	P03951	4	186265945-186288806	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Heparin-binding, Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"liver: 88.9"	"Cell type enhanced"	"Detected in some"	27	"Alveolar cells type 2: 19.3;Distal tubular cells: 10.0;Hepatocytes: 59.9"	"Cancer enriched"	"Detected in some"	13	"liver cancer: 16.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	11	"Hep G2: 14.0"	"Not detected"	"Not detected"							HPA039808			Approved	Vesicles	"Secreted to blood"	NA	NA		4400000000	Vesicles		"HPA039808: AB_2676693"			"unprognostic (1.28e-1)"		"unprognostic (3.15e-1)"		"prognostic favorable (3.29e-5)"	"unprognostic (1.88e-1)"			"unprognostic (2.08e-1)"	"unprognostic (2.11e-1)"	"unprognostic (1.85e-3)"	"unprognostic (2.91e-2)"	"unprognostic (7.65e-2)"			0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.3	2.7	0.1	0.1	5.5	0.2	0.3	0.1	0.1	4.8	0.1	0.1	0.1	10.2	88.9	2.8	0.1	0.1	0.1	0.1	19.0	0.0	0.2	0.1	0.3	0.1	0.0	0.4	0.1	0.1	0.1	0.1	6.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	14.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.1	0.4	0.2	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.2	0.0	19.3	0.0	0.0	0.0	0.0	0.3	2.5	0.0	4.5	1.8	0.0	0.0	10.0	0.8	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	59.9	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.3	0.0	0.0	4.7	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
F12		ENSG00000131187	"Coagulation factor XII"	P00748	5	177402140-177409576	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	26	"liver: 180.1"	"Cell type enriched"	"Detected in many"	8	"Hepatocytes: 391.6"	"Cancer enriched"	"Detected in many"	21	"liver cancer: 171.0"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"classical monocyte: 2.5;eosinophil: 6.9"	"Group enriched"	"Detected in many"	5	"granulocytes: 6.9;monocytes: 2.5"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 8.7;MCF7: 11.1;PC-3: 8.2;SH-SY5Y: 5.6;U-937: 5.8"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			HPA003825	Approved				"Secreted to blood"	NA	NA	1040000	6600000000			"HPA003825: AB_1078790"	"unprognostic (9.75e-2)"	"unprognostic (1.71e-1)"	"unprognostic (2.93e-1)"	"unprognostic (4.47e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.32e-1)"	"prognostic favorable (4.63e-5)"	"unprognostic (6.97e-2)"	"unprognostic (1.26e-2)"	"unprognostic (3.96e-2)"	"unprognostic (4.41e-1)"	"unprognostic (6.54e-2)"	"prognostic unfavorable (7.09e-4)"	"unprognostic (4.11e-2)"	"unprognostic (3.69e-1)"	"unprognostic (3.40e-6)"	"unprognostic (6.48e-2)"	0.1	0.0	0.1	0.1	0.1	0.7	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.1	0.1	0.1	0.1	0.2	180.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.5	1.0	6.9	2.5	0.7	0.3	1.0	0.8	2.0	0.0	0.6	0.0	0.0	0.2	0.0	0.1	0.0	0.0	2.3	1.4	0.0	0.4	0.0	0.3	1.4	0.7	0.4	0.0	8.7	1.9	1.4	0.3	0.9	0.2	0.7	3.1	0.2	1.3	0.1	0.4	0.1	0.2	2.1	0.4	3.3	0.0	11.1	0.1	2.6	0.0	2.6	8.2	0.6	0.2	1.9	1.1	0.0	2.6	5.6	0.3	1.0	0.7	0.0	0.4	0.0	0.0	0.2	1.1	0.0	0.3	0.5	0.0	0.1	0.1	5.8	0.6	0.0	2.5	6.9	0.3	0.1	0.2	0.5	0.3	0.2	0.1	0.2	0.0	0.1	0.9	0.7	0.9	1.0	0.0	1.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	8.5	7.4	29.5	0.4	0.8	17.8	0.0	0.0	1.8	3.9	0.0	0.0	6.1	19.4	0.7	34.8	0.0	3.5	0.2	0.9	2.0	0.0	391.6	0.5	0.0	9.9	17.8	13.2	32.7	0.6	1.8	8.5	1.0	5.5	0.2	9.4	20.1	0.0	9.1	0.5	0.0	0.7	13.0	12.8	47.4	0.1	0.7	30.8	5.8
F13A1	F13A	ENSG00000124491	"Coagulation factor XIII A chain"	P00488	6	6144085-6321013	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Acyltransferase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 110.1"	"Cell type enriched"	"Detected in many"	6	"Hofbauer cells: 646.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 27.6;myeloid DC: 33.7"	"Group enriched"	"Detected in many"	5	"dendritic cells: 33.7;monocytes: 27.6"	"Cell line enhanced"	"Detected in some"		"AF22: 15.7;LHCN-M2: 5.8;RH-30: 29.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"HPA001804, CAB002155"	Enhanced				"Secreted to blood"	NA	NA		1400000000			"CAB002155: AB_564077, HPA001804: AB_1078792"	"unprognostic (4.44e-1)"	"unprognostic (5.90e-2)"	"unprognostic (2.65e-2)"	"unprognostic (3.93e-2)"	"unprognostic (5.02e-2)"	"unprognostic (3.75e-2)"	"unprognostic (5.27e-2)"	"unprognostic (1.96e-1)"	"unprognostic (2.68e-2)"	"unprognostic (6.84e-3)"	"unprognostic (4.96e-2)"	"unprognostic (1.97e-1)"	"prognostic unfavorable (6.61e-6)"	"unprognostic (2.79e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.57e-1)"	"unprognostic (2.54e-3)"	56.6	19.4	2.2	11.4	6.5	3.1	57.9	2.2	1.8	13.3	21.8	2.6	2.5	2.2	4.7	35.6	13.4	16.8	12.6	55.4	2.0	2.2	17.5	1.3	14.5	52.7	5.8	1.4	10.2	8.9	5.3	9.3	110.1	7.5	16.4	15.1	11.6	11.5	3.3	18.5	10.4	10.6	20.1	5.0	5.1	11.5	16.7	2.5	2.7	22.4	8.3	6.1	23.7	6.5	0.0	33.7	6.6	27.6	0.0	0.1	63.5	0.0	0.0	15.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	5.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	29.5	0.5	0.0	0.0	0.2	0.2	0.1	0.0	0.0	0.1	0.0	2.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	5.7	27.6	0.2	0.1	4.9	0.1	0.0	0.0	0.0	33.7	0.0	0.0	0.0	6.6	0.0	0.1	2.4	0.0	63.5	2.2	6.5	2.2	1.8	2.0	2.2	5.8	1.4	7.5	2.5	0.0	3.4	0.8	0.0	16.7	0.0	7.5	10.2	4.0	0.0	0.0	0.0	4.0	0.0	0.0	3.8	4.7	0.0	0.0	0.0	3.4	16.5	0.0	1.1	0.8	646.4	0.0	0.0	4.3	113.2	4.2	4.0	57.6	18.6	1.0	0.0	0.7	0.1	0.0	0.7	3.1	4.1	58.2	9.2	1.4	1.0	13.2	8.5	0.0	0.0	0.0
F2		ENSG00000180210	"Coagulation factor II, thrombin"	P00734	11	46719180-46739506	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	593	"liver: 324.8"	"Cell type enriched"	"Detected in some"	37	"Hepatocytes: 904.6"	"Cancer enriched"	"Detected in some"	110	"liver cancer: 508.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	21	"Hep G2: 78.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB016780, HPA051476, HPA054698"	Enhanced				"Secreted to blood"	NA	NA	108000000000	43000000000			"CAB016780: , HPA051476: AB_2681498, HPA054698: AB_2682578"	"unprognostic (1.98e-1)"	"unprognostic (2.52e-1)"	"unprognostic (2.64e-2)"	"unprognostic (1.85e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.81e-1)"	"unprognostic (2.23e-2)"	"unprognostic (3.94e-2)"		"unprognostic (5.79e-2)"	"unprognostic (8.29e-2)"	"unprognostic (4.46e-2)"	"prognostic unfavorable (6.75e-12)"	"unprognostic (5.65e-3)"	"unprognostic (5.80e-2)"		"unprognostic (1.54e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	324.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.1	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	78.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.5	0.0	0.5	0.0	0.1	0.4	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	0.6	22.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	904.6	0.0	0.0	0.0	24.5	19.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0
F3	"CD142, TF"	ENSG00000117525	"Coagulation factor III, tissue factor"	P13726	1	94529225-94541800	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"		"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	12	"Basal glandular cells: 636.0;Exocrine glandular cells: 410.4;Muller glia cells: 389.7;Pancreatic endocrine cells: 1078.7;Peritubular cells: 498.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.8"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"A-431: 117.4;HaCaT: 55.6;HBEC3-KT: 144.4;U-2197: 54.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009438, HPA049292, HPA069132"	Uncertain		Approved	Vesicles	"Secreted to blood"	NA	NA	603000		Vesicles		"CAB009438: AB_668005, HPA049292: AB_2680701, HPA069132: AB_2686092"	"unprognostic (3.86e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.04e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.23e-3)"	"unprognostic (4.93e-2)"	"unprognostic (8.00e-2)"	"unprognostic (5.88e-1)"	"unprognostic (1.35e-1)"	"prognostic unfavorable (1.07e-4)"	"unprognostic (1.25e-1)"	"prognostic unfavorable (2.02e-8)"	"unprognostic (4.84e-2)"	"unprognostic (4.08e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.08e-1)"	45.5	9.8	27.0	14.1	42.9	2.1	55.1	3.4	27.9	14.8	18.7	20.9	18.7	18.3	30.5	23.7	21.3	25.4	30.9	18.8	26.9	14.5	6.6	2.8	31.4	5.8	14.1	20.3	41.6	35.0	6.1	28.8	65.4	39.2	29.7	22.2	49.9	29.2	33.0	2.4	17.7	19.2	5.9	46.3	2.9	18.2	16.4	16.0	0.0	21.8	17.3	11.9	24.7	22.3	0.5	0.9	2.8	0.8	0.7	0.4	0.2	117.4	0.2	0.2	0.0	12.8	6.3	6.6	16.7	10.0	18.1	19.7	2.1	25.2	0.0	8.6	20.7	3.9	55.6	1.5	144.4	29.9	0.1	0.1	0.0	3.6	0.3	4.2	0.0	0.0	10.9	3.2	8.5	41.9	34.4	0.1	0.1	0.1	0.1	12.6	0.2	0.1	2.4	1.1	0.7	0.2	0.1	1.2	0.0	2.2	0.3	0.1	0.3	13.3	5.5	0.4	3.6	0.1	1.6	0.0	11.0	0.3	54.8	5.0	0.1	0.1	0.1	8.4	0.6	0.4	1.7	0.8	0.1	0.3	0.3	0.4	0.2	0.3	0.2	0.2	0.5	0.3	0.3	2.8	0.7	0.2	0.9	0.2	0.2	27.0	42.9	3.4	27.1	26.9	14.5	14.1	20.3	39.2	16.0	122.1	188.9	0.5	636.0	14.4	1.5	21.1	7.6	72.3	238.8	14.0	0.0	13.6	0.0	120.9	5.6	10.5	10.3	0.0	410.4	4.8	48.3	85.3	2.3	0.6	5.4	3.2	12.6	12.3	4.0	9.8	260.4	4.9	3.3	3.6	40.9	389.7	1078.7	11.0	498.9	0.3	13.3	6.5	7.2	1.1	3.4	6.6	6.4	0.8	9.5	358.5
F5		ENSG00000198734	"Coagulation factor V"	P12259	1	169514166-169586588	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"		"Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 27.9;liver: 88.8;placenta: 32.2"	"Cell type enhanced"	"Detected in many"	22	"Cholangiocytes: 79.0;Cytotrophoblasts: 65.0;Hepatocytes: 221.3;Syncytiotrophoblasts: 49.8"	"Cancer enriched"	"Detected in many"	7	"liver cancer: 69.6"	"Region enriched"	"Detected in many"	11	"pons and medulla: 27.9"	"Cell type enhanced"	"Detected in some"		"eosinophil: 8.7;neutrophil: 8.0"	"Group enriched"	"Detected in many"	13	"granulocytes: 8.7;monocytes: 4.2;T-cells: 7.0"	"Group enriched"	"Detected in some"	23	"Hep G2: 13.8;OE19: 52.9"	"Group enriched"	"Detected in many"	5	"basal ganglia: 2.8;hippocampal formation: 7.4;pons and medulla: 4.6;thalamus: 5.8"	"Group enriched"	"Detected in many"	7	"amygdala: 59.9;basal ganglia: 33.8;cerebral cortex: 88.3;hippocampal formation: 79.2;olfactory region: 58.9"	HPA002036			Approved	"Golgi apparatus"	"Secreted to blood"	NA	NA	7670000000	13000000000	"Golgi apparatus"		"HPA002036: AB_1078787"	"unprognostic (3.67e-2)"	"unprognostic (2.77e-4)"	"unprognostic (5.42e-2)"	"unprognostic (2.56e-4)"	"unprognostic (2.03e-1)"	"unprognostic (2.39e-4)"	"unprognostic (3.46e-3)"	"unprognostic (9.25e-3)"	"unprognostic (2.02e-1)"	"unprognostic (8.99e-3)"	"unprognostic (6.55e-3)"	"unprognostic (1.32e-1)"	"unprognostic (2.01e-2)"	"prognostic unfavorable (3.39e-4)"	"unprognostic (7.15e-2)"	"unprognostic (3.41e-1)"	"unprognostic (4.31e-1)"	1.1	0.4	0.4	1.4	0.5	1.5	0.8	1.0	0.4	0.4	0.4	6.7	0.0	0.5	0.4	2.2	0.4	1.6	14.1	13.9	2.5	0.5	1.2	88.8	1.1	1.1	1.4	0.1	0.4	1.3	0.1	2.0	32.2	27.9	1.0	0.4	17.8	4.4	0.1	0.4	1.3	0.5	0.5	2.6	1.9	2.2	0.7	1.1	0.0	0.7	0.2	2.6	1.5	0.4	0.0	0.5	8.7	4.2	0.0	7.0	1.1	0.0	0.2	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.8	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	52.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	4.2	8.7	0.0	0.2	0.0	0.0	1.7	0.2	0.5	0.0	0.3	0.0	8.0	0.0	0.0	0.0	7.0	1.1	0.4	0.5	1.0	0.4	2.5	0.5	1.4	0.1	27.9	1.1	3.0	1.1	0.0	4.4	0.1	0.1	8.6	79.0	5.3	3.4	0.0	2.0	65.0	0.0	1.6	0.7	1.0	0.0	0.0	0.2	1.6	7.7	0.3	0.0	221.3	4.7	0.0	24.2	3.1	18.7	0.0	0.0	0.2	3.3	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	49.8	1.3	0.0	9.0
F7		ENSG00000057593	"Coagulation factor VII"	P08709	13	113105788-113120681	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	39	"liver: 68.0"	"Cell type enriched"	"Detected in some"	6	"Hepatocytes: 131.2"	"Cancer enriched"	"Detected in some"	17	"liver cancer: 41.4"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	15	"gdT-cell: 1.7;MAIT T-cell: 1.2;memory CD8 T-cell: 1.6"	"Lineage enriched"	"Detected in single"	17	"T-cells: 1.7"	"Group enriched"	"Detected in some"	9	"CACO-2: 16.6;Hep G2: 10.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA004826			Approved	Mitochondria	"Secreted to blood"	NA	NA	351000000	1500000000	Mitochondria		"HPA004826: AB_10602805"	"unprognostic (2.06e-1)"	"unprognostic (2.55e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.34e-1)"	"unprognostic (3.27e-1)"	"unprognostic (1.91e-1)"	"unprognostic (1.50e-3)"	"unprognostic (3.81e-1)"	"unprognostic (4.36e-3)"	"unprognostic (1.16e-1)"	"unprognostic (4.19e-3)"	"unprognostic (1.15e-1)"	"unprognostic (1.35e-3)"	"unprognostic (3.36e-3)"	"unprognostic (1.09e-1)"	"unprognostic (2.86e-1)"	"unprognostic (1.47e-1)"	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.2	0.4	0.2	0.1	0.1	0.1	0.3	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	68.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.0	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	1.7	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	16.6	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	10.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.7	0.0	1.2	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	2.4	0.0	0.0	0.6	0.4	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.3	0.2	0.0	0.5	0.0	0.0	131.2	0.1	0.0	0.0	3.7	3.1	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.1	0.1	0.0	0.1	0.1	0.9	0.1	0.1	0.5	0.0	0.0
F8	"DXS1253E, F8C, FVIII, HEMA"	ENSG00000185010	"Coagulation factor VIII"	P00451	X	154835788-155026940	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Blood coagulation, Hemostasis"		"Disease mutation, FDA approved drug targets, Hemophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	11	"Ito cells: 376.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-2197: 15.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			CAB018777	Enhanced				"Secreted to blood"	NA	NA		6400000			"CAB018777: AB_640320"	"unprognostic (2.09e-1)"	"unprognostic (5.66e-4)"	"unprognostic (4.94e-2)"	"unprognostic (8.32e-5)"	"unprognostic (1.26e-1)"	"unprognostic (5.05e-2)"	"unprognostic (6.05e-2)"	"unprognostic (8.27e-2)"	"unprognostic (6.58e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.67e-2)"	"unprognostic (5.58e-2)"	"unprognostic (1.24e-2)"	"unprognostic (2.16e-3)"	"unprognostic (1.69e-1)"	"unprognostic (1.17e-2)"	"unprognostic (4.44e-2)"	48.9	9.4	6.8	3.1	7.2	1.5	32.2	1.5	8.6	11.9	10.3	2.2	6.1	2.3	11.1	8.5	18.4	5.4	4.4	38.0	4.9	4.4	17.1	31.3	24.4	25.6	5.6	1.2	18.8	7.2	6.0	14.0	2.8	5.1	20.5	3.5	8.8	4.0	7.1	30.3	2.0	4.3	12.8	3.3	39.0	3.2	17.2	1.8	1.1	15.8	15.0	3.0	17.5	20.2	2.3	3.0	5.2	3.3	4.0	12.9	2.7	4.8	3.9	0.8	1.8	6.1	9.6	0.2	2.6	1.7	1.9	3.1	0.1	5.8	10.4	7.3	2.7	4.2	0.5	0.9	0.9	1.7	4.2	1.5	2.2	2.0	0.0	2.9	1.7	5.0	6.8	0.5	1.6	2.2	3.3	1.1	5.1	0.8	8.0	9.1	2.3	1.4	1.6	1.2	1.5	4.0	1.2	1.3	1.4	1.7	1.1	3.2	2.4	6.3	0.6	3.3	1.0	1.4	4.3	1.1	9.5	4.8	15.0	2.8	4.7	3.9	5.0	8.7	10.8	5.0	3.7	3.3	0.5	6.5	2.8	12.9	2.3	3.9	6.8	3.0	1.6	2.0	5.1	5.2	4.0	2.6	0.4	5.2	2.7	6.8	7.2	1.5	8.6	4.9	4.4	5.6	1.2	5.1	1.8	0.0	4.6	2.2	1.5	1.5	7.9	14.6	12.7	2.7	2.3	3.5	2.0	0.9	6.6	2.3	0.9	33.2	0.5	0.0	0.6	0.7	2.8	1.7	1.1	9.2	2.9	6.4	0.0	376.3	25.4	1.9	10.6	3.2	0.0	1.8	0.7	6.5	6.9	0.0	4.9	8.4	3.3	6.5	3.3	1.6	2.5	1.0	0.1	4.9	0.4	0.9
F9	FIX	ENSG00000101981	"Coagulation factor IX"	P00740	X	139530758-139563458	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets, Hemophilia, Thrombophilia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	2334	"liver: 233.6"	"Cell type enriched"	"Detected in some"	20	"Hepatocytes: 475.1"	"Cancer enriched"	"Detected in single"	1354	"liver cancer: 67.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HL-60: 1.8;RH-30: 2.0;SiHa: 1.6;U-698: 1.1"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"								"Secreted to blood"	NA	NA		11000000000										"prognostic favorable (6.69e-4)"											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	233.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.8	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	1.6	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.3	0.0	1.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	0.2	17.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.3	0.0	0.0	0.0	0.0	0.0	475.1	0.0	0.0	0.0	15.4	17.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCGR3A	"CD16, CD16a, FCG3, FCGR3"	ENSG00000203747	"Fc fragment of IgG receptor IIIa"	P08637	1	161541759-161550737	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 223.6;lymphoid tissue: 60.8"	"Cell type enhanced"	"Detected in many"	22	"Hofbauer cells: 191.4;Kupffer cells: 556.1;Macrophages: 266.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 109.4;non-classical monocyte: 223.6"	"Group enriched"	"Detected in many"	4	"granulocytes: 73.0;monocytes: 223.6"	"Cell line enhanced"	"Detected in some"		"BEWO: 1.0;HaCaT: 1.7;SH-SY5Y: 1.3;U-2197: 1.1;U-266/70: 1.8"									"CAB032435, HPA055431"	Supported				"Secreted to blood"	NA	NA		2500000000			"CAB032435: AB_626925, HPA055431: AB_2682815"	"unprognostic (5.27e-2)"	"unprognostic (9.95e-2)"	"unprognostic (2.37e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.82e-1)"	"unprognostic (2.24e-2)"	"unprognostic (6.06e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.98e-2)"	"unprognostic (7.52e-2)"	"prognostic unfavorable (3.22e-6)"	"unprognostic (1.14e-1)"	"unprognostic (4.66e-2)"	"unprognostic (1.03e-2)"	"unprognostic (7.51e-2)"	11.9	9.7	7.5	20.5	12.4	4.4	4.1	1.6	7.0	1.9	2.1	5.5	0.8	0.8	1.1	2.4	1.0	2.4	5.1	6.4	6.3	7.3	2.6	22.5	43.2	8.0	12.7	1.9	1.4	2.9	1.8	3.9	14.6	6.8	2.6	2.3	2.2	2.7	1.3	1.3	0.3	1.2	14.3	25.7	60.8	1.3	1.2	8.0	1.4	1.8	1.3	1.3	6.3	2.3	0.1	11.7	73.0	223.6	7.9	33.9	35.8	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.5	1.7	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.3	0.8	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.3	0.5	0.5	0.0	0.0	0.8	0.5	0.4	0.0	0.0	0.5	1.3	0.4	0.2	0.0	0.5	0.0	0.1	0.0	0.0	0.1	1.1	0.0	1.8	0.0	0.4	0.0	0.0	0.0	0.3	1.6	0.5	33.9	109.4	0.3	0.1	0.3	13.2	11.7	0.0	0.2	12.2	73.0	7.9	223.6	0.2	0.1	35.8	7.5	12.4	1.6	7.0	6.3	7.3	12.7	1.9	6.8	8.0	20.8	30.6	13.0	0.0	0.5	0.1	0.4	7.6	10.7	19.4	3.5	2.0	1.1	0.0	0.0	0.9	0.8	0.0	0.0	0.0	1.1	0.3	0.0	17.4	3.4	191.4	0.0	0.0	9.2	556.1	1.5	0.3	266.3	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.6	1.3	19.4	0.0	0.0	0.5	0.0	1.7	99.7	0.0	0.1
FCGR3B	"CD16, CD16b, FCG3, FCGR3"	ENSG00000162747	"Fc fragment of IgG receptor IIIb"	O75015	1	161623196-161631963	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	8	"blood: 334.5"	"Cell type enhanced"	"Detected in some"	19	"Alveolar cells type 1: 3.0;Alveolar cells type 2: 11.1;Ciliated cells: 4.0;Club cells: 5.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	95	"neutrophil: 334.5"	"Lineage enriched"	"Detected in many"	95	"granulocytes: 334.5"	"Cell line enhanced"	"Detected in single"		"K-562: 1.5"														"Secreted to blood"	NA	NA						"unprognostic (1.60e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.59e-3)"	"unprognostic (4.16e-2)"	"unprognostic (1.15e-1)"	"unprognostic (6.52e-2)"	"unprognostic (3.97e-2)"	"unprognostic (6.96e-3)"	"unprognostic (2.53e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.07e-1)"	"unprognostic (8.67e-2)"	"unprognostic (5.16e-2)"	"unprognostic (1.35e-1)"	"unprognostic (8.37e-3)"	"unprognostic (2.28e-1)"	"unprognostic (9.24e-2)"	9.9	0.8	1.8	30.8	1.5	13.8	1.5	0.9	1.8	0.9	0.8	0.5	0.2	0.0	0.4	0.5	1.7	2.8	6.8	4.6	1.2	0.9	0.9	2.9	15.2	16.9	5.0	0.5	1.2	1.2	0.0	0.6	4.5	1.9	1.5	0.0	1.3	0.9	0.9	0.8	1.4	0.8	2.0	4.0	44.3	1.3	1.5	0.9	0.6	0.8	0.2	0.9	11.1	4.7	0.0	0.1	334.5	3.5	0.1	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.4	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.4	0.0	0.3	0.0	0.0	0.0	0.5	0.5	1.2	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.1	334.5	0.1	3.5	0.0	0.0	0.5	1.8	1.5	0.9	1.8	1.2	0.9	5.0	0.5	1.9	0.9	3.0	11.1	0.0	0.0	0.0	0.0	0.3	0.0	4.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.8	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.0	0.0	0.0
FGA		ENSG00000171560	"Fibrinogen alpha chain"	P02671	4	154583126-154590766	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity"		"Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	740	"liver: 2009.3"	"Cell type enriched"	"Detected in many"	40	"Hepatocytes: 16694.6"	"Cancer enriched"	"Detected in many"	43	"liver cancer: 2431.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	15	"Hep G2: 96.9"	"Not detected"	"Not detected"							"CAB016776, HPA051370, HPA064755"	Supported		Approved	"Endoplasmic reticulum"	"Secreted to blood"	NA	NA	407000000	170000000000	"Endoplasmic reticulum"		"CAB016776: , HPA051370: AB_2681458, HPA064755: AB_2685345"		"unprognostic (5.95e-2)"	"unprognostic (6.25e-2)"	"unprognostic (2.02e-1)"		"unprognostic (5.68e-2)"	"prognostic favorable (7.33e-4)"	"unprognostic (1.29e-3)"			"unprognostic (1.84e-1)"		"prognostic unfavorable (4.23e-6)"	"unprognostic (4.20e-1)"	"unprognostic (1.41e-1)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	2.7	2009.3	0.1	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	96.9	0.0	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	1.4	0.0	0.0	0.1	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	24.4	83.9	0.0	0.0	0.0	0.4	420.4	17.4	5.7	0.0	0.0	0.0	1.7	5.5	23.9	0.0	0.0	256.9	1.5	0.0	0.0	0.0	0.0	16694.6	0.1	0.0	0.0	255.3	257.1	29.3	0.6	0.0	0.0	0.0	0.0	0.0	31.5	0.0	1.1	1.0	0.0	0.0	0.0	14.4	0.6	0.0	0.1	4.3	0.0	0.0
FGB		ENSG00000171564	"Fibrinogen beta chain"	P02675	4	154562956-154571086	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity"		"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	189	"liver: 1908.6"	"Cell type enriched"	"Detected in some"	33	"Hepatocytes: 15347.2"	"Cancer enriched"	"Detected in many"	42	"liver cancer: 2262.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	12	"Hep G2: 77.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA001900, HPA001901, CAB008624"	Enhanced		Enhanced	"Endoplasmic reticulum"	"Secreted to blood"	NA	NA		120000000000	"Endoplasmic reticulum"		"CAB008624: AB_1615610, HPA001900: AB_1078865, HPA001901: AB_1078864"	"unprognostic (1.16e-1)"	"unprognostic (3.89e-2)"	"unprognostic (4.65e-2)"	"unprognostic (3.44e-1)"			"unprognostic (2.20e-3)"	"unprognostic (1.42e-2)"			"unprognostic (1.79e-1)"		"prognostic unfavorable (5.72e-5)"	"unprognostic (2.48e-2)"	"unprognostic (7.91e-2)"			0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	10.1	1908.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	77.7	0.0	1.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.2	0.0	0.7	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.4	153.8	0.0	0.0	0.0	0.4	257.4	0.0	0.0	3.5	0.0	0.0	1.7	3.0	0.4	0.0	0.0	467.2	3.2	0.1	0.0	0.0	0.0	15347.2	0.3	0.0	1.7	349.9	342.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	19.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.8	0.0	0.0
FGF1	"AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1"	ENSG00000113578	"Fibroblast growth factor 1"	P05230	5	142592178-142698070	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"brain: 65.0;heart muscle: 35.5;kidney: 41.5"	"Cell type enhanced"	"Detected in some"	18	"Cardiomyocytes: 49.6;Collecting duct cells: 19.2;Cone photoreceptor cells: 15.7;Muller glia cells: 68.6"	"Cancer enriched"	"Detected in many"	12	"glioma: 33.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BJ: 19.8;BJ hTERT+: 14.8;BJ hTERT+ SV40 Large T+: 16.3;BJ hTERT+ SV40 Large T+ RasG12V: 20.6;HBF TERT88: 29.5;hTEC/SVTERT24-B: 20.6;LHCN-M2: 13.7;U-2 OS: 14.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003265, CAB017519"	Enhanced		Supported	Nucleoplasm	"Secreted in other tissues"	NA	NA			Nucleoplasm		"CAB017519: AB_629473, HPA003265: AB_1848522"	"unprognostic (1.25e-2)"	"unprognostic (2.43e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.41e-3)"	"unprognostic (2.55e-2)"	"unprognostic (3.52e-1)"	"unprognostic (2.77e-1)"	"unprognostic (2.39e-1)"	"unprognostic (3.63e-1)"	"unprognostic (1.57e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.54e-1)"	"prognostic favorable (2.59e-5)"	"unprognostic (3.72e-4)"	"unprognostic (2.49e-1)"	"prognostic favorable (3.45e-5)"	"unprognostic (3.01e-4)"	7.3	3.5	44.2	2.0	43.1	1.5	9.7	10.5	59.9	1.8	1.7	65.0	0.0	1.6	3.1	8.7	2.3	2.1	2.7	35.5	47.4	33.0	41.5	2.0	2.9	1.4	62.6	13.8	1.5	1.4	3.4	1.6	2.3	36.3	2.2	1.8	0.8	5.8	2.6	2.3	2.0	1.7	2.6	57.7	5.5	1.1	2.2	48.6	0.0	4.9	0.8	2.2	1.7	0.4	1.2	1.0	1.8	0.6	0.1	2.3	0.2	2.4	0.1	0.1	0.7	0.5	1.5	0.8	19.8	14.8	16.3	20.6	0.1	0.1	0.5	1.4	6.8	0.9	0.3	0.0	1.5	29.5	0.1	0.0	0.0	0.3	0.1	0.3	0.0	0.2	0.7	0.5	20.6	1.2	4.4	0.0	0.1	0.0	0.7	13.7	0.3	0.0	0.4	0.6	0.0	0.6	0.1	0.7	0.2	0.6	0.1	0.5	1.0	0.0	0.4	0.2	3.9	0.0	0.1	0.4	2.6	14.7	0.3	9.3	0.3	0.1	0.1	3.7	0.1	0.7	0.3	0.3	1.8	2.3	0.1	1.8	0.4	0.8	0.9	0.2	1.2	0.9	1.9	1.7	0.1	0.6	1.0	0.5	0.2	44.2	43.1	10.5	22.6	47.4	33.0	62.6	13.8	36.3	48.6	0.0	0.0	0.0	3.4	0.3	1.6	49.6	0.0	0.0	3.4	19.2	15.7	0.5	0.0	0.6	0.3	0.0	0.0	0.0	0.0	0.4	1.8	1.4	0.0	0.0	0.1	0.0	0.0	1.8	0.0	0.4	0.0	0.0	3.3	0.0	0.0	68.6	0.7	0.0	0.4	0.0	9.6	6.5	4.7	0.0	0.1	0.0	0.7	0.0	0.0	0.3
FGF2	FGFB	ENSG00000138685	"Fibroblast growth factor 2"	P09038	4	122826708-122898236	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins, Transporters"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	5	"Fibroblasts: 12.4;Smooth muscle cells: 15.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"BJ: 57.4;BJ hTERT+: 33.7;fHDF/TERT166: 62.3;hTERT-HME1: 34.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000125, HPA065502"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies"	"Secreted in other tissues"	NA	NA	92500		"Nucleoplasm, Nuclear bodies"		"CAB000125: , HPA065502: "	"unprognostic (1.53e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.08e-1)"	"unprognostic (7.42e-2)"	"unprognostic (2.10e-1)"	"unprognostic (3.33e-1)"	"unprognostic (6.98e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.82e-1)"	"unprognostic (1.79e-1)"	"prognostic unfavorable (9.85e-4)"	"unprognostic (3.37e-1)"	"unprognostic (4.61e-3)"	"unprognostic (2.36e-1)"	"unprognostic (1.81e-1)"	"unprognostic (4.45e-2)"	"unprognostic (3.45e-3)"	28.1	3.8	19.4	6.9	21.3	0.7	12.1	6.5	15.3	10.2	14.2	10.3	1.9	2.6	17.9	6.3	6.4	10.1	9.4	5.6	17.1	11.0	5.5	2.9	8.3	2.5	9.9	10.7	16.8	2.4	10.1	4.0	8.1	18.6	10.3	5.6	7.5	4.6	11.9	2.0	2.3	4.1	16.2	17.3	1.9	7.6	3.0	12.3	0.0	3.1	3.8	2.7	7.5	14.5	0.8	0.8	0.5	0.5	0.3	1.0	0.0	1.2	3.1	1.8	6.9	4.4	7.4	0.0	57.4	33.7	24.1	14.0	0.0	0.1	0.0	6.7	62.3	19.0	0.2	1.8	0.1	24.3	4.5	0.8	0.0	6.5	0.0	13.0	0.3	0.0	3.9	0.4	23.8	34.4	12.1	2.6	0.0	1.7	1.9	6.2	0.0	0.0	0.0	5.2	0.0	1.4	0.0	0.9	0.0	7.6	0.0	1.0	0.9	11.1	0.0	0.4	10.8	0.0	0.1	2.4	20.0	3.9	7.4	4.9	3.4	3.6	0.0	5.7	0.0	2.1	0.5	0.5	0.4	0.3	0.4	0.2	0.4	0.5	0.4	0.2	0.8	0.7	1.0	0.4	0.3	0.4	0.8	0.7	0.0	19.4	21.3	6.5	15.3	17.1	11.0	9.9	10.7	18.6	12.3	6.0	0.0	0.0	1.5	1.4	3.5	3.9	0.0	0.0	2.3	7.0	0.0	1.8	3.3	6.9	8.7	5.8	0.0	0.0	0.8	0.0	12.4	5.2	0.0	0.4	0.4	0.0	1.7	7.4	0.0	2.5	9.2	0.9	5.0	1.0	0.0	8.4	6.7	0.0	7.8	0.4	1.8	0.0	15.5	3.1	0.2	1.1	4.0	0.0	0.0	0.3
FGFR2	"BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25"	ENSG00000066468	"Fibroblast growth factor receptor 2"	P21802	10	121478334-121598458	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Apoptosis	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 74.8"	"Cell type enhanced"	"Detected in many"	16	"Cholangiocytes: 191.1;Club cells: 52.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	15	"basophil: 10.8;eosinophil: 4.6"	"Lineage enriched"	"Detected in single"	35	"granulocytes: 10.8"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 58.9;BEWO: 19.8;CACO-2: 15.4;HaCaT: 17.8;HAP1: 19.1;NTERA-2: 18.9;T-47d: 15.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010886, HPA035305"	Uncertain		Supported	"Nucleoplasm,Vesicles,Cell Junctions"	"Secreted - unknown location"	NA	NA		500000	"Cell Junctions"	"Nucleoplasm, Vesicles"	"CAB010886: AB_259379, HPA035305: AB_10672862"	"unprognostic (5.53e-2)"	"prognostic favorable (8.79e-4)"	"unprognostic (1.08e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.73e-1)"	"prognostic favorable (9.32e-4)"	"unprognostic (1.53e-1)"	"unprognostic (4.96e-3)"	"unprognostic (1.74e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.74e-2)"	"unprognostic (1.01e-1)"	"unprognostic (6.11e-2)"	"unprognostic (2.54e-1)"	"unprognostic (6.93e-2)"	"unprognostic (2.25e-1)"	2.1	8.8	16.4	3.0	30.3	0.0	9.9	15.8	21.3	6.8	14.1	55.7	5.6	4.2	22.0	6.6	10.2	12.5	12.5	1.4	20.6	11.1	11.4	16.1	13.1	1.0	41.2	13.3	7.4	12.8	25.5	2.5	6.2	30.2	11.7	8.7	16.4	23.8	24.3	0.4	45.4	4.7	18.3	74.8	0.5	9.3	2.9	32.1	0.8	23.4	1.6	3.4	6.9	8.5	0.1	0.1	10.8	0.1	0.1	0.3	0.0	2.2	0.1	9.2	58.9	0.0	0.0	19.8	0.1	0.0	0.0	0.0	15.4	0.3	0.0	4.2	0.9	0.0	17.8	19.1	4.0	0.0	0.0	4.1	0.0	0.0	0.3	0.4	0.0	3.8	0.0	8.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	18.9	2.7	0.0	0.0	0.0	2.3	5.7	5.0	0.1	0.1	0.1	10.8	0.0	11.5	15.8	0.0	0.0	0.1	2.9	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	10.8	0.1	4.6	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.1	0.5	0.1	0.0	0.1	0.0	0.0	16.4	30.3	15.8	21.3	20.6	11.1	41.2	13.3	30.2	32.1	17.9	31.8	0.0	29.5	35.6	0.0	2.7	191.1	18.7	52.4	34.9	0.0	12.6	0.0	4.0	2.9	0.5	2.6	0.0	0.2	2.7	17.5	9.8	0.0	4.3	2.0	0.0	2.4	3.1	0.3	6.5	1.1	1.3	5.0	1.0	32.0	1.6	0.6	1.4	5.6	11.5	0.1	0.0	2.1	0.9	7.7	24.2	3.3	1.5	3.0	27.7
FLT1	"FLT, VEGFR1"	ENSG00000102755	"Fms related tyrosine kinase 1"	P17948	13	28300344-28495145	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Chemotaxis, Differentiation"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	8	"placenta: 155.3"	"Cell type enhanced"	"Detected in many"	16	"Extravillous trophoblasts: 778.4;Ito cells: 284.2;Syncytiotrophoblasts: 942.6"	"Cancer enhanced"	"Detected in all"		"renal cancer: 28.7"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"memory B-cell: 1.1;naive B-cell: 3.7;neutrophil: 2.1"	"Group enriched"	"Detected in many"	5	"B-cells: 3.7;granulocytes: 2.1"	"Cell line enhanced"	"Detected in some"		"BJ: 17.4;BJ hTERT+: 13.8;HMC-1: 86.4;HUVEC TERT2: 15.6;WM-115: 31.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011740, HPA014290, CAB068189, CAB068190"	Enhanced		Supported	"Plasma membrane,Actin filaments"	"Secreted to blood"	NA	NA	876000	54000	"Plasma membrane"	"Actin filaments"	"CAB068189: AB_2665636, CAB068190: AB_2665637, HPA011740: AB_1858737, HPA014290: AB_1858738"	"unprognostic (3.33e-2)"	"unprognostic (3.52e-3)"	"unprognostic (1.13e-3)"	"unprognostic (5.02e-2)"	"unprognostic (3.65e-1)"	"unprognostic (5.03e-2)"	"unprognostic (8.25e-2)"	"unprognostic (2.27e-3)"	"unprognostic (9.91e-2)"	"unprognostic (6.61e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.57e-1)"	"prognostic unfavorable (2.19e-4)"	"unprognostic (4.20e-2)"	"unprognostic (6.00e-2)"	"unprognostic (1.57e-1)"	"unprognostic (6.32e-2)"	18.9	4.0	9.9	4.0	14.3	1.2	13.5	8.0	15.9	7.1	4.6	3.5	1.7	3.5	7.2	2.2	3.4	4.0	6.9	18.3	11.4	7.3	10.3	7.6	12.3	2.5	10.3	3.2	5.1	5.4	13.4	3.7	155.3	13.8	5.1	3.1	9.1	3.0	5.0	12.5	2.6	3.4	7.3	9.6	7.2	4.6	6.8	10.2	0.0	19.1	3.8	2.8	7.6	9.2	3.7	0.5	2.1	0.1	0.2	0.4	0.2	0.0	0.0	0.0	0.1	0.1	0.2	0.0	17.4	13.8	6.3	3.7	0.0	0.0	0.0	0.0	2.2	0.0	0.0	1.6	0.0	11.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	86.4	0.1	0.0	0.0	0.2	0.0	15.6	1.4	0.4	0.0	0.0	0.0	1.0	0.8	9.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	2.0	0.1	0.0	0.0	0.0	11.4	0.0	0.0	1.5	0.0	0.3	0.0	0.0	0.5	0.2	0.0	0.1	0.0	31.0	0.2	0.1	0.1	0.1	0.1	0.0	1.1	0.1	0.1	0.0	3.7	0.4	0.4	2.1	0.2	0.1	0.5	0.2	0.2	9.9	14.3	8.0	15.9	11.4	7.3	10.3	3.2	13.8	10.2	0.0	8.9	2.2	0.5	3.7	5.9	12.6	5.1	2.7	1.2	0.0	3.9	155.4	1.7	0.0	116.6	192.1	0.0	0.0	0.0	778.4	17.5	1.1	1.1	2.1	28.1	1.6	0.0	284.2	16.1	130.7	17.3	5.3	0.0	0.0	0.0	172.0	0.0	0.0	45.6	0.0	7.3	90.5	6.6	12.9	2.8	4.3	942.6	2.9	0.0	0.5
FLT4	"PCL, VEGFR3"	ENSG00000037280	"Fms related tyrosine kinase 4"	P35916	5	180601506-180649624	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 56.3"	"Group enriched"	"Detected in some"	5	"Extravillous trophoblasts: 31.7;Ito cells: 65.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	5	"MAIT T-cell: 7.7"	"Lineage enriched"	"Detected in single"	35	"T-cells: 7.7"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 8.3;BEWO: 10.1;HEK 293: 12.5;HUVEC TERT2: 8.1;JURKAT: 10.0;T-47d: 11.9;TIME: 12.6"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB000099, HPA046519, HPA067906, HPA074389"	Approved		Supported	"Nuclear speckles,Plasma membrane,Cell Junctions"	"Secreted to blood"	NA	NA		270000000	"Nuclear speckles, Plasma membrane"	"Cell Junctions"	"CAB000099: , HPA046519: AB_2732527, HPA067906: AB_2732775, HPA074389: "	"unprognostic (7.35e-2)"	"unprognostic (1.63e-1)"	"unprognostic (9.45e-3)"	"unprognostic (3.81e-1)"	"unprognostic (9.26e-2)"	"unprognostic (3.20e-3)"	"unprognostic (1.13e-2)"	"unprognostic (1.80e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.70e-1)"	"unprognostic (2.13e-2)"	"unprognostic (3.69e-1)"	"unprognostic (1.88e-2)"	"unprognostic (9.41e-3)"	"unprognostic (1.83e-1)"	"unprognostic (8.26e-2)"	"unprognostic (1.32e-1)"	14.8	7.1	1.6	4.9	6.0	0.7	28.5	1.3	2.7	6.3	7.3	1.9	2.1	3.1	7.3	6.2	5.7	9.2	5.3	6.4	1.7	0.9	11.7	10.2	14.1	23.6	2.0	0.8	5.8	2.3	2.3	6.2	56.3	2.1	4.9	1.4	6.7	3.3	4.4	4.8	2.8	4.7	4.7	1.5	14.5	2.4	3.5	2.0	0.3	19.4	4.4	2.3	6.1	14.7	0.0	0.1	0.2	0.0	0.0	7.7	0.2	0.1	2.0	2.7	8.3	0.0	0.0	10.1	0.2	0.1	0.0	0.0	0.3	0.3	0.2	0.8	0.1	0.5	0.3	2.8	0.1	0.2	0.1	12.5	1.0	0.4	0.4	0.1	7.4	0.2	0.2	0.0	0.1	0.3	0.3	8.1	10.0	0.3	0.3	1.7	4.5	0.1	0.4	5.8	0.2	0.5	6.5	0.0	0.1	0.1	0.2	0.2	0.9	0.1	0.2	0.0	2.7	11.9	0.2	12.6	0.1	5.9	0.2	0.1	0.2	0.1	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.9	0.0	7.7	0.0	0.4	1.6	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.2	1.6	6.0	1.3	2.7	1.7	0.9	2.0	0.8	2.1	2.0	0.0	1.7	0.9	0.2	0.8	0.0	4.5	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.0	0.2	9.2	0.0	0.0	0.0	31.7	0.6	0.2	2.3	0.4	1.1	0.0	0.0	65.1	5.7	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	4.3	1.0	0.8	0.7	0.0	0.1
FN1	"CIG, FINC, GFND2, LETS, MSF"	ENSG00000115414	"Fibronectin 1"	P02751	2	215360440-215436172	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Angiogenesis, Cell adhesion, Cell shape"	Heparin-binding	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ductus deferens: 235.4;placenta: 433.0"	"Cell type enhanced"	"Detected in many"	19	"Extravillous trophoblasts: 2156.8;Fibroblasts: 526.4;Hepatocytes: 963.3"	"Cancer enhanced"	"Detected in all"		"thyroid cancer: 833.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 845.3;HSkMC: 395.4;hTERT-HME1: 232.5;hTERT-RPE1: 257.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000126, HPA027066"	Enhanced				"Secreted to blood"	NA	NA		47000000000			"CAB000126: , HPA027066: AB_10602500"	"unprognostic (8.08e-2)"	"unprognostic (1.09e-3)"	"unprognostic (2.20e-2)"	"unprognostic (3.45e-3)"	"unprognostic (1.82e-2)"	"unprognostic (3.47e-3)"	"unprognostic (3.36e-2)"	"unprognostic (5.91e-3)"	"unprognostic (2.96e-2)"	"unprognostic (2.91e-3)"	"unprognostic (1.41e-2)"	"unprognostic (2.84e-1)"	"prognostic unfavorable (3.44e-8)"	"prognostic unfavorable (8.82e-5)"	"unprognostic (7.88e-2)"	"unprognostic (7.74e-2)"	"prognostic unfavorable (3.33e-4)"	20.2	4.5	3.1	13.0	5.2	0.2	13.1	2.2	4.3	21.9	57.1	4.4	235.4	3.5	25.1	27.5	37.4	26.5	20.9	57.3	3.9	2.9	5.8	166.3	81.5	7.9	4.6	5.0	16.9	3.3	1.7	3.5	433.0	6.1	17.1	25.1	5.1	10.4	141.2	9.8	7.0	13.5	114.9	4.6	1.9	21.8	9.0	2.7	9.4	5.4	17.4	2.6	64.7	16.9	0.2	0.8	0.0	0.6	0.0	0.3	0.0	0.2	1.9	2.6	0.5	107.3	845.3	0.1	43.6	29.1	44.2	31.4	26.4	1.0	0.0	0.2	144.9	1.2	4.5	0.4	99.3	23.8	0.0	0.1	0.0	0.6	82.3	77.6	0.0	0.1	395.4	0.6	104.4	232.5	257.3	51.2	0.0	0.1	0.1	88.0	0.3	0.0	0.0	1.3	0.0	0.3	0.0	0.0	0.1	1.1	0.3	0.1	0.6	5.2	2.7	28.3	119.4	0.4	0.0	98.1	63.9	6.8	70.0	8.0	0.1	0.0	0.0	76.0	0.0	16.6	0.0	0.6	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.3	0.0	0.0	0.0	0.8	0.0	0.0	3.1	5.2	2.2	4.3	3.9	2.9	4.6	5.0	6.1	2.7	62.5	83.1	7.8	3.5	48.9	5.1	27.2	35.7	24.1	28.4	15.7	0.0	51.6	0.0	4.9	1.5	166.7	0.0	0.0	8.1	2156.8	526.4	18.4	17.4	963.3	368.5	1.6	20.2	165.1	27.1	2.6	172.6	39.4	104.6	1.8	4.3	1.4	19.0	0.0	83.1	0.6	9.7	71.1	163.2	1.1	4.5	32.6	172.1	0.9	3.7	1.6
GHR	GHBP	ENSG00000112964	"Growth hormone receptor"	P10912	5	42423777-42721878	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"	Endocytosis	Receptor	"Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adipose tissue: 44.4;breast: 31.5;liver: 82.4;skeletal muscle: 23.4"	"Cell type enhanced"	"Detected in many"	19	"Hepatocytes: 103.6;Syncytiotrophoblasts: 33.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in some"	5	"HSkMC: 13.6;T-47d: 34.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045339, HPA057705"	Enhanced		Supported	"Plasma membrane,Cytosol,Cytoplasmic bodies"	"Secreted to blood"	NA	NA	2200000	21000000	"Plasma membrane, Cytosol, Cytoplasmic bodies"		"HPA045339: AB_2679294, HPA057705: AB_2683507"	"unprognostic (2.18e-2)"	"unprognostic (5.45e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.96e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.57e-1)"	"prognostic favorable (2.73e-6)"	"unprognostic (1.06e-1)"	"unprognostic (3.92e-2)"	"unprognostic (3.73e-2)"	"unprognostic (6.15e-3)"	"unprognostic (2.67e-2)"	"unprognostic (1.67e-3)"	"unprognostic (4.29e-4)"	"unprognostic (7.82e-2)"	"unprognostic (7.33e-4)"	"unprognostic (8.35e-6)"	44.4	2.8	0.7	5.4	1.3	0.3	31.5	0.4	1.4	4.0	6.9	0.5	1.7	0.6	5.7	3.9	2.4	2.5	3.9	6.0	1.3	1.6	5.3	82.4	2.3	2.2	1.2	1.4	5.0	1.3	3.6	2.0	4.0	2.0	8.7	2.5	2.4	2.3	7.4	23.4	3.0	2.4	5.2	1.0	2.6	3.5	1.6	0.2	0.1	2.9	4.3	0.5	3.8	8.4	0.6	0.3	1.8	0.5	0.4	0.3	0.1	0.0	0.0	0.3	3.1	2.1	0.5	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.1	2.6	0.0	0.0	1.6	0.0	0.0	0.0	0.4	0.0	0.0	13.6	4.4	0.0	0.6	0.1	0.0	0.0	0.0	0.0	1.1	0.1	0.0	0.0	0.2	0.0	0.5	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.1	0.0	2.1	0.4	34.7	0.0	1.8	3.0	1.3	1.6	0.3	0.3	0.0	0.0	0.3	0.0	1.6	1.8	0.3	0.4	0.2	0.2	0.1	0.3	0.2	0.1	0.1	0.6	0.2	0.3	1.7	0.4	0.5	0.3	0.2	0.1	0.7	1.3	0.4	1.4	1.3	1.6	1.2	1.4	2.0	0.2	0.0	0.3	0.0	2.8	4.1	0.6	13.6	2.5	0.0	0.0	1.8	0.0	8.6	1.7	0.0	3.3	2.9	0.0	0.0	0.2	0.9	9.3	3.5	0.0	103.6	1.6	0.0	2.9	4.9	1.9	1.8	17.3	0.3	1.7	0.0	2.0	0.8	0.2	0.0	11.3	8.8	0.2	12.9	4.4	0.0	0.3	3.1	33.6	0.0	1.5	0.9
IFNAR2	IFNABR	ENSG00000159110	"Interferon alpha and beta receptor subunit 2"	P48551	21	33229901-33265675	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Karpas-707: 52.3;U-266/70: 66.4;U-266/84: 34.4"														"Secreted to blood"	NA	NA		610000				"unprognostic (2.00e-2)"	"unprognostic (7.83e-3)"	"unprognostic (4.98e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.04e-1)"	"unprognostic (4.50e-3)"	"unprognostic (8.05e-2)"	"unprognostic (4.17e-2)"	"unprognostic (2.11e-2)"	"unprognostic (7.65e-2)"	"unprognostic (4.42e-1)"	"prognostic unfavorable (7.54e-7)"	"unprognostic (9.70e-3)"	"unprognostic (2.39e-1)"	"unprognostic (5.12e-3)"	"unprognostic (1.85e-2)"	16.9	8.7	9.9	28.1	11.3	19.1	18.3	10.7	13.0	10.2	12.2	10.6	9.6	12.8	12.0	10.1	8.1	11.1	15.5	13.6	10.3	9.7	13.4	20.5	21.6	41.7	13.3	8.3	11.9	10.2	11.2	10.9	15.7	10.2	9.9	13.2	7.9	14.4	11.6	6.6	6.6	14.1	13.0	13.2	40.9	9.9	4.6	12.1	34.7	11.3	6.6	25.3	24.2	10.7	9.9	37.6	37.1	25.3	12.2	23.7	14.2	4.1	4.7	2.5	5.7	3.0	7.1	4.1	4.2	11.2	3.6	3.8	6.3	4.7	6.5	3.1	6.5	5.5	2.6	3.5	2.3	3.5	4.1	5.3	23.8	5.2	5.8	4.4	4.0	8.9	5.0	2.2	4.0	4.9	6.4	11.4	10.2	7.5	52.3	3.5	2.4	10.3	4.9	4.5	5.5	3.1	3.5	12.9	12.8	7.6	8.3	6.5	3.7	7.2	6.4	6.1	2.7	1.1	7.6	7.5	3.7	2.2	2.9	2.3	66.4	34.4	16.1	5.3	14.4	8.6	13.7	14.5	22.7	12.2	23.7	12.8	9.9	15.2	11.5	13.6	6.7	11.2	12.3	37.1	12.2	25.3	37.6	23.7	14.2	9.9	11.3	10.7	13.0	10.3	9.7	13.3	8.3	10.2	12.1	56.6	17.3	28.9	40.1	6.1	5.2	2.5	25.5	28.1	20.5	10.4	5.9	24.6	3.3	61.4	2.4	32.2	8.1	0.0	54.3	61.5	11.8	37.0	31.1	17.4	40.5	19.1	2.9	38.6	68.7	2.4	6.9	46.3	18.6	33.3	3.7	5.7	58.2	3.6	8.5	8.4	5.4	0.0	13.3	2.9	22.4	5.0	19.7	40.3	3.8	62.9
IFNG		ENSG00000111537	"Interferon gamma"	P01579	12	68154768-68159747	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Antiviral defense, Growth regulation"	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 14.4;lung: 14.5"	"Cell type enriched"	"Detected in some"	14	"T-cells: 93.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	5	"gdT-cell: 7.3;memory CD4 T-cell: 3.3;memory CD8 T-cell: 8.6;naive CD8 T-cell: 5.2"	"Lineage enriched"	"Detected in many"	7	"T-cells: 8.6"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 2.3;U-266/70: 2.3;U-698: 1.2"					"Low region specificity"	"Detected in some"			CAB010344	Approved				"Secreted to blood"	NA	NA	1470				"CAB010344: AB_2123447"	"unprognostic (2.16e-4)"	"unprognostic (1.93e-3)"	"unprognostic (9.21e-2)"	"unprognostic (1.04e-4)"	"unprognostic (5.14e-1)"	"unprognostic (3.96e-3)"	"unprognostic (1.33e-1)"	"unprognostic (3.17e-4)"	"unprognostic (7.79e-2)"	"unprognostic (7.97e-3)"	"unprognostic (1.63e-2)"	"unprognostic (5.36e-2)"	"unprognostic (7.62e-9)"	"unprognostic (3.54e-2)"	"unprognostic (5.36e-1)"	"unprognostic (6.32e-2)"	"unprognostic (7.38e-3)"	2.4	0.9	0.3	4.5	0.3	14.4	0.5	0.1	1.0	1.4	0.9	0.5	0.0	0.2	0.6	1.4	1.3	0.2	0.6	1.0	0.3	0.3	0.7	4.1	14.5	8.5	1.5	0.4	0.4	0.2	0.0	0.5	0.8	0.6	1.2	0.4	1.1	1.4	0.2	1.7	0.3	0.7	0.7	1.3	4.1	0.8	0.2	0.0	0.8	1.3	3.1	4.7	2.2	0.6	0.5	0.0	0.2	0.0	1.2	8.6	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.0	3.3	8.6	0.0	0.5	0.8	5.2	0.2	1.2	0.0	0.0	0.2	1.1	0.3	0.3	0.1	1.0	0.3	0.3	1.5	0.4	0.6	0.0	0.0	0.0	0.5	0.4	2.9	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.8	0.1	0.0	0.0	1.3	3.0	0.0	0.0	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	3.4	0.0	93.0	0.1	0.1
IL12B	"CLMF, CLMF2, IL-12B, NKSF, NKSF2"	ENSG00000113302	"Interleukin 12B"	P29460	5	159314783-159330887	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		Cytokine	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 10.8"	"Cell type enriched"	"Detected in single"	60	"monocytes: 11.8"	"Cancer enriched"	"Detected in single"	20	"testis cancer: 3.4"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.9"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Karpas-707: 3.0;NB-4: 2.7;SCLC-21H: 3.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA040970	Supported				"Secreted to blood"	NA	NA	140000				"HPA040970: AB_10796234"	"unprognostic (5.96e-5)"	"unprognostic (4.59e-5)"	"unprognostic (1.05e-1)"	"unprognostic (3.40e-1)"		"unprognostic (9.13e-4)"	"unprognostic (6.89e-2)"	"unprognostic (2.58e-4)"	"unprognostic (6.69e-3)"	"unprognostic (3.83e-2)"	"unprognostic (4.50e-2)"	"unprognostic (2.53e-1)"	"unprognostic (7.15e-3)"	"unprognostic (9.25e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.02e-2)"	0.2	0.2	0.2	0.7	0.2	1.4	0.2	0.4	0.2	0.3	0.2	0.2	0.2	0.2	0.2	1.2	0.4	0.2	0.7	0.2	0.2	0.2	0.6	0.3	0.9	1.8	0.2	0.2	0.2	0.2	0.0	2.4	0.2	0.2	0.2	0.6	0.2	0.7	0.2	0.2	1.3	0.5	0.2	0.2	1.8	0.9	0.5	0.2	10.8	0.4	0.2	0.9	0.3	0.2	1.1	0.3	2.9	0.5	1.0	0.2	0.0	0.3	0.4	0.6	0.7	0.1	0.0	0.2	0.5	0.0	0.0	0.5	0.6	0.9	0.5	0.1	0.1	0.2	0.4	0.1	0.1	0.0	0.5	0.9	0.1	1.5	0.2	0.1	0.4	1.1	0.3	0.3	0.1	0.0	0.7	0.1	0.4	0.2	3.0	0.0	0.2	0.5	2.7	0.6	0.1	0.4	0.6	0.8	1.8	0.0	0.2	3.7	0.2	0.3	0.3	0.0	0.8	0.4	0.4	0.4	0.5	0.2	0.2	0.2	0.2	0.1	0.3	0.7	0.5	0.2	1.7	0.5	0.2	0.2	0.1	0.1	1.1	0.2	0.1	0.1	0.3	0.2	0.2	2.9	1.0	0.1	0.3	0.1	0.0	0.2	0.2	0.4	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IL17A	"CTLA8, IL-17, IL-17A, IL17"	ENSG00000112115	"Interleukin 17A"	Q16552	6	52186387-52190638	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"lymphoid tissue: 7.6;tongue: 12.2;urinary bladder: 4.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	37	"Karpas-707: 7.3;U-266/84: 4.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA052258	Uncertain				"Secreted to blood"	NA	NA	9920				"HPA052258: "		"unprognostic (5.55e-1)"	"unprognostic (2.18e-4)"			"unprognostic (3.05e-4)"		"unprognostic (1.41e-2)"						"unprognostic (2.22e-2)"				0.2	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.4	0.0	0.0	1.3	0.5	0.6	0.0	0.1	0.0	0.1	0.1	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.1	0.0	0.1	0.1	1.0	0.1	0.0	0.1	0.3	0.1	0.0	0.0	0.0	12.2	7.6	4.4	0.5	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IL1B	"IL-1B, IL1-BETA, IL1F2"	ENSG00000125538	"Interleukin 1 beta"	P01584	2	112829751-112836903	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	"Inflammatory response"	"Cytokine, Mitogen, Pyrogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 62.3;lymphoid tissue: 35.4"	"Cell type enriched"	"Detected in many"	7	"Macrophages: 764.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	5	"neutrophil: 34.4"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 34.4"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 93.2;HBEC3-KT: 42.4;HMC-1: 34.6;hTEC/SVTERT24-B: 46.6;hTERT-RPE1: 40.3;U-87 MG: 85.2"	"Low region specificity"	"Detected in some"												"Secreted to blood"	NA	NA	2330					"unprognostic (1.55e-3)"	"prognostic unfavorable (1.31e-4)"	"unprognostic (2.75e-2)"	"unprognostic (5.71e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.12e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.63e-3)"	"unprognostic (3.72e-2)"	"unprognostic (5.57e-2)"	"prognostic unfavorable (7.49e-5)"	"unprognostic (1.29e-2)"	"unprognostic (4.42e-2)"	"unprognostic (5.09e-2)"	"unprognostic (4.01e-2)"	19.6	3.3	4.2	20.4	15.3	62.3	0.8	1.1	10.8	1.6	3.2	12.7	0.2	1.2	3.0	1.5	3.5	3.4	7.5	3.7	19.0	3.6	1.7	4.0	17.3	5.0	5.9	0.3	3.4	2.4	2.4	3.0	10.3	24.9	2.6	2.6	1.0	2.2	0.8	0.4	0.9	3.7	3.5	29.7	35.4	20.9	1.6	5.8	0.8	1.1	13.5	14.0	10.4	1.2	0.0	6.9	34.4	7.0	0.0	0.0	1.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	93.2	0.4	1.0	0.0	0.0	0.0	2.6	0.0	1.6	2.1	0.0	42.4	5.8	0.0	0.0	4.1	0.0	0.0	0.3	0.0	34.6	0.1	1.3	46.6	15.7	40.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.1	3.5	0.1	0.0	0.0	0.0	5.6	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.4	0.0	2.2	0.0	0.1	0.0	0.0	0.0	0.0	85.2	1.9	3.2	0.5	4.2	1.5	0.0	7.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	34.4	0.0	2.7	0.0	0.0	1.0	4.2	15.3	1.1	10.8	19.0	3.6	5.9	0.3	24.9	5.8	8.9	45.3	1.4	4.6	27.4	0.0	4.3	0.0	13.4	7.9	1.8	0.0	1.2	0.0	12.2	0.1	2.2	0.3	0.0	0.5	2.1	9.9	2.3	39.4	0.0	109.6	0.0	0.0	1.3	54.0	0.0	0.0	764.6	21.9	0.0	2.2	0.0	3.6	6.2	0.0	0.5	0.2	0.0	4.3	0.0	0.2	17.8	3.7	2.2	0.0	4.6
IL1R1	"CD121A, D2S1473, IL1R, IL1RA"	ENSG00000115594	"Interleukin 1 receptor type 1"	P14778	2	102064544-102179874	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters"	"Inflammatory response"	"Hydrolase, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Club cells: 93.3;Ito cells: 139.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 4.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 95.6;ASC TERT1: 42.7;HHSteC: 30.0;HSkMC: 117.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001237, HPA005823, CAB007779, HPA029560"	Approved		Approved	"Nucleoplasm,Vesicles,Plasma membrane,Cytosol"	"Secreted to blood"	NA	NA		1000000	"Nucleoplasm, Vesicles"	"Plasma membrane, Cytosol"	"CAB007779: AB_562073, HPA001237: , HPA005823: AB_2667445, HPA029560: AB_2673094"	"unprognostic (6.16e-3)"	"unprognostic (3.55e-2)"	"unprognostic (3.33e-1)"	"unprognostic (1.22e-1)"	"unprognostic (4.26e-2)"	"unprognostic (7.10e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.36e-2)"	"unprognostic (1.44e-1)"	"unprognostic (3.16e-1)"	"unprognostic (4.26e-2)"	"unprognostic (7.77e-2)"	"prognostic unfavorable (6.92e-6)"	"unprognostic (2.48e-2)"	"unprognostic (6.95e-2)"	"unprognostic (4.83e-2)"	"unprognostic (7.73e-2)"	48.6	25.2	2.6	18.2	5.2	4.0	92.4	2.4	3.9	47.8	21.0	2.5	34.3	5.2	15.2	30.2	18.2	17.1	25.8	27.0	4.2	2.5	23.7	74.8	40.5	28.0	5.6	1.1	25.1	17.1	16.9	7.3	66.2	10.9	26.0	8.4	8.6	12.7	36.4	15.5	13.5	13.0	15.1	10.0	19.2	15.6	13.4	2.8	3.5	33.6	9.0	9.6	32.0	36.4	0.1	0.1	4.0	0.5	0.8	1.8	0.2	0.2	1.8	0.0	1.5	95.6	42.7	0.6	4.0	18.2	2.8	4.3	0.8	0.5	0.0	2.9	8.0	5.0	0.8	0.0	0.3	2.4	7.9	0.0	0.1	0.4	4.4	30.0	0.0	0.0	117.7	0.3	3.2	0.7	1.2	1.2	0.0	0.5	0.1	4.1	0.8	0.0	0.1	0.1	0.8	0.1	0.0	0.3	0.0	2.7	1.9	0.0	0.0	1.8	1.1	0.0	0.5	1.6	0.1	0.0	8.2	0.5	13.7	0.3	0.0	0.0	0.0	3.2	0.0	0.5	0.6	0.5	0.1	0.0	0.0	0.7	0.1	1.1	0.0	0.1	0.1	0.0	0.1	4.0	0.8	0.0	0.1	1.8	0.2	2.6	5.2	2.4	3.9	4.2	2.5	5.6	1.1	10.9	2.8	23.8	55.6	3.7	27.6	27.6	0.0	3.9	28.1	40.2	93.3	5.2	0.0	5.3	3.3	21.6	6.4	58.3	0.0	0.0	18.7	76.6	77.2	84.5	1.1	43.2	5.1	0.0	1.2	139.3	12.4	9.4	25.9	21.6	18.6	9.0	0.7	7.3	15.4	0.0	1.4	6.2	1.0	6.5	23.1	0.7	0.9	33.8	20.0	2.6	0.9	19.6
IL23A	"IL-23, IL-23A, IL23P19, P19, SGRF"	ENSG00000110944	"Interleukin 23 subunit alpha"	Q9NPF7	12	56334174-56340410	"FDA approved drug targets, Predicted secreted proteins"	"Antiviral defense, Immunity, Inflammatory response, Innate immunity, Tissue remodeling"	Cytokine	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 17.0;lymphoid tissue: 15.2;testis: 12.1"	"Cell type enhanced"	"Detected in many"	10	"Ductal cells: 26.3;monocytes: 58.7;Pancreatic endocrine cells: 46.8;Spermatocytes: 41.1"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	6	"MAIT T-cell: 8.4;memory B-cell: 10.6;memory CD4 T-cell: 15.5;memory CD8 T-cell: 7.4;naive B-cell: 10.6;naive CD4 T-cell: 17.0;naive CD8 T-cell: 10.6;T-reg: 8.4"	"Group enriched"	"Detected in many"	14	"B-cells: 10.6;T-cells: 17.0"	"Cell line enhanced"	"Detected in some"		"A-431: 9.4;CAPAN-2: 16.5;U-266/70: 27.6;U-266/84: 12.4"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in some"			HPA001554	Approved		Approved	Cytosol	"Secreted to blood"	NA	NA	11000		Cytosol		"HPA001554: AB_1079135"	"unprognostic (2.34e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.06e-1)"	"unprognostic (5.24e-2)"	"unprognostic (4.01e-3)"	"unprognostic (4.40e-1)"	"unprognostic (1.43e-3)"	"unprognostic (1.30e-1)"	"unprognostic (6.79e-2)"	"unprognostic (3.38e-2)"	"unprognostic (4.16e-2)"	"unprognostic (3.03e-10)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.83e-1)"	"unprognostic (4.50e-3)"	0.7	0.5	0.4	3.9	0.5	3.6	0.4	0.3	0.3	0.5	0.6	0.3	0.3	0.0	1.3	0.8	6.0	0.5	2.0	0.3	0.4	0.5	1.3	1.4	1.2	7.5	0.4	0.3	0.3	1.1	0.0	1.1	0.6	0.3	1.0	0.2	0.3	1.8	0.3	0.3	0.8	2.5	1.0	0.4	2.8	0.7	12.1	0.3	12.9	0.6	10.4	15.2	7.4	0.6	10.6	0.5	0.1	0.2	1.0	17.0	5.9	9.4	0.2	0.3	0.3	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.4	16.5	0.5	4.9	0.0	0.5	0.9	0.0	1.6	0.0	0.6	0.3	0.3	0.1	0.7	0.0	0.2	0.6	0.1	0.0	0.0	0.4	2.1	0.0	2.2	0.4	4.1	0.0	0.4	0.3	0.5	1.4	0.2	0.3	0.2	0.1	0.4	5.7	4.7	0.3	0.4	0.2	0.2	0.8	1.4	0.1	4.4	0.3	0.3	0.3	0.3	1.1	27.6	12.4	1.2	0.3	2.4	0.2	0.0	0.2	0.0	1.7	0.0	8.4	10.6	15.5	7.4	0.5	10.6	17.0	10.6	0.1	1.0	0.0	0.0	8.4	5.9	0.4	0.5	0.3	0.3	0.4	0.5	0.4	0.3	0.3	0.3	3.0	2.1	14.5	10.2	3.2	0.0	0.3	0.0	2.7	5.7	1.8	0.0	0.3	1.7	26.3	4.7	0.6	0.3	0.0	6.4	0.3	1.4	5.0	0.0	0.6	2.4	0.0	0.0	0.0	0.0	3.2	0.3	8.1	8.5	58.7	0.0	0.1	46.8	0.0	0.7	0.5	0.1	0.0	1.9	41.1	5.3	3.4	0.0	10.2	0.0	13.9
IL4R	CD124	ENSG00000077238	"Interleukin 4 receptor"	P24394	16	27313668-27364778	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"granulocytes: 107.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 34.4"	"Group enriched"	"Detected in all"	6	"B-cells: 34.4;granulocytes: 11.9"	"Cell line enhanced"	"Detected in many"		"Daudi: 36.5;HBEC3-KT: 35.1;U-698: 34.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB004451, HPA050124, HPA070380"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Centriolar satellite"	"Secreted to blood"	NA	NA		49000	"Nucleoplasm, Plasma membrane"	"Centriolar satellite"	"CAB004451: AB_626889, HPA050124: AB_2681026, HPA070380: "	"unprognostic (6.80e-2)"	"unprognostic (6.35e-2)"	"unprognostic (2.84e-1)"	"prognostic favorable (6.43e-4)"	"unprognostic (1.12e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.33e-2)"	"unprognostic (1.95e-3)"	"unprognostic (1.34e-1)"	"unprognostic (1.54e-1)"	"unprognostic (2.41e-1)"	"unprognostic (1.97e-1)"	"prognostic unfavorable (1.23e-5)"	"unprognostic (1.49e-2)"	"unprognostic (1.73e-1)"	"unprognostic (1.36e-1)"	"unprognostic (9.58e-2)"	20.7	14.8	8.7	31.6	10.6	36.9	12.0	4.4	7.7	20.8	30.3	5.9	11.5	10.9	18.0	12.8	24.7	13.6	25.1	12.3	6.7	4.4	13.3	39.1	40.9	44.8	10.8	1.7	14.7	11.3	3.8	5.5	16.1	10.1	18.8	15.1	12.3	7.7	11.5	7.2	9.9	18.6	39.6	13.6	31.8	21.1	10.4	9.8	9.1	8.6	13.7	38.4	31.6	15.4	34.4	1.6	11.9	2.6	3.3	4.0	1.8	11.5	3.0	2.0	3.9	1.0	4.6	4.2	7.3	8.5	2.9	2.4	6.2	32.0	36.5	9.1	11.5	5.7	12.3	2.1	35.1	2.5	31.6	1.0	6.8	1.8	9.5	13.2	1.8	19.4	7.0	14.2	13.5	8.0	15.5	15.7	2.1	2.9	3.1	4.7	5.1	0.1	5.5	2.4	10.4	2.7	0.1	15.2	2.9	13.6	13.2	0.6	0.3	1.0	7.0	1.6	5.3	2.7	7.0	23.5	6.7	3.0	5.9	5.1	1.8	0.5	34.0	0.7	6.1	0.0	0.5	2.6	4.7	1.7	1.1	1.3	7.7	2.6	1.7	1.6	34.4	4.0	1.9	11.9	3.3	0.6	1.6	1.8	1.8	8.7	10.6	4.4	7.7	6.7	4.4	10.8	1.7	10.1	9.8	26.8	51.7	49.6	35.5	11.7	0.0	2.2	20.4	17.4	30.7	1.8	0.0	15.0	0.0	31.7	0.1	31.5	27.6	0.0	28.2	3.5	13.9	27.2	107.5	47.4	22.9	0.0	22.4	54.6	31.1	0.2	0.3	21.3	13.5	40.5	32.8	0.0	35.6	22.1	0.0	1.1	0.0	38.8	27.4	0.5	1.9	13.0	20.8	20.3	15.0	38.2
IL5	"EDF, IL-5, TRF"	ENSG00000113525	"Interleukin 5"	P05113	5	132541444-132556838	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"blood: 3.8;testis: 10.6"	"Cell type enriched"	"Detected in some"	9	"Spermatocytes: 24.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	6	"memory B-cell: 3.8"	"Lineage enriched"	"Detected in single"	6	"B-cells: 3.8"	"Cell line enhanced"	"Detected in some"		"CACO-2: 2.5;HEK 293: 2.2;Hep G2: 7.2;TIME: 3.4"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			CAB010304	Approved				"Secreted to blood"	NA	NA	4130				"CAB010304: AB_2296159"	"unprognostic (1.66e-1)"	"unprognostic (4.76e-2)"	"unprognostic (5.30e-3)"	"unprognostic (2.35e-1)"	"unprognostic (9.07e-2)"		"unprognostic (7.98e-2)"	"unprognostic (2.03e-2)"		"unprognostic (3.51e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.53e-1)"	"unprognostic (2.09e-1)"	"unprognostic (5.27e-2)"	"unprognostic (5.84e-3)"	"unprognostic (1.91e-1)"	0.1	0.1	0.3	0.3	1.0	0.0	0.1	0.3	1.3	0.2	0.1	0.0	0.0	1.0	0.5	0.0	0.1	0.7	1.1	0.4	1.0	0.3	0.1	0.3	0.1	0.0	0.3	0.0	0.2	0.1	0.0	2.0	0.0	0.9	0.1	0.3	0.0	0.1	0.0	0.1	0.1	1.8	0.1	0.3	0.1	0.3	10.6	0.0	0.4	0.7	0.0	0.2	0.2	0.2	3.8	0.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.8	0.0	0.6	0.0	1.0	0.0	0.0	0.0	0.0	0.1	2.2	0.0	0.2	7.2	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.9	0.6	0.8	0.0	0.0	0.0	0.0	0.2	1.0	0.0	0.5	0.1	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.3	0.0	0.4	0.9	0.4	0.8	0.0	0.2	0.8	0.0	0.0	0.0	0.5	0.0	0.0	3.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.3	1.0	0.3	1.3	1.0	0.3	0.3	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.2	1.1	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	1.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.7	0.7	0.1	0.0	0.0	0.0	0.0
IL6	"BSF2, HGF, HSF, IFNB2, IL-6"	ENSG00000136244	"Interleukin 6"	P05231	7	22725884-22732002	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase"	"Cytokine, Growth factor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 60.1;lymphoid tissue: 48.0"	"Cell type enriched"	"Detected in many"	9	"Smooth muscle cells: 589.1"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"basal ganglia: 10.0;cerebral cortex: 4.4;hippocampal formation: 3.9;pons and medulla: 12.8"	"Group enriched"	"Detected in some"	70	"memory B-cell: 6.1;naive B-cell: 7.7"	"Lineage enriched"	"Detected in single"	77	"B-cells: 7.7"	"Group enriched"	"Detected in some"	4	"BJ hTERT+: 208.4;GAMG: 141.1"					"Low region specificity"	"Detected in single"			"CAB023406, CAB072821"	Supported		Approved	Vesicles	"Secreted to blood"	NA	NA	5700		Vesicles		"CAB023406: AB_617317, CAB072821: "	"unprognostic (1.13e-1)"	"unprognostic (1.55e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.35e-1)"	"unprognostic (3.59e-2)"	"unprognostic (9.88e-3)"	"unprognostic (1.35e-1)"	"unprognostic (3.07e-3)"	"unprognostic (3.25e-1)"	"unprognostic (2.17e-1)"	"unprognostic (2.48e-2)"	"unprognostic (8.57e-2)"	"prognostic unfavorable (1.10e-11)"	"unprognostic (2.45e-3)"	"unprognostic (2.10e-1)"	"unprognostic (4.31e-2)"	"unprognostic (7.80e-2)"	60.1	5.6	1.4	48.0	10.0	15.3	11.5	0.7	4.4	2.9	8.1	1.2	0.4	0.7	2.1	4.6	14.3	7.8	16.1	21.6	3.9	1.5	1.3	5.2	34.9	3.0	1.8	0.2	5.3	8.3	5.7	14.2	4.5	12.8	6.5	7.5	3.3	3.1	0.8	6.9	2.8	4.5	8.2	7.0	3.5	6.5	3.2	1.2	0.1	4.5	12.7	3.5	34.9	8.4	7.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.8	208.4	3.9	13.4	0.0	0.0	0.0	6.8	1.3	141.1	0.1	0.0	0.0	5.3	8.2	0.0	0.0	0.3	0.0	4.4	0.0	0.0	0.5	0.0	39.8	5.7	3.8	1.4	0.0	0.8	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	10.4	0.0	0.0	0.0	13.5	0.0	0.0	0.7	0.0	0.0	1.2	1.3	0.1	2.4	0.4	0.0	2.3	0.0	9.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	0.0	0.0	0.0	7.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.4	10.0	0.7	4.4	3.9	1.5	1.8	0.2	12.8	1.2	6.0	27.2	7.2	1.9	39.6	0.0	0.9	0.0	13.4	20.5	3.5	0.0	0.5	0.0	5.8	0.3	40.7	0.0	0.0	2.4	3.1	63.9	7.3	5.8	0.0	4.2	0.0	0.0	3.1	6.1	0.0	0.0	46.2	38.8	7.2	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.0	589.1	0.0	0.0	29.2	1.1	0.0	0.0	9.0
KLK1	Klk6	ENSG00000167748	"Kallikrein 1"	P06870	19	50819148-50823787	"Enzymes, FDA approved drug targets, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	56	"pancreas: 742.6;salivary gland: 473.0"	"Cell type enhanced"	"Detected in many"	19	"Exocrine glandular cells: 663.7;Mucus-secreting cells: 890.7;Pancreatic endocrine cells: 205.3"	"Group enriched"	"Detected in many"	6	"colorectal cancer: 20.0;pancreatic cancer: 50.9;renal cancer: 84.1"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	10	"memory B-cell: 10.9;naive B-cell: 3.8"	"Lineage enriched"	"Detected in single"	14	"B-cells: 10.9"	"Cell line enriched"	"Detected in some"	4	"RPMI-8226: 29.2"														"Secreted to digestive system"	NA	NA		4300000				"unprognostic (1.51e-3)"	"unprognostic (1.23e-2)"	"unprognostic (4.20e-1)"	"unprognostic (1.73e-2)"	"unprognostic (1.10e-1)"	"unprognostic (8.72e-2)"	"unprognostic (1.92e-2)"	"unprognostic (7.47e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.49e-2)"	"unprognostic (8.06e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.42e-2)"	"unprognostic (2.55e-1)"	"unprognostic (6.49e-2)"	"unprognostic (2.10e-1)"	"unprognostic (6.23e-2)"	0.1	0.2	0.1	0.3	0.1	0.0	0.1	0.1	0.1	0.2	2.5	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.0	3.8	0.1	0.1	0.1	0.1	0.1	0.1	742.6	0.0	0.1	0.1	0.1	0.2	1.9	0.1	473.0	0.1	0.1	1.8	0.6	0.1	0.1	0.3	0.1	0.1	0.1	0.1	1.2	0.2	0.2	0.1	0.1	10.9	0.7	0.1	0.3	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.3	0.2	0.2	0.3	1.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	0.0	29.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	10.9	0.0	0.0	0.2	3.8	0.0	0.0	0.1	0.0	0.2	0.7	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	1.1	17.9	1.4	17.3	0.0	0.3	0.0	0.0	1.2	0.0	0.0	0.0	38.1	2.8	0.4	0.1	46.5	0.0	663.7	0.0	1.6	15.7	9.2	0.0	0.6	0.0	112.7	0.0	0.8	0.0	5.8	2.9	5.0	9.0	890.7	0.0	205.3	113.2	0.0	0.2	0.0	0.0	0.1	0.3	0.7	47.2	0.0	0.0	128.7	3.4
KLKB1	KLK3	ENSG00000164344	"Kallikrein B1"	P03952	4	186208979-186258471	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis, Inflammatory response"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	76	"liver: 102.9"	"Cell type enriched"	"Detected in some"	11	"Hepatocytes: 203.0"	"Cancer enriched"	"Detected in some"	17	"liver cancer: 27.6"	"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	7	"gdT-cell: 1.3"	"Lineage enriched"	"Detected in single"	8	"T-cells: 1.3"	"Cell line enhanced"	"Detected in some"		"NTERA-2: 7.3;SCLC-21H: 5.0;SK-MEL-30: 2.2;U-937: 2.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"								"Secreted to blood"	NA	NA	28900000000	4900000000				"unprognostic (4.80e-2)"	"unprognostic (4.53e-3)"	"unprognostic (4.36e-2)"	"unprognostic (4.17e-2)"	"unprognostic (5.93e-2)"	"unprognostic (1.90e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.83e-1)"	"unprognostic (8.14e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.38e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.45e-2)"	"unprognostic (6.01e-2)"	"unprognostic (7.30e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.59e-2)"	0.3	0.3	0.8	0.3	1.2	0.0	0.3	0.7	0.5	0.3	0.4	0.3	0.3	0.7	0.4	0.4	0.3	0.2	0.7	0.5	0.6	0.5	1.3	102.9	0.3	0.3	0.5	0.5	0.3	1.3	0.5	1.0	0.4	0.4	0.3	0.3	0.5	0.3	0.3	0.5	0.1	0.6	0.3	0.3	0.5	0.0	0.3	0.3	0.4	0.3	0.3	0.4	0.3	0.3	0.1	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.2	0.8	0.2	0.0	0.0	0.0	0.2	0.0	0.4	0.3	0.3	0.0	0.2	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.2	0.0	0.0	0.4	0.0	7.3	0.1	0.0	0.1	0.0	0.2	1.3	0.0	5.0	0.4	0.2	0.0	2.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.8	1.2	0.7	0.5	0.6	0.5	0.5	0.5	0.4	0.3	0.0	0.0	0.0	0.0	0.0	4.2	3.9	17.8	1.4	0.0	1.8	15.7	0.0	0.0	1.1	2.2	0.4	0.2	0.0	0.5	0.0	0.0	0.0	0.0	203.0	0.2	0.0	2.9	5.5	3.2	0.8	0.6	0.0	0.0	0.0	0.3	14.6	0.7	0.3	0.0	0.9	3.6	0.0	0.2	1.4	0.9	0.0	0.0	0.0	0.4	0.0
LEPR	"CD295, OBR"	ENSG00000116678	"Leptin receptor"	P48357	1	65420652-65641559	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 82.8"	"Cell type enhanced"	"Detected in many"	18	"Endothelial cells: 59.1;Hepatocytes: 196.4"	"Cancer enriched"	"Detected in many"	7	"liver cancer: 13.1"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 6.9"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 15.7;K-562: 46.5;RPTEC TERT1: 22.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA030899	Approved	Supported			"Secreted to blood"	NA	NA	8240000	8300000			"HPA030899: AB_10610003"	"unprognostic (1.59e-2)"	"unprognostic (1.09e-3)"	"unprognostic (3.09e-1)"	"unprognostic (8.95e-2)"	"unprognostic (2.32e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.58e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.78e-1)"	"unprognostic (6.59e-3)"	"unprognostic (1.79e-1)"	"unprognostic (2.41e-1)"	"unprognostic (7.53e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.27e-1)"	"unprognostic (3.49e-2)"	"unprognostic (1.73e-1)"	15.9	5.5	3.8	3.7	4.3	3.3	23.5	2.5	3.9	15.0	9.2	5.6	5.4	3.2	20.6	7.3	10.9	11.7	10.1	9.2	4.3	4.9	14.6	82.8	20.3	9.0	4.9	3.3	18.4	16.7	3.9	13.1	12.8	8.2	10.8	4.1	18.1	12.0	5.7	5.6	10.2	7.3	12.9	7.0	6.4	11.9	6.6	3.1	1.9	13.1	11.2	6.9	13.6	8.6	0.6	1.8	6.9	1.9	1.1	2.3	1.8	1.3	0.8	1.1	1.2	5.0	4.7	3.9	5.9	3.4	2.0	1.9	0.6	3.2	0.5	4.4	7.5	0.5	1.1	0.9	5.2	5.5	7.0	1.5	7.7	3.6	0.1	3.0	0.5	0.6	13.2	3.0	1.2	4.7	15.7	5.9	0.6	46.5	0.9	9.5	0.3	0.6	0.1	1.8	0.8	0.1	0.1	0.9	0.3	22.5	0.6	0.7	11.4	1.4	0.6	1.6	6.7	2.1	2.1	2.2	2.1	4.4	0.4	3.2	1.3	0.9	0.2	4.5	2.2	2.0	6.9	1.9	2.8	1.3	1.5	1.3	0.6	1.1	1.1	1.8	0.3	0.9	1.5	1.1	1.1	1.7	1.2	2.3	1.8	3.8	4.3	2.5	3.9	4.3	4.9	4.9	3.3	8.2	3.1	0.0	16.5	3.0	1.9	31.4	4.9	3.5	10.2	2.7	4.5	8.7	0.0	1.2	3.3	1.5	1.0	59.1	0.4	0.0	0.9	2.3	20.2	3.3	1.1	196.4	1.9	1.6	0.0	27.6	6.5	1.5	31.9	5.8	33.7	2.8	0.9	0.0	1.6	1.7	7.1	6.8	0.9	0.0	17.7	1.1	0.6	25.7	2.2	0.5	0.8	1.4
LIPF	"HGL, HLAL"	ENSG00000182333	"Lipase F, gastric type"	P07098	10	88664441-88678814	"Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	24	"stomach 1: 762.9"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in some"	75	"stomach cancer: 278.5"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.9"	"Cell type enriched"	"Detected in single"	16	"eosinophil: 1.5"	"Lineage enriched"	"Detected in single"	16	"granulocytes: 1.5"	"Cell line enhanced"	"Detected in some"		"HMC-1: 6.4;MOLT-4: 5.0;NTERA-2: 5.3;REH: 3.1;THP-1: 10.0;U-2 OS: 3.6;U-266/70: 4.9"	"Region enriched"	"Detected in single"	51	"olfactory region: 9.9"					HPA045930	Enhanced				"Secreted to digestive system"	NA	NA					"HPA045930: AB_10959518"										"unprognostic (1.53e-1)"				"unprognostic (1.83e-1)"				0.1	0.0	0.1	0.1	0.5	0.0	0.1	0.1	1.9	0.1	0.2	28.2	0.1	8.2	0.1	0.1	31.6	0.1	0.6	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.0	0.1	9.9	0.1	0.1	0.0	0.1	0.1	0.1	0.1	762.9	0.1	0.1	0.2	0.1	1.1	0.1	0.1	0.1	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.1	5.3	0.0	0.0	3.1	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.0	0.0	0.0	3.6	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.1	1.9	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0
LPL	LIPD	ENSG00000175445	"Lipoprotein lipase"	P06858	8	19901717-19967258	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Lipid degradation, Lipid metabolism"	"Heparin-binding, Hydrolase"	"Disease mutation, FDA approved drug targets, Hyperlipidemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 178.6;breast: 146.2;heart muscle: 121.4"	"Cell type enhanced"	"Detected in many"	20	"Cardiomyocytes: 482.3;Hofbauer cells: 114.1;Horizontal cells: 195.5;Sertoli cells: 232.8"	"Cancer enhanced"	"Detected in all"		"glioma: 39.2"	"Region enhanced"	"Detected in many"		"basal ganglia: 16.3"	"Cell type enhanced"	"Detected in some"		"non-classical monocyte: 7.1"	"Lineage enriched"	"Detected in many"	5	"monocytes: 7.1"	"Cell line enriched"	"Detected in some"	5	"AF22: 91.4"	"Region enhanced"	"Detected in many"		"basal ganglia: 40.6"	"Region enriched"	"Detected in many"	4	"basal ganglia: 64.0"	HPA048749			Supported	Vesicles	"Secreted to blood"	NA	NA		880000	Vesicles		"HPA048749: AB_2680511"	"unprognostic (5.52e-2)"	"unprognostic (3.16e-1)"	"unprognostic (6.41e-2)"	"unprognostic (3.03e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.88e-4)"	"unprognostic (1.05e-1)"	"unprognostic (6.78e-2)"	"unprognostic (8.20e-2)"	"unprognostic (2.54e-2)"	"unprognostic (5.28e-1)"	"unprognostic (1.18e-1)"	"unprognostic (4.20e-3)"	"unprognostic (4.16e-3)"	"unprognostic (1.19e-1)"	"prognostic unfavorable (6.07e-4)"	178.6	4.3	2.0	11.4	16.3	0.6	146.2	3.9	8.0	1.0	16.9	0.3	27.3	0.8	1.3	1.1	1.1	0.7	8.2	121.4	2.8	2.3	4.8	0.6	20.7	7.0	4.5	0.7	2.7	1.8	32.6	0.9	7.1	1.7	0.9	1.8	8.4	9.2	85.1	53.8	1.8	3.1	1.3	2.8	0.8	1.8	0.7	3.4	0.0	2.7	9.7	1.0	3.2	6.1	0.0	0.7	1.3	7.1	0.0	0.1	0.4	0.0	0.0	91.4	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	18.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	2.2	0.0	0.0	0.0	0.0	14.5	0.0	0.0	1.8	0.0	0.0	0.0	0.0	3.5	0.0	0.4	0.0	0.0	1.8	0.0	0.7	0.0	0.0	0.0	0.0	0.0	7.4	0.0	1.6	1.3	0.0	2.8	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.4	2.0	16.3	3.9	2.3	2.8	2.3	4.5	0.7	1.7	3.4	11.9	93.6	0.0	0.1	1.3	1.0	482.3	0.0	5.3	1.2	0.0	2.0	0.3	13.3	0.0	0.6	5.4	0.0	0.0	0.0	0.6	3.1	0.3	5.8	0.0	114.1	195.5	0.0	4.3	13.4	1.0	1.1	23.8	13.5	2.8	0.0	1.7	0.0	0.0	0.0	0.0	2.2	232.8	19.1	0.3	0.2	0.5	0.3	0.0	0.0	0.1
MET	"DFNB97, HGFR, RCCP2"	ENSG00000105976	"MET proto-oncogene, receptor tyrosine kinase"	P08581	7	116672390-116798386	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Alveolar cells type 2: 78.1;Club cells: 116.0;Urothelial cells: 88.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"A-431: 45.3;CAPAN-2: 49.5"	"Group enriched"	"Detected in many"	5	"amygdala: 3.5;basal ganglia: 9.9;cerebral cortex: 7.6;hippocampal formation: 8.0;olfactory region: 9.1"	"Low region specificity"	"Detected in many"			"CAB005282, CAB018577, HPA055607"	Approved		Approved	"Plasma membrane,Cytosol"	"Secreted to blood"	NA	NA	179000000	70000000	"Plasma membrane, Cytosol"		"CAB005282: AB_631940, CAB018577: AB_649068, HPA055607: AB_2682860"	"unprognostic (1.60e-2)"	"unprognostic (7.71e-2)"	"unprognostic (2.53e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.57e-3)"	"prognostic unfavorable (6.75e-4)"	"unprognostic (1.68e-1)"	"unprognostic (3.22e-2)"	"unprognostic (3.81e-2)"	"unprognostic (2.52e-2)"	"prognostic unfavorable (1.21e-7)"	"unprognostic (1.86e-1)"	"unprognostic (1.25e-1)"	"unprognostic (5.53e-2)"	"unprognostic (8.88e-2)"	"unprognostic (2.01e-2)"	"unprognostic (2.20e-1)"	16.2	1.1	1.8	4.5	2.3	4.3	11.2	0.9	15.2	9.9	6.5	2.4	2.4	4.4	7.5	5.2	5.1	4.6	12.3	5.4	5.7	1.8	20.1	30.2	15.6	1.4	3.6	2.1	2.0	9.3	0.7	8.1	24.4	2.6	8.0	6.6	34.1	12.2	8.4	12.8	7.2	8.6	4.0	2.3	5.7	10.6	2.7	2.4	0.5	21.4	7.0	2.1	10.1	15.0	0.2	0.3	1.2	0.2	0.3	0.4	0.0	45.3	26.1	0.0	0.1	2.0	2.0	1.8	25.9	10.5	14.0	11.8	5.4	49.5	2.0	43.2	16.2	37.7	12.0	4.4	24.7	28.6	0.1	5.6	0.0	27.1	4.7	0.3	0.0	0.0	2.6	9.8	9.1	30.0	25.3	9.6	0.0	0.9	0.2	25.9	1.0	0.0	0.0	3.9	7.2	26.6	0.0	22.0	0.0	24.5	5.2	3.8	0.0	10.6	3.4	10.1	4.7	0.0	0.2	17.6	20.9	7.4	11.0	20.0	0.5	4.0	0.2	22.9	0.0	2.9	1.1	0.2	0.4	0.4	0.1	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	1.2	0.3	0.1	0.3	0.1	0.0	1.8	2.3	0.9	15.2	5.7	1.8	3.6	2.1	2.6	2.4	26.8	78.1	2.4	56.1	34.7	0.9	10.0	15.3	22.7	116.0	29.6	0.0	57.9	0.0	28.0	0.0	11.7	11.2	0.0	39.8	5.0	4.0	55.8	0.0	26.0	6.1	0.0	6.9	1.3	1.0	0.0	0.6	2.0	3.3	1.8	19.7	7.4	69.4	7.0	0.0	13.5	0.3	0.0	2.3	0.0	0.6	15.6	18.2	0.0	12.7	88.5
MMP1	CLG	ENSG00000196611	"Matrix metallopeptidase 1"	P03956	11	102789920-102798160	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation, Host-virus interaction"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 62.4;stomach 1: 27.2"	"Cell type enriched"	"Detected in some"	7	"Pancreatic endocrine cells: 1303.6"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 344.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 90.2;HBF TERT88: 89.3;HUVEC TERT2: 234.8;WM-115: 115.7"									HPA004920			Approved	Vesicles	"Secreted to extracellular matrix"	NA	NA	7730000	430000	Vesicles		"HPA004920: AB_2667293"	"unprognostic (4.11e-3)"	"prognostic unfavorable (4.66e-4)"	"unprognostic (4.20e-3)"	"unprognostic (1.19e-3)"	"unprognostic (6.46e-2)"	"unprognostic (6.50e-2)"	"prognostic unfavorable (4.22e-6)"	"unprognostic (7.83e-3)"	"unprognostic (2.94e-2)"	"unprognostic (5.44e-2)"	"unprognostic (1.11e-3)"	"unprognostic (1.75e-1)"	"prognostic unfavorable (9.86e-10)"	"unprognostic (1.67e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.26e-2)"	"unprognostic (5.11e-2)"	0.2	0.1	0.3	12.3	0.3	0.0	0.9	0.3	0.3	0.3	2.7	0.3	0.2	3.2	4.8	0.2	3.3	0.1	62.4	0.4	0.2	0.1	0.7	1.3	4.7	0.2	0.2	0.2	0.2	1.6	0.0	0.2	8.6	0.5	0.7	3.0	0.3	2.0	0.2	0.2	0.3	8.8	0.2	0.4	1.8	27.2	2.2	0.2	0.4	0.3	1.3	0.9	11.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.8	90.2	36.9	9.6	0.7	0.0	0.0	0.4	21.6	14.2	0.3	0.0	12.6	89.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	37.9	3.2	0.0	234.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	14.7	1.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	12.1	30.6	0.0	1.3	0.1	0.0	0.0	0.0	0.7	0.0	115.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.9	0.3	0.3	0.3	0.3	0.2	0.1	0.2	0.2	0.5	0.2	3.0	1.6	0.0	14.4	2.1	0.0	0.0	35.7	0.0	23.9	3.5	0.0	0.0	0.0	3.5	0.0	0.1	0.0	0.0	184.0	0.0	0.2	5.4	0.0	0.0	0.3	0.0	0.0	0.0	1.9	0.0	0.0	0.2	0.0	7.2	0.0	0.0	1303.6	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.1	0.0	0.0	25.0
MMP10	STMY2	ENSG00000166670	"Matrix metallopeptidase 10"	P09238	11	102770503-102780628	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"endometrium 1: 89.4"	"Cell type enhanced"	"Detected in some"	14	"Basal glandular cells: 38.9;Club cells: 70.5;Collecting duct cells: 27.9;Pancreatic endocrine cells: 62.0"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 102.2"	"Region enriched"	"Detected in single"	9	"pons and medulla: 2.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ: 12.6;HUVEC TERT2: 16.2;SCLC-21H: 5.2"	"Not detected"	"Not detected"							CAB002159	Uncertain		Approved	"Plasma membrane,Cytosol"	"Secreted to extracellular matrix"	NA	NA	765000		Cytosol	"Plasma membrane"	"CAB002159: AB_564103"	"unprognostic (8.76e-2)"	"unprognostic (3.38e-1)"	"unprognostic (1.98e-3)"	"unprognostic (2.72e-3)"	"unprognostic (7.17e-3)"	"unprognostic (1.52e-2)"	"unprognostic (5.67e-8)"	"unprognostic (2.08e-3)"	"unprognostic (2.20e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.67e-2)"	"unprognostic (2.67e-1)"	"unprognostic (6.99e-5)"	"unprognostic (2.66e-2)"	"unprognostic (7.98e-2)"	"unprognostic (5.46e-2)"	"prognostic favorable (7.12e-4)"	0.1	0.1	0.0	2.6	0.2	0.1	0.1	0.0	0.3	1.7	0.5	0.0	0.0	0.4	89.4	0.1	0.2	0.1	0.5	0.1	0.0	0.1	0.1	3.6	11.0	0.1	0.0	0.0	0.5	0.3	0.1	0.9	19.8	2.8	3.2	0.2	0.0	2.9	0.1	0.1	0.1	0.7	0.1	0.0	0.2	3.3	0.5	0.0	1.2	0.1	0.0	1.9	0.6	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.8	0.2	0.0	0.0	0.2	12.6	0.7	0.1	0.1	0.3	0.0	0.0	3.7	1.9	0.2	2.9	0.0	1.4	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.6	0.0	16.2	0.0	0.7	0.0	0.0	0.0	0.0	0.3	3.0	0.5	1.7	0.0	0.0	0.0	0.0	0.7	5.2	0.0	2.5	0.0	0.0	0.9	0.0	0.0	2.0	3.9	1.3	0.4	0.5	0.0	0.0	0.0	0.6	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.1	0.0	0.0	2.8	0.0	0.0	0.0	0.0	38.9	0.7	0.0	0.0	0.0	5.3	70.5	27.9	0.0	0.0	0.0	9.8	5.0	0.0	0.0	0.0	12.9	0.0	0.2	5.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.2	0.0	2.8	0.0	0.0	62.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.1	0.0	0.0	0.0	7.4
MMP11	STMY3	ENSG00000099953	"Matrix metallopeptidase 11"	P24347	22	23768226-23784316	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"endometrium 1: 44.1;placenta: 119.6"	"Cell type enhanced"	"Detected in many"	15	"Extravillous trophoblasts: 34.6;Syncytiotrophoblasts: 15.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 7.8"	"Group enriched"	"Detected in many"	5	"B-cells: 2.4;dendritic cells: 7.8"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 18.7;hTERT-RPE1: 9.7;REH: 7.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002593, HPA068864"	Approved				"Secreted to extracellular matrix"	NA	NA					"CAB002593: , HPA068864: AB_2686051"	"unprognostic (1.06e-1)"	"unprognostic (3.08e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.84e-3)"	"unprognostic (2.77e-2)"	"unprognostic (6.73e-2)"	"unprognostic (2.14e-2)"	"unprognostic (5.15e-1)"	"unprognostic (2.73e-2)"	"unprognostic (2.20e-1)"	"unprognostic (1.89e-3)"	"unprognostic (7.04e-2)"	"prognostic unfavorable (2.62e-4)"	"unprognostic (8.05e-2)"	"unprognostic (6.78e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.68e-2)"	1.7	0.6	0.2	1.0	0.6	0.1	1.6	1.0	0.5	13.4	1.8	0.4	0.4	1.9	44.1	1.1	0.8	2.2	2.0	3.1	0.5	0.0	1.7	0.5	0.7	1.8	0.4	0.2	7.7	1.1	0.2	0.3	119.6	0.5	1.4	1.0	0.8	2.5	0.4	0.5	2.0	4.0	2.7	0.3	0.9	0.7	3.4	0.2	2.6	0.5	0.6	0.9	1.6	2.1	2.4	7.8	0.0	0.0	0.0	1.0	0.1	0.1	0.0	2.3	18.7	2.8	4.2	0.0	0.2	5.0	0.6	0.4	0.0	0.6	0.6	3.5	1.3	0.9	0.1	1.0	0.0	0.2	0.0	0.3	0.0	0.0	1.0	2.1	0.0	0.0	2.7	0.4	0.5	0.0	9.7	2.9	0.2	0.3	0.0	0.6	0.1	0.0	0.0	0.6	0.5	0.1	7.8	0.0	0.2	0.3	0.0	2.9	5.0	1.9	0.3	0.0	3.0	1.7	0.0	1.3	0.3	0.0	0.7	0.0	0.1	0.0	2.5	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	2.4	1.0	0.3	0.0	0.0	0.0	7.8	0.0	0.1	0.2	0.6	1.0	0.5	0.5	0.0	0.4	0.2	0.5	0.2	0.0	4.5	0.8	0.8	0.9	0.4	4.3	2.5	1.4	0.0	0.0	0.0	0.3	1.7	5.9	6.6	0.2	0.0	0.0	0.6	34.6	5.7	0.4	1.1	0.0	0.7	0.0	1.7	1.3	0.0	8.0	0.6	0.0	1.7	0.0	0.8	0.5	1.6	0.0	0.4	2.2	0.6	0.0	2.0	1.1	2.7	0.5	15.6	0.0	0.8	0.3
MMP12	HME	ENSG00000262406	"Matrix metallopeptidase 12"	P39900	11	102862736-102875034	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 42.4;urinary bladder: 13.2"	"Cell type enriched"	"Detected in some"	5	"Extravillous trophoblasts: 80.4"	"Low cancer specificity"	"Detected in all"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	12	"BJ: 4.2;fHDF/TERT166: 14.6;hTEC/SVTERT24-B: 8.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Secreted to extracellular matrix"	NA	NA						"unprognostic (7.33e-2)"	"unprognostic (3.20e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.74e-1)"	"unprognostic (1.67e-1)"	"prognostic unfavorable (1.42e-4)"	"unprognostic (1.69e-2)"	"unprognostic (7.31e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.52e-3)"	"unprognostic (5.45e-2)"	"unprognostic (3.05e-6)"	"unprognostic (1.08e-2)"	"unprognostic (4.66e-2)"	"unprognostic (1.73e-1)"	"unprognostic (6.92e-2)"	2.7	0.0	0.0	21.2	0.0	0.0	0.0	0.0	0.0	0.3	6.9	0.0	0.0	3.3	0.0	5.9	0.0	0.0	1.0	0.0	0.0		0.0	0.4	0.6	18.9	0.0	0.0	0.1	0.0	0.0	0.0	9.7	0.0	0.3	8.4	0.0	0.9	0.0	0.0	0.0	3.8	4.6	0.0	42.4	1.3	0.1	0.0	5.5	0.0	1.5	9.9	13.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.4	0.2	0.0	0.1	0.0	0.0	0.0	14.6	0.1	0.5	0.0	0.0	0.4	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.5	0.6	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.0	0.0	0.0	0.0	0.0	17.0	80.4	0.0	0.0	0.0	0.0	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	1.4
MMP13	CLG3	ENSG00000137745	"Matrix metallopeptidase 13"	P45452	11	102942995-102955734	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lung: 12.6;vagina: 10.8"	"Group enriched"	"Detected in some"	8	"Club cells: 30.7;Urothelial cells: 14.0"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 70.9"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"HaCaT: 19.5;PC-3: 7.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB002742	Supported				"Secreted to extracellular matrix"	NA	NA					"CAB002742: "	"unprognostic (8.98e-3)"	"unprognostic (1.54e-1)"	"unprognostic (4.75e-2)"	"unprognostic (4.57e-2)"	"unprognostic (3.05e-2)"	"unprognostic (1.59e-3)"		"unprognostic (1.32e-1)"	"unprognostic (6.35e-3)"	"unprognostic (1.69e-1)"	"unprognostic (7.55e-3)"	"unprognostic (2.24e-1)"	"unprognostic (1.73e-8)"	"unprognostic (2.12e-2)"	"unprognostic (3.14e-1)"	"unprognostic (4.14e-2)"	"unprognostic (4.33e-2)"	0.5	0.1	0.0	0.8	0.0	1.3	0.4	0.0	0.2	1.3	0.1	0.0	0.0	0.6	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.1	12.6	0.1	0.0	0.0	0.1	0.0	0.0	3.1	0.1	0.1	1.2	0.0	0.0	0.6	0.0	0.0	1.0	0.5	0.0	0.0	0.1	0.1	1.9	0.0	1.4	0.0	0.0	0.1	4.6	10.8	1.0	0.7	2.7	0.5	1.9	1.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	19.5	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.1	0.0	0.0	0.0	7.4	0.0	0.0	0.1	0.0	1.9	0.0	0.1	0.1	2.3	0.0	0.0	0.0	0.0	0.0	2.8	1.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	2.7	0.5	0.6	1.3	0.4	1.0	0.5	0.7	0.8	0.3	1.0	0.6	1.1	1.9	1.9	0.3	0.7	0.4	0.5	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.1	0.0	2.7	30.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.0
MMP16	"C8orf57, DKFZp761D112, MT3-MMP"	ENSG00000156103	"Matrix metallopeptidase 16"	P51512	8	88032009-88328025	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 15.9"	"Cell type enhanced"	"Detected in some"	11	"Bipolar cells: 3.9;Early spermatids: 4.9;Fibroblasts: 9.9;Late spermatids: 4.7"	"Cancer enhanced"	"Detected in many"		"glioma: 4.8"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 20.4;HUVEC TERT2: 8.8;SH-SY5Y: 11.4;U-138 MG: 9.7;WM-115: 20.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023693	Uncertain		Approved	Vesicles,Cytosol	"Secreted to extracellular matrix"	NA	NA			Cytosol	Vesicles	"HPA023693: AB_1854025"	"unprognostic (2.58e-1)"	"unprognostic (2.42e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.87e-1)"	"unprognostic (7.09e-2)"	"unprognostic (3.31e-2)"	"unprognostic (2.39e-3)"	"unprognostic (1.45e-3)"	"unprognostic (2.46e-1)"	"unprognostic (2.61e-1)"	"unprognostic (9.42e-2)"	"unprognostic (2.92e-1)"	"unprognostic (2.09e-8)"	"unprognostic (6.90e-3)"	"unprognostic (1.16e-1)"	"unprognostic (3.62e-1)"	"unprognostic (2.19e-3)"	2.4	1.3	11.0	1.4	6.8	0.5	4.9	8.3	15.9	5.3	2.2	2.9	0.7	0.8	4.9	2.1	1.7	2.1	7.3	2.7	8.7	6.9	0.8	0.9	1.0	1.0	5.5	9.1	3.3	2.1	1.5	1.7	3.0	6.3	3.2	1.7	0.6	1.2	2.4	0.7	1.1	1.3	4.0	4.6	1.5	1.4	1.5	5.5	0.0	3.2	0.7	1.0	2.6	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	5.5	20.4	0.7	1.4	0.0	7.5	1.1	2.1	1.3	0.0	0.0	0.0	0.0	3.3	1.2	0.0	4.0	0.0	2.6	0.0	2.4	0.0	0.0	0.0	1.7	0.0	0.3	1.0	0.0	3.1	0.9	3.8	8.8	0.0	0.0	0.7	1.1	0.0	0.0	0.0	1.2	0.0	2.0	0.2	0.4	0.0	0.4	0.0	0.1	11.4	0.0	0.0	0.1	1.6	0.8	0.0	4.9	9.7	5.5	0.1	2.8	0.0	0.0	0.0	3.9	0.0	20.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.0	6.8	8.3	14.1	8.7	6.9	5.5	9.1	6.3	5.5	0.0	0.0	0.0	0.0	1.0	3.9	0.6	0.0	0.0	0.0	0.0	2.0	0.0	1.7	0.0	4.9	2.9	0.0	0.0	0.0	0.0	9.9	0.0	0.0	0.0	0.3	1.6	0.0	0.6	0.0	4.7	0.9	0.6	1.7	0.0	0.0	3.2	0.2	0.0	1.1	0.0	0.3	0.0	1.3	0.0	0.9	0.1	0.0	0.0	0.0	0.0
MMP17	MT4-MMP	ENSG00000198598	"Matrix metallopeptidase 17"	Q9ULZ9	12	131828393-131851783	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 23.3"	"Cell type enriched"	"Detected in some"	7	"Melanocytes: 27.0"	"Cancer enriched"	"Detected in many"	10	"melanoma: 29.9"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	9	"classical monocyte: 2.2;intermediate monocyte: 2.1;memory B-cell: 1.4;myeloid DC: 1.2;naive B-cell: 1.7;non-classical monocyte: 2.7"	"Group enriched"	"Detected in many"	9	"B-cells: 1.7;dendritic cells: 1.2;monocytes: 2.7"	"Group enriched"	"Detected in many"	4	"REH: 17.3;SK-MEL-30: 42.1;WM-115: 62.3"	"Group enriched"	"Detected in many"	5	"amygdala: 51.6;basal ganglia: 52.2;cerebral cortex: 70.8;hippocampal formation: 73.1;hypothalamus: 21.6"	"Low region specificity"	"Detected in all"								"Secreted to extracellular matrix"	NA	NA						"unprognostic (9.11e-2)"	"unprognostic (1.27e-2)"	"unprognostic (1.69e-2)"	"unprognostic (3.71e-3)"	"unprognostic (5.62e-2)"	"unprognostic (1.85e-2)"	"unprognostic (8.90e-3)"	"unprognostic (2.14e-2)"	"unprognostic (2.60e-1)"	"unprognostic (2.66e-4)"	"unprognostic (7.68e-2)"	"unprognostic (5.88e-2)"	"unprognostic (9.26e-10)"	"unprognostic (1.15e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.21e-3)"	"unprognostic (2.81e-2)"	4.6	2.0	12.6	3.0	23.3	6.2	2.5	1.4	21.5	5.6	3.0	3.1	0.0	1.4	4.2	0.9	2.1	2.1	7.0	1.1	22.5	10.1	0.5	0.5	1.8	5.5	3.7	7.6	9.0	5.0	3.1	0.7	1.1	2.2	1.6	0.8	1.6	8.5	2.5	1.6	9.7	1.9	1.7	1.6	4.8	1.4	2.9	3.5	0.0	0.8	1.5	1.6	2.8	2.8	1.7	1.2	0.2	2.7	0.1	0.0	1.1	0.1	5.3	0.2	0.5	4.3	1.7	0.1	2.7	6.7	2.6	2.7	0.0	1.5	0.0	2.2	4.2	1.6	2.3	2.2	2.5	0.5	0.0	0.3	0.9	1.9	0.0	5.3	0.0	3.8	2.6	0.7	3.7	0.9	1.0	3.5	0.0	1.0	0.1	3.3	4.7	0.1	4.0	2.4	1.6	3.2	17.3	0.0	2.0	0.0	0.0	2.3	0.7	0.3	0.9	42.1	0.7	4.9	10.0	2.7	0.7	0.7	3.8	0.3	0.0	0.0	0.0	1.4	0.5	62.3	0.1	2.2	0.0	0.0	2.1	0.0	1.4	0.0	0.0	1.2	1.7	0.0	0.0	0.2	0.1	2.7	0.0	0.0	1.1	12.6	23.3	1.4	17.9	22.5	10.1	3.7	7.6	2.2	3.5	0.0	0.0	0.0	0.1	2.3	0.5	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.1	1.0	0.2	0.0	0.0	0.6	3.2	0.0	1.3	4.0	0.0	0.9	0.4	27.0	0.0	0.0	0.2	0.0	0.0	1.8	0.3	0.0	0.0	1.0	0.5	0.4	1.0	0.0	0.0	0.0	0.1
MMP19	"MMP18, RASI-1"	ENSG00000123342	"Matrix metallopeptidase 19"	Q99542	12	55835433-55842966	"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Angiogenesis, Collagen degradation, Differentiation"	"Developmental protein, Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 60.7"	"Cell type enhanced"	"Detected in many"	8	"Extravillous trophoblasts: 42.0;Hofbauer cells: 31.2;Kupffer cells: 30.5;Macrophages: 48.2;monocytes: 38.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	16	"classical monocyte: 3.2;myeloid DC: 1.0"	"Group enriched"	"Detected in many"	16	"dendritic cells: 1.0;monocytes: 3.2"	"Cell line enriched"	"Detected in many"	6	"BEWO: 57.2"	"Region enriched"	"Detected in single"	6	"olfactory region: 8.8"	"Low region specificity"	"Detected in all"			HPA070804			Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to extracellular matrix"	NA	NA		800000	"Endoplasmic reticulum, Vesicles"		"HPA070804: AB_2686315"	"unprognostic (2.61e-1)"	"unprognostic (6.56e-2)"	"unprognostic (2.28e-2)"	"unprognostic (2.42e-1)"	"unprognostic (4.77e-3)"	"unprognostic (4.77e-3)"	"unprognostic (2.01e-2)"	"unprognostic (4.03e-2)"	"unprognostic (2.85e-2)"	"unprognostic (4.30e-2)"	"unprognostic (2.37e-1)"	"unprognostic (2.09e-1)"	"prognostic unfavorable (8.56e-9)"	"unprognostic (5.06e-3)"	"unprognostic (1.28e-3)"	"unprognostic (2.73e-2)"	"unprognostic (4.00e-2)"	60.7	1.9	0.2	10.9	0.7	0.0	9.9	0.2	0.5	7.6	3.9	0.4	1.4	0.8	12.7	6.0	3.6	11.8	30.3	4.7	0.6	0.1	4.1	3.0	14.0	15.5	0.5	0.2	7.4	8.1	0.0	0.5	24.5	1.0	2.9	2.8	3.1	2.0	3.5	2.1	2.7	4.1	7.7	0.8	27.4	5.0	2.9	0.2	2.7	3.3	1.8	7.1	5.9	3.5	0.0	1.0	0.1	3.2	0.0	0.0	0.6	0.8	0.0	0.0	0.0	6.3	8.1	57.2	6.0	7.1	2.5	2.9	0.3	0.2	0.0	0.0	8.4	0.1	0.0	0.0	1.8	3.4	0.3	0.0	0.0	0.0	0.1	5.2	0.0	0.2	8.4	0.2	1.5	1.6	3.0	0.4	0.0	0.1	0.0	8.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.4	0.0	1.1	2.9	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.1	9.7	1.5	3.3	0.0	0.2	0.0	0.0	0.0	4.5	0.0	0.0	0.0	3.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.2	0.7	0.2	0.5	0.6	0.1	0.5	0.2	1.0	0.2	0.0	5.8	0.9	0.2	6.4	0.5	0.6	5.1	2.7	5.7	0.0	3.9	14.4	0.0	0.3	0.4	2.1	0.0	0.0	0.4	42.0	24.0	0.4	2.3	0.5	31.2	0.0	0.0	4.9	30.5	0.4	5.5	48.2	11.8	38.7	0.0	0.3	0.1	0.0	4.9	0.0	1.7	0.0	9.6	0.0	0.2	3.8	15.7	0.0	0.0	0.1
MMP2	"CLG4, CLG4A, TBE-1"	ENSG00000087245	"Matrix metallopeptidase 2"	P08253	16	55389700-55506691	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Angiogenesis, Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	11	"Extravillous trophoblasts: 217.4;Fibroblasts: 249.9;Leydig cells: 315.0;Peritubular cells: 393.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC diff: 292.5;ASC TERT1: 85.2;hTERT-RPE1: 329.2;U-87 MG: 93.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA001939, CAB002788"	Approved		Approved	Vesicles	"Secreted to extracellular matrix"	NA	NA	1600000000	160000000	Vesicles		"CAB002788: , HPA001939: AB_1079395"	"unprognostic (7.26e-2)"	"unprognostic (1.36e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.14e-3)"	"unprognostic (5.03e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.74e-1)"	"unprognostic (9.36e-3)"	"unprognostic (4.81e-3)"	"unprognostic (3.79e-2)"	"unprognostic (4.59e-3)"	"unprognostic (6.12e-2)"	"unprognostic (1.28e-3)"	"unprognostic (1.59e-2)"	"unprognostic (8.00e-2)"	"unprognostic (8.98e-2)"	"unprognostic (4.63e-2)"	197.5	9.0	1.2	13.2	1.6	0.0	136.4	0.8	1.4	74.3	74.4	2.4	36.9	5.6	85.0	123.0	52.3	25.7	115.4	54.0	0.9	0.5	9.4	3.5	38.9	3.9	1.5	1.1	71.0	6.5	0.7	2.2	58.9	2.2	66.8	18.7	36.4	18.6	20.4	68.6	68.2	22.6	57.1	1.8	12.4	20.5	57.0	1.1	1.3	20.6	31.8	9.1	84.1	105.3	0.0	0.0	0.9	0.7	0.0	0.0	0.0	0.3	0.1	9.7	0.1	292.5	85.2	15.9	25.0	57.5	5.0	4.0	0.0	0.1	0.0	20.1	44.1	1.9	2.7	0.0	0.2	2.9	0.0	0.0	0.0	0.6	0.1	27.7	0.0	0.7	72.6	0.0	26.0	0.2	329.2	32.7	0.0	0.0	0.1	16.8	0.0	0.0	0.3	7.7	0.0	0.0	0.0	2.3	0.0	0.8	0.3	0.1	17.6	4.6	0.0	0.1	45.4	0.0	1.7	45.9	79.6	7.6	15.2	3.2	0.0	0.0	0.0	93.1	1.3	14.5	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	0.0	0.0	0.0	1.2	1.6	0.8	1.4	0.9	0.5	1.5	1.1	2.2	1.1	0.0	0.3	0.0	13.0	108.4	5.2	3.1	0.0	0.0	3.4	10.4	0.0	5.4	0.0	1.7	11.5	11.9	0.0	0.0	0.3	217.4	249.9	2.7	0.0	0.0	25.6	1.6	27.1	15.4	0.0	26.9	315.0	5.3	121.4	0.0	0.0	5.0	6.9	0.0	393.8	0.0	1.8	12.9	70.0	1.2	2.1	89.5	14.4	0.0	0.0	3.8
MMP20		ENSG00000137674	"Matrix metallopeptidase 20"	O60882	11	102576835-102625332	"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Amelogenesis imperfecta, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 1.0;testis: 3.5"	"Cell type enriched"	"Detected in some"	10	"Early spermatids: 66.1"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	7	"OE19: 7.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Secreted to extracellular matrix"	NA	NA						"unprognostic (4.62e-3)"		"unprognostic (2.61e-2)"	"unprognostic (1.68e-3)"		"unprognostic (1.75e-1)"		"unprognostic (2.13e-1)"		"unprognostic (3.06e-1)"	"unprognostic (2.97e-2)"	"unprognostic (6.75e-2)"	"unprognostic (9.58e-5)"	"unprognostic (6.10e-2)"		"unprognostic (2.35e-1)"		0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0			0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.0	0.0	0.2	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5			0.0		1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.1	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	6.5	0.0	0.0	0.3	0.0	0.5	0.0	0.0	0.5
MMP21		ENSG00000154485	"Matrix metallopeptidase 21"	Q8N119	10	125766453-125775821	"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets, Heterotaxy"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	13	"epididymis: 37.6"	"Cell type enhanced"	"Detected in single"	32	"Distal tubular cells: 1.7"	"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in single"		"naive B-cell: 1.1"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"BEWO: 1.1;NB-4: 1.2;U-266/70: 2.1;U-266/84: 1.8"	"Not detected"	"Not detected"												"Secreted to extracellular matrix"	NA	NA						"unprognostic (1.32e-2)"	"unprognostic (1.28e-1)"	"unprognostic (8.51e-2)"	"unprognostic (2.19e-2)"	"unprognostic (4.02e-2)"	"unprognostic (2.21e-2)"	"unprognostic (4.22e-3)"	"unprognostic (1.01e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.48e-1)"	"unprognostic (2.89e-2)"	"unprognostic (3.62e-2)"	"unprognostic (9.70e-8)"	"unprognostic (1.30e-2)"	"unprognostic (7.69e-2)"	"unprognostic (7.00e-2)"	"unprognostic (2.18e-1)"	0.2	0.1	0.1	0.1	0.4	0.1	0.3	0.7	0.0	0.1	0.2			0.1	0.1	37.6	0.1	0.4	0.2	0.9	0.0	0.4	0.1	1.0	0.1	0.1	0.0		2.8	0.8	0.0	0.3	0.0		0.6	0.1		0.5	0.1	0.0	0.1	0.5	0.1	0.0	0.7	0.2	0.1			0.6		0.1	0.2	0.0	1.1	0.0	0.0	0.1	0.5	0.6	0.0	0.1	0.0	0.0	0.8	0.3	0.0	1.1	0.2	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.5	0.0	0.0	0.2	0.2	0.1	0.0	0.3	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.0	1.2	0.1	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.1	0.1	0.2	0.3	0.0	0.1	0.0	0.1	0.0	0.0	0.3	0.7	0.0	2.1	1.8	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.6	0.0	0.0	1.1	0.0	0.4	0.0	0.5	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MMP24	MT5-MMP	ENSG00000125966	"Matrix metallopeptidase 24"	Q9Y5R2	20	35226654-35277000	"Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion"	"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 38.5"	"Cell type enhanced"	"Detected in some"	10	"Alveolar cells type 1: 14.9;Cholangiocytes: 12.7;Ductal cells: 7.5;Horizontal cells: 14.3;Proximal tubular cells: 7.3"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in all"	5	"cerebellum: 38.5"	"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"A549: 20.1;CACO-2: 30.6;EFO-21: 9.0;RPTEC TERT1: 13.8;U-2 OS: 10.4"	"Low region specificity"	"Detected in all"			"Region enriched"	"Detected in all"	4	"cerebellum: 91.3"	"HPA049280, HPA078816"	Approved		Approved	"Nucleoli,Plasma membrane"	"Secreted to extracellular matrix"	Yes	No			"Nucleoli, Plasma membrane"		"HPA049280: , HPA078816: "	"unprognostic (1.52e-3)"	"unprognostic (1.36e-1)"	"unprognostic (1.18e-1)"	"unprognostic (4.51e-4)"	"unprognostic (2.47e-2)"	"unprognostic (7.61e-3)"	"unprognostic (1.22e-1)"	"unprognostic (4.59e-2)"	"unprognostic (2.32e-2)"	"unprognostic (8.82e-2)"	"unprognostic (9.20e-3)"	"unprognostic (7.12e-2)"	"prognostic favorable (8.17e-11)"	"unprognostic (3.32e-2)"	"unprognostic (5.63e-2)"	"unprognostic (1.69e-2)"	"unprognostic (9.90e-4)"	1.6	1.3	4.0	0.4	7.8	0.6	0.4	38.5	8.9	0.7	0.3	1.3	0.2	2.8	1.6	0.9	0.2	2.8	0.6	1.0	2.7	3.2	8.6	0.9	6.1	0.3	1.8	1.5	0.9	8.0	0.0	3.8	0.6	1.7	2.2	0.1	0.5	0.4	6.0	0.2	1.5	1.7	2.5	0.9	0.6	0.7	0.4	1.4	0.2	0.8	0.2	0.2	0.5	0.2	0.8	0.4	2.2	0.8	0.6	1.2	0.3	0.3	20.1	0.0	0.1	0.1	0.0	0.6	1.1	1.3	2.1	1.1	30.6	5.4	0.0	9.0	1.4	0.7	0.3	4.7	0.0	0.9	0.1	0.2	1.1	0.6	0.3	0.0	0.0	0.2	0.1	0.1	0.1	0.0	0.6	0.0	0.1	0.0	0.3	0.2	0.2	0.1	0.1	7.7	0.0	1.4	0.0	0.1	0.0	13.8	0.1	8.0	5.5	1.4	0.5	0.2	1.8	0.3	0.1	0.3	4.3	10.4	1.0	0.4	0.1	0.1	0.0	0.9	0.1	0.6	1.0	0.6	0.1	1.0	0.7	1.2	0.6	0.7	0.8	0.4	0.8	0.6	0.6	2.2	0.6	0.8	0.2	0.0	0.3	4.0	7.8	38.5	5.3	2.7	3.2	1.8	1.5	1.7	1.4	14.9	1.0	0.0	0.1	0.1	3.6	0.6	12.7	0.0	2.3	1.8	0.0	0.0	5.0	7.5	0.6	0.7	0.3	0.0	0.8	0.1	0.2	0.4	0.0	0.2	0.0	14.3	0.0	0.0	0.3	0.0	0.3	0.0	1.7	0.0	0.0	0.2	2.1	0.0	0.0	7.3	0.3	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0
MMP25	"MMP20, MMPL1, MT6-MMP"	ENSG00000008516	"Matrix metallopeptidase 25"	Q9NPA2	16	3046681-3060726	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 17.6;bone marrow: 25.6;lymphoid tissue: 54.1"	"Group enriched"	"Detected in some"	4	"Alveolar cells type 2: 10.7;Kupffer cells: 5.9;monocytes: 23.4"	"Cancer enhanced"	"Detected in many"		"testis cancer: 7.1"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	6	"basophil: 10.2;eosinophil: 6.0;neutrophil: 17.6"	"Lineage enriched"	"Detected in many"	10	"granulocytes: 17.6"	"Cell line enriched"	"Detected in some"	12	"HMC-1: 50.5"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"CAB025177, HPA055640"	Uncertain		Supported	"Plasma membrane"	"Secreted to blood"	NA	NA			"Plasma membrane"		"CAB025177: , HPA055640: "	"unprognostic (4.51e-3)"	"unprognostic (9.28e-3)"	"unprognostic (7.57e-2)"	"unprognostic (2.95e-3)"	"unprognostic (2.26e-1)"	"prognostic favorable (1.09e-5)"	"unprognostic (1.36e-1)"	"unprognostic (7.39e-3)"	"unprognostic (7.63e-3)"	"unprognostic (2.29e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.53e-2)"	"unprognostic (2.37e-3)"	"unprognostic (1.17e-2)"	"unprognostic (8.30e-2)"	"unprognostic (4.01e-1)"	"unprognostic (2.02e-1)"	4.0	0.3	0.6	12.3	0.4	25.6	0.8	0.5	0.6	0.8	1.1	0.2	0.0	1.0	0.4	0.5	0.8	3.8	1.1	2.8	0.5	0.4	0.7	2.5	10.7	54.1	1.8	0.0	0.6	0.8	0.0	0.5	2.0	1.1	0.6	1.0	1.0	0.9	0.0	2.4	0.6	1.8	0.5	0.4	43.9	1.1	0.7	0.5	4.1	0.7	0.9	4.2	1.5	2.5	0.0	0.3	17.6	0.2	1.7	0.5	0.1	0.2	0.1	0.7	1.5	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.3	0.3	0.2	0.0	0.3	0.6	0.3	0.0	0.0	4.0	0.8	0.1	0.1	0.0	0.0	0.1	50.5	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.1	0.3	0.0	0.5	0.2	3.0	1.4	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.1	0.3	3.6	0.1	0.1	0.4	0.1	0.0	1.2	0.1	0.1	0.0	1.0	0.1	10.2	0.2	6.0	0.3	0.0	0.5	0.0	0.2	0.2	0.0	0.0	0.3	0.2	17.6	1.7	0.0	0.3	0.3	0.1	0.6	0.4	0.5	0.6	0.5	0.4	1.8	0.0	1.1	0.5	3.0	10.7	0.0	0.2	0.3	0.6	0.4	0.0	0.0	1.2	1.8	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.5	0.1	0.2	0.5	1.1	0.0	0.1	0.0	0.0	0.0	5.9	0.0	0.0	2.0	0.0	23.4	0.0	0.1	1.1	0.0	0.7	0.0	0.0	0.0	0.4	0.0	0.1	0.3	0.0	3.1	0.1	0.1
MMP26	"endometase, MGC126590, MGC126592"	ENSG00000167346	"Matrix metallopeptidase 26"	Q9NRE1	11	4704927-4992429	"Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	13	"endometrium 1: 19.1"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	20	"endometrial cancer: 8.8;prostate cancer: 2.0"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																"Secreted to extracellular matrix"	NA	NA									"unprognostic (4.21e-3)"								"unprognostic (2.63e-1)"						0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	19.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		1.4	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MMP28	"EPILYSIN, MM28, MMP-25, MMP-28"	ENSG00000271447	"Matrix metallopeptidase 28"	Q9H239	17	35756249-35795707	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Basal keratinocytes: 34.2;Enterocytes: 39.1;Mucus-secreting cells: 31.9;Paneth cells: 47.6;Urothelial cells: 34.5"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 7.2;naive CD8 T-cell: 5.9"	"Lineage enriched"	"Detected in many"	5	"T-cells: 7.2"	"Cell line enriched"	"Detected in some"	7	"HaCaT: 28.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA057288, HPA057890"			Approved	"Nucleoplasm,Focal adhesion sites"	"Secreted to extracellular matrix"	NA	NA			Nucleoplasm	"Focal adhesion sites"	"HPA057288: , HPA057890: "	"unprognostic (7.99e-3)"	"unprognostic (3.27e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.01e-1)"	"unprognostic (7.52e-2)"	"unprognostic (1.63e-1)"	"unprognostic (6.90e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.99e-1)"	"prognostic unfavorable (6.28e-6)"	"unprognostic (9.37e-2)"	"unprognostic (1.31e-1)"	"unprognostic (8.87e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.76e-2)"	"unprognostic (3.27e-3)"	8.0	1.6	1.8	2.7	3.7	0.5	4.3	0.0	5.1	1.7	7.3	1.6	1.4	3.0	3.2	4.8	4.3	1.5	12.3	0.5	2.8		0.8	0.2	10.3	0.4	0.0	2.9	0.1	1.3	0.5	0.0	0.7	1.3	2.9	4.1	2.7	0.1	2.1	0.6	4.5	9.3	4.3	0.2	0.6	7.2	13.4	0.2	0.0	4.2	4.4	2.5	5.5	2.2	1.1	1.5	0.1	0.2	1.3	7.2	0.9	0.1	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.1	0.7	0.0	0.1	28.7	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.1	0.0	0.0	0.0	2.6	0.0	0.1	0.0	0.2	0.2	0.0	0.1	0.0	0.2	0.1	0.2	0.0	3.9	0.2	0.6	0.0	0.0	0.0	1.6	0.2	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	2.0	1.1	0.4	1.7	0.1	0.9	7.2	5.9	0.1	1.3	0.2	1.5	0.0	0.9											26.8	20.8	0.0	5.1	34.2	0.4	1.0	2.5	5.3	5.7	7.0	0.0	0.0	0.0	0.1	5.0	8.1	39.1	0.0	0.3	0.0	1.6	1.8	0.0	0.0	0.1	1.6	3.5	6.2	0.0	7.1	1.1	0.9	3.3	0.0	31.9	9.1	9.7	47.6	2.8	0.7	0.5	6.5	2.0	0.5	2.5	29.0	0.0	0.7	18.5	34.5
MMP3	"STMY, STMY1"	ENSG00000149968	"Matrix metallopeptidase 3"	P08254	11	102835801-102843803	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"epididymis: 177.5;salivary gland: 73.4"	"Cell type enhanced"	"Detected in some"	10	"Basal glandular cells: 11.5;Basal keratinocytes: 7.4;Club cells: 11.4;Early spermatids: 14.6"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 59.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	17	"BJ: 101.3;BJ hTERT+: 275.6;fHDF/TERT166: 119.3"					"Low region specificity"	"Detected in many"			HPA007875	Uncertain		Supported	Vesicles	"Secreted to extracellular matrix"	NA	NA	2540000	170000	Vesicles		"HPA007875: AB_1079396"	"unprognostic (2.27e-1)"	"prognostic unfavorable (9.73e-4)"	"unprognostic (1.63e-3)"	"unprognostic (5.11e-3)"	"unprognostic (3.78e-1)"	"unprognostic (5.11e-2)"	"unprognostic (5.26e-6)"	"unprognostic (3.46e-2)"	"unprognostic (7.14e-2)"	"unprognostic (2.87e-1)"	"prognostic unfavorable (4.09e-4)"	"unprognostic (3.26e-2)"	"unprognostic (1.22e-15)"	"unprognostic (3.17e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.43e-2)"	"unprognostic (2.34e-1)"	19.1	0.0	0.2	14.4	0.3	0.0	6.9	0.2	0.5	0.2	1.5	0.3	0.2	1.8	28.3	177.5	0.2	0.0	1.4	0.2	0.2	0.0	0.3	0.5	0.4	0.2	0.2	0.2	0.3	0.2	0.0	0.2	0.2	0.2	1.2	1.7	0.2	73.4	1.5	7.3	12.6	0.7	5.9	0.2	0.2	2.8	1.4	0.2	0.2	0.6	1.5	0.9	7.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	101.3	275.6	1.8	0.5	0.0	0.0	0.0	0.0	119.3	6.8	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	8.1	0.4	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	9.4	0.8	0.1	0.0	0.0	0.0	0.0	3.9	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.2	0.5	0.2	0.0	0.2	0.2	0.2	0.2	3.0	0.0	0.0	11.5	7.4	0.0	0.2	5.1	0.0	11.4	0.0	0.0	0.1	0.0	0.7	14.6	0.0	0.0	0.0	1.2	2.2	1.3	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.3	0.6	0.0	0.0	0.0	0.0	1.0	0.0	0.9	3.0	0.2	0.0	0.1	5.2
MMP7	"MPSL1, PUMP-1"	ENSG00000137673	"Matrix metallopeptidase 7"	P09237	11	102520508-102530753	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 93.0;kidney: 129.5;salivary gland: 79.3"	"Cell type enriched"	"Detected in many"	6	"Ductal cells: 5335.6"	"Cancer enhanced"	"Detected in all"		"pancreatic cancer: 352.1"	"Region enriched"	"Detected in single"	5	"pons and medulla: 1.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 23.2;CAPAN-2: 129.5;EFO-21: 30.7;RPTEC TERT1: 56.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB025869, HPA051358"	Supported		Approved	Nucleoplasm,Vesicles	"Secreted to extracellular matrix"	NA	NA	2810000		"Nucleoplasm, Vesicles"		"CAB025869: , HPA051358: AB_2681452"	"unprognostic (1.06e-3)"	"unprognostic (9.51e-2)"	"unprognostic (4.15e-2)"	"unprognostic (1.38e-1)"	"unprognostic (7.70e-3)"	"unprognostic (7.28e-2)"	"prognostic unfavorable (2.53e-4)"	"prognostic unfavorable (3.38e-4)"	"unprognostic (3.96e-2)"	"unprognostic (5.63e-2)"	"unprognostic (6.59e-3)"	"unprognostic (1.51e-1)"	"unprognostic (6.36e-3)"	"unprognostic (1.42e-2)"	"unprognostic (5.54e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.46e-1)"	6.8	0.2	0.2	1.2	0.2	0.0	28.8	0.2	0.2	5.2	0.2	0.2	2.1	0.0	17.2	12.3	3.3	16.4	93.0	0.2	0.2	0.2	129.5	1.4	5.0	0.9	0.2	0.2	3.9	23.5	0.0	0.7	2.7	1.3	42.0	0.0	0.2	79.3	6.7	0.2	7.8	0.3	0.5	0.2	0.2	0.9	9.4	0.2	1.2	0.3	1.4	4.5	19.9	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	23.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.3	129.5	0.0	30.7	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	56.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.4	0.0	0.2	0.0	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	1.3	0.2	80.4	30.5	0.0	310.5	0.9	0.0	0.6	119.8	113.8	646.0	964.8	0.0	0.3	0.0	5335.6	3.9	0.3	0.0	0.0	184.1	0.2	0.4	323.2	2.3	0.0	103.8	0.0	0.0	0.0	0.0	6.5	10.9	7.3	0.0	113.6	0.0	0.0	723.2	0.0	0.0	6.0	0.0	0.0	0.4	0.0	0.1	2.0	0.7	0.0	0.0	640.3
MMP8	CLG1	ENSG00000118113	"Matrix metallopeptidase 8"	P22894	11	102711795-102727050	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"bone marrow: 119.3"	"Cell type enriched"	"Detected in single"	32	"Hofbauer cells: 4.3"	"Cancer enriched"	"Detected in single"	17	"melanoma: 5.7"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.7"	"Group enriched"	"Detected in some"	32	"neutrophil: 1.4;non-classical monocyte: 4.9"	"Group enriched"	"Detected in many"	32	"granulocytes: 1.4;monocytes: 4.9"	"Cell line enriched"	"Detected in some"	8	"WM-115: 40.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA021221, HPA022935"	Enhanced				"Secreted to extracellular matrix"	NA	NA		83000			"HPA021221: AB_1854043, HPA022935: AB_1854044"	"unprognostic (3.03e-1)"	"unprognostic (8.49e-5)"	"unprognostic (1.08e-2)"	"unprognostic (3.95e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.01e-2)"		"unprognostic (7.68e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.92e-2)"	"unprognostic (6.64e-3)"		"unprognostic (2.45e-6)"	"unprognostic (2.33e-4)"	"unprognostic (1.33e-1)"	"unprognostic (4.97e-1)"	"unprognostic (2.30e-2)"	1.9	0.1	0.2	0.2	0.4	119.3	0.3	0.1	1.7	0.1	0.2	0.0	0.0	0.1	0.6	0.1	0.1	0.1	0.1	9.0	0.2	0.3	0.4	0.8	12.6	2.6	0.3	0.0	0.9	0.9	0.1	0.6	1.4	0.2	0.1	0.1	0.1	0.3	0.1	0.6	0.3	0.1	0.2	0.3	18.7	0.2	0.1	0.1	5.2	1.9	0.0	0.1	0.2	7.6	0.0	0.0	1.4	4.9	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	4.9	0.0	0.0	1.7	0.2	0.4	0.1	1.7	0.2	0.3	0.3	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MMP9	CLG4B	ENSG00000100985	"Matrix metallopeptidase 9"	P14780	20	46008908-46016561	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"adipose tissue: 64.0;blood: 63.2;bone marrow: 89.4;lymphoid tissue: 80.1"	"Cell type enhanced"	"Detected in many"	25	"Hofbauer cells: 273.8;Macrophages: 115.1;Melanocytes: 54.0"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	141	"neutrophil: 63.2"	"Lineage enriched"	"Detected in single"	339	"granulocytes: 63.2"	"Cell line enriched"	"Detected in some"	12	"NB-4: 89.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201"	Enhanced		Approved	Cytosol	"Secreted to blood"	NA	NA	43300000	57000000	Cytosol		"CAB000348: , CAB068199: AB_2665675, CAB068200: AB_2665676, CAB068201: AB_2665677, HPA001238: AB_1079398, HPA063909: AB_2685150"	"unprognostic (4.62e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.85e-2)"	"prognostic favorable (2.55e-4)"	"unprognostic (6.65e-3)"	"unprognostic (2.82e-1)"	"prognostic unfavorable (7.19e-4)"	"unprognostic (1.54e-1)"	"unprognostic (8.57e-2)"	"unprognostic (3.21e-2)"	"unprognostic (4.15e-2)"	"unprognostic (1.96e-1)"	"prognostic unfavorable (4.05e-5)"	"unprognostic (4.65e-1)"	"unprognostic (9.85e-3)"	"unprognostic (2.48e-2)"	"unprognostic (2.17e-3)"	64.0	0.5	0.6	38.6	0.7	89.4	4.3	0.4	0.6	0.8	1.2	0.1	0.0	2.8	0.6	0.2	0.9	1.5	0.6	4.0	0.5	0.6	1.4	2.0	13.3	80.1	0.6	0.0	2.7	1.4	0.0	0.8	2.6	0.5	0.6	0.8	0.5	12.5	0.0	1.3	1.3	4.2	0.3	0.5	53.7	2.5	2.7	0.0	23.6	1.3	2.3	44.5	4.5	2.9	0.0	0.0	63.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.8	0.0	7.5	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.9	0.0	89.4	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	1.0	0.0	0.3	0.0	2.7	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	63.2	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.4	0.6	0.5	0.6	0.6	0.0	0.5	0.0	0.0	8.5	0.0	0.0	30.5	1.6	0.4	0.0	0.0	0.0	0.0	7.9	0.9	0.0	0.8	0.6	0.5	0.0	0.0	1.5	2.0	1.7	0.1	1.1	0.0	273.8	3.2	0.0	0.0	1.9	0.0	0.0	115.1	54.0	3.6	0.0	0.5	1.6	0.0	0.0	0.3	4.3	0.0	12.3	5.4	5.5	24.6	1.6	0.0	0.0	0.0
PCSK9	"FH3, HCHOLA3, NARC-1"	ENSG00000169174	"Proprotein convertase subtilisin/kexin type 9"	Q8NBP7	1	55039548-55064852	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Apoptosis, Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"liver: 47.1;lung: 14.6"	"Cell type enhanced"	"Detected in some"	13	"Alveolar cells type 1: 14.9;Alveolar cells type 2: 15.3;Hepatocytes: 17.0"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"cerebellum: 6.9;pons and medulla: 2.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 29.1;CACO-2: 13.5;HaCaT: 38.9;HeLa: 33.9;RPTEC TERT1: 19.2"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"								"Secreted to blood"	NA	NA	143000000	300000000				"unprognostic (1.28e-3)"	"unprognostic (6.93e-2)"	"unprognostic (4.02e-1)"	"unprognostic (2.19e-2)"	"unprognostic (7.30e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.20e-3)"	"unprognostic (1.14e-2)"	"unprognostic (5.44e-3)"	"unprognostic (1.22e-2)"	"unprognostic (2.09e-3)"	"unprognostic (3.70e-2)"	"unprognostic (2.45e-4)"	"unprognostic (1.49e-1)"	"unprognostic (1.86e-1)"	"unprognostic (2.13e-1)"	"prognostic unfavorable (2.40e-4)"	0.2	0.1	0.0	6.1	0.5	0.4	0.0	6.9	0.2	0.6	4.4	0.0	0.0	3.9	0.2	0.7	5.2	0.4	2.6	0.0	0.0	0.0	0.1	47.1	14.6	0.0	0.1	0.0	0.1	11.0	0.0	0.0	0.0	2.6	0.0	1.9	0.1	0.3	0.3	0.0	0.8	5.1	0.8	0.1	0.2	1.0	0.4	0.0	0.0	0.0	6.1	0.9	0.6	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.1	6.5	0.9	0.0	2.1	1.5	0.1	0.0	0.0	0.0	0.0	13.5	4.6	0.0	5.3	2.5	0.1	38.9	1.1	11.8	0.0	0.0	0.0	0.0	33.9	9.4	0.7	0.0	0.0	2.3	8.8	8.5	6.2	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	5.5	0.5	0.7	0.0	0.0	0.3	19.2	0.0	0.5	0.0	3.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	6.9	0.2	0.0	0.0	0.1	0.0	2.6	0.0	14.9	15.3	0.0	0.0	0.5	0.0	0.6	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.5	0.0	1.3	0.0	0.4	0.1	0.0	17.0	0.1	0.0	4.1	1.8	1.6	0.2	0.0	0.0	1.7	0.0	2.2	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.5	0.0	0.0	2.9	0.2
PGF	"D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760"	ENSG00000119630	"Placental growth factor"	P49763	14	74941834-74955784	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"placenta: 177.3"	"Group enriched"	"Detected in many"	16	"Extravillous trophoblasts: 1478.5;Syncytiotrophoblasts: 1775.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	6	"BEWO: 93.4;HUVEC TERT2: 44.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA041624			Approved	Nucleoplasm,Mitochondria,Cytosol	"Secreted to blood"	No	No	20800		Nucleoplasm	"Mitochondria, Cytosol"	"HPA041624: AB_10794522"	"unprognostic (1.67e-2)"	"unprognostic (4.62e-2)"	"unprognostic (9.25e-3)"	"unprognostic (1.34e-3)"	"unprognostic (8.67e-3)"	"unprognostic (2.41e-1)"	"prognostic unfavorable (1.40e-4)"	"unprognostic (7.26e-2)"	"unprognostic (1.48e-1)"	"unprognostic (4.45e-1)"	"unprognostic (1.45e-2)"	"unprognostic (3.51e-3)"	"prognostic unfavorable (1.33e-6)"	"unprognostic (2.52e-3)"	"unprognostic (1.20e-1)"	"unprognostic (3.49e-2)"	"unprognostic (1.14e-1)"	4.3	2.7	1.9	4.4	2.4	0.0	4.3	1.6	3.5	13.1	2.3	2.3	4.0	1.3	2.9	6.3	3.9	9.2	3.4	5.1	2.4	4.1	3.1	2.6	3.6	4.9	2.9	2.0	3.8	1.9	5.4	2.0	177.3	4.6	7.5	1.1	3.5	3.8	6.7	3.3	6.0	4.3	4.6	1.7	1.2	1.7	3.3	2.0	1.4	24.2	4.4	2.9	5.1	5.9	0.7	0.7	1.1	1.0	0.0	2.4	0.2	0.3	0.3	0.3	0.3	0.4	0.0	93.4	0.8	0.8	0.4	0.5	2.2	0.1	0.0	2.0	0.6	0.0	0.1	0.4	4.2	0.3	0.0	0.5	0.0	0.0	2.2	0.3	0.0	2.4	1.1	1.0	1.7	0.4	0.1	44.0	0.0	0.0	0.0	12.4	0.1	0.0	0.1	0.4	0.0	0.7	0.0	11.6	0.0	0.1	0.2	7.0	3.8	0.0	0.1	1.6	5.9	0.0	0.1	8.9	0.0	2.3	0.0	3.7	0.0	0.0	0.1	1.4	0.1	0.1	0.0	0.2	1.1	2.4	1.0	0.0	0.7	0.3	0.7	0.3	0.3	0.6	1.0	0.0	0.0	0.8	0.7	0.5	0.2	1.9	2.4	1.6	2.2	2.4	4.1	2.9	2.0	4.6	2.0	8.9	5.8	0.8	13.0	21.9	0.8	2.8	0.0	1.4	7.9	0.0	13.7	75.1	0.0	0.9	0.1	15.8	0.5	0.0	0.4	1478.5	42.9	3.3	5.8	0.0	33.1	0.0	6.8	7.4	0.3	0.6	12.0	4.5	20.3	0.0	1.1	1.9	0.6	0.2	18.4	0.4	7.5	103.5	62.6	0.2	3.4	17.1	1775.1	0.9	1.7	4.7
PLA2G1B	"PLA2, PLA2A, PPLA2"	ENSG00000170890	"Phospholipase A2 group IB"	P04054	12	120322111-120327789	"Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Lipid metabolism, Phospholipid metabolism"	Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	933	"pancreas: 2360.6"	"Cell type enriched"	"Detected in many"	10	"Exocrine glandular cells: 17927.2"	"Cancer enriched"	"Detected in many"	185	"pancreatic cancer: 763.5"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 2.5"	"Group enriched"	"Detected in many"	19	"NK-cells: 1.3;T-cells: 2.5"	"Cell line enhanced"	"Detected in some"		"EFO-21: 2.2;Hep G2: 6.4;U-2 OS: 4.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA047822, HPA060803"	Enhanced				"Secreted to digestive system"	NA	NA		3900000			"HPA047822: AB_2680169, HPA060803: AB_2684369"	"unprognostic (1.28e-4)"	"unprognostic (6.02e-2)"	"unprognostic (1.84e-2)"	"unprognostic (2.86e-2)"	"unprognostic (2.74e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.63e-2)"	"unprognostic (3.61e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.03e-1)"	"unprognostic (2.80e-4)"	"unprognostic (2.15e-1)"	"unprognostic (1.97e-1)"	"unprognostic (3.60e-1)"	"unprognostic (8.61e-4)"	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.1	0.0	0.1	0.1	1.1	0.1	0.1	0.1	1.1	2360.6	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	1.3	2.5	0.9	0.2	0.0	1.2	0.2	0.0	0.0	0.0	0.0	0.0	0.3	1.6	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.3	0.0	0.0	1.4	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.8	0.2	0.0	0.0	0.0	0.7	0.4	0.0	0.0	0.0	0.5	0.0	0.3	1.3	0.3	1.6	0.0	0.0	0.3	0.0	0.1	0.6	0.0	1.0	0.2	4.7	0.6	0.6	0.0	1.2	0.4	0.0	0.6	0.0	0.0	0.0	0.0	0.9	0.0	1.7	0.0	0.0	0.3	0.0	0.0	2.5	0.9	0.0	1.3	0.0	0.0	0.0	0.9	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	11.9	65.5	0.0	0.1	0.0	0.0	0.3	0.0	1.4	1.2	0.0	0.0	0.0	1.7	16.1	7.5	0.0	0.7	0.0	17927.2	0.0	0.0	0.2	0.0	1.6	0.0	0.0	1.2	0.0	0.0	27.8	2.8	0.3	0.0	76.7	1.0	0.0	1839.8	1.1	3.2	2.1	0.0	0.0	0.0	0.2	0.2	0.1	0.0	0.7	1.2	0.0
PLA2G2A	"PLA2B, PLA2L"	ENSG00000188257	"Phospholipase A2 group IIA"	P14555	1	19975431-19980416	"Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins"	"Inflammatory response, Lipid metabolism, Phospholipid metabolism"	"Antimicrobial, Bacteriolytic enzyme, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 377.9"	"Cell type enhanced"	"Detected in many"	11	"Enterocytes: 366.3;Exocrine glandular cells: 945.9;Glandular cells: 937.5;Paneth cells: 354.3;Undifferentiated cells: 591.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 875.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	23	"Hep G2: 23.4;OE19: 64.1;RT4: 21.5"					"Not detected"	"Not detected"			HPA015236	Enhanced				"Secreted to blood"	NA	NA	1000000	290000			"HPA015236: AB_10601047"	"unprognostic (2.33e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.79e-2)"	"unprognostic (7.85e-3)"	"unprognostic (8.71e-2)"	"unprognostic (9.27e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.80e-1)"	"prognostic favorable (1.49e-4)"	"unprognostic (1.68e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.58e-2)"	"unprognostic (3.77e-15)"	"unprognostic (2.72e-2)"	"unprognostic (9.14e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.51e-1)"	25.2	1.0	0.0	13.1	0.0	0.6	14.0	0.0	0.6	1.4	63.9	0.0	0.1	35.0	0.7	22.7	31.5	11.7	2.4	105.4	0.0	0.0	1.6	377.9	3.0	6.5	0.0	0.0	35.6	2.4	0.6	0.5	15.5	0.0	27.1	68.2	6.1	9.5	1.0	30.6	5.0	99.0	39.7	0.0	0.6	4.0	9.8	0.0	0.0	16.0	8.9	19.3	39.0	72.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	64.1	0.0	0.0	0.0	0.6	0.0	21.5	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	4.1	6.7	10.0	12.4	0.0	7.2	5.1	2.7	6.8	0.0	0.0	2.8	1.7	0.0	3.0	8.4	366.3	0.0	945.9	3.3	308.9	937.5	4.6	51.6	8.2	0.0	59.8	35.0	6.0	7.5	158.5	4.9	13.5	0.0	270.5	0.0	3.6	354.3	1.1	0.0	0.0	0.0	11.3	0.5	0.1	14.6	5.7	8.4	591.0	9.1
PLAT		ENSG00000104368	"Plasminogen activator, tissue type"	P00750	8	42175233-42207724	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Plasminogen activation"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 132.2"	"Cell type enhanced"	"Detected in many"	22	"Basal glandular cells: 379.6;Glandular cells: 176.4;granulocytes: 158.4;Urothelial cells: 792.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 2.1;T-reg: 2.3"	"Group enriched"	"Detected in many"	7	"granulocytes: 1.6;T-cells: 2.3"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 85.9;HMC-1: 55.1;hTERT-RPE1: 61.0;LHCN-M2: 55.7;U-2197: 58.1;WM-115: 115.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003412, CAB009335"	Supported		Approved	"Actin filaments"	"Secreted to blood"	NA	NA	9900000	12000	"Actin filaments"		"CAB009335: AB_2237146, HPA003412: AB_1858205"	"prognostic favorable (7.57e-4)"	"unprognostic (2.23e-1)"	"unprognostic (4.08e-1)"	"unprognostic (3.39e-1)"	"unprognostic (4.88e-3)"	"unprognostic (9.39e-2)"	"unprognostic (4.65e-3)"	"unprognostic (5.78e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.75e-1)"	"unprognostic (2.98e-3)"	"unprognostic (2.46e-1)"	"prognostic unfavorable (4.95e-4)"	"unprognostic (8.72e-3)"	"unprognostic (1.37e-2)"	"unprognostic (2.63e-2)"	"unprognostic (6.09e-2)"	19.3	14.9	5.2	12.9	6.8	0.4	13.3	2.2	6.2	24.5	17.1	9.1	19.0	11.2	35.5	28.1	18.1	19.1	18.5	7.3	6.0	5.9	67.6	2.8	15.9	1.9	8.2	3.6	18.4	5.8	132.2	5.1	15.5	9.4	27.4	12.2	39.4	6.1	12.7	5.8	2.0	31.7	23.0	7.0	1.0	14.6	12.2	3.8	0.6	11.2	14.7	7.4	47.9	13.7	0.3	0.1	1.6	0.0	0.0	2.3	0.3	0.5	0.2	4.2	1.0	7.7	10.5	0.1	18.1	32.0	7.7	6.6	0.2	85.9	0.0	0.6	2.3	3.7	1.4	0.0	4.0	15.9	7.9	1.4	0.1	0.1	0.1	37.9	0.0	55.1	10.5	0.0	18.8	0.7	61.0	14.4	0.0	0.5	0.1	55.7	0.0	0.0	0.0	5.6	0.0	7.6	0.0	15.6	0.0	2.5	0.0	0.0	0.9	0.0	0.1	24.6	8.2	0.1	0.0	27.5	1.5	5.7	58.1	1.8	0.0	0.1	0.0	1.2	0.0	115.5	1.6	0.0	0.0	0.3	0.0	1.0	0.3	2.1	0.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	2.3	0.3	5.2	6.8	2.2	6.2	6.0	5.9	8.2	3.6	9.4	3.8	0.0	20.2	2.4	379.6	9.6	4.1	7.6	0.0	5.3	11.4	0.0	3.9	0.5	0.0	0.6	0.8	82.6	0.0	0.0	0.6	1.1	19.9	176.4	158.4	1.0	1.5	1.6	0.0	36.8	0.6	0.8	3.4	7.8	21.9	2.8	0.0	2.0	30.5	0.0	2.5	0.1	3.7	12.9	17.6	0.7	0.4	11.8	0.6	3.8	0.4	792.4
PLAU	"UPA, URK"	ENSG00000122861	"Plasminogen activator, urokinase"	P00749	10	73909177-73917497	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis, Plasminogen activation"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 48.4"	"Cell type enhanced"	"Detected in many"	17	"Basal glandular cells: 550.8;Pancreatic endocrine cells: 366.2;Urothelial cells: 779.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	9	"myeloid DC: 2.4;neutrophil: 4.5;plasmacytoid DC: 4.5"	"Group enriched"	"Detected in many"	11	"dendritic cells: 4.5;granulocytes: 4.5"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 70.3;LHCN-M2: 67.8;RPTEC TERT1: 257.8;U-251 MG: 69.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA070796	Supported				"Secreted to blood"	NA	NA	647000	58000			"HPA070796: "	"unprognostic (1.96e-2)"	"unprognostic (2.99e-2)"	"unprognostic (7.40e-2)"	"prognostic favorable (3.38e-4)"	"unprognostic (4.73e-2)"	"prognostic unfavorable (2.70e-4)"	"unprognostic (1.39e-2)"	"prognostic unfavorable (4.04e-4)"	"unprognostic (2.26e-1)"	"unprognostic (6.58e-2)"	"prognostic unfavorable (1.32e-4)"	"unprognostic (1.61e-1)"	"prognostic unfavorable (3.51e-4)"	"unprognostic (2.83e-1)"	"unprognostic (3.37e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.77e-2)"	26.7	2.4	1.0	15.5	2.1	11.3	9.7	1.6	1.5	6.9	5.8	2.9	4.9	3.8	10.7	21.2	9.1	6.5	10.7	14.3	1.3	1.0	23.3	2.3	23.4	5.5	1.6	1.5	6.8	3.7	3.6	1.8	48.4	3.1	7.5	6.7	4.5	10.6	5.0	12.2	9.0	8.1	8.4	2.5	23.8	7.8	5.8	1.3	4.8	10.9	11.6	8.2	16.3	9.3	0.1	4.5	4.5	0.4	0.0	0.0	0.3	13.3	7.1	3.0	0.1	0.2	5.1	0.1	8.1	37.9	3.3	5.2	0.1	70.3	0.0	15.0	1.1	35.0	9.2	0.0	13.5	3.8	0.7	0.0	0.0	0.3	0.1	6.2	1.2	2.6	13.5	1.6	22.6	8.7	37.6	9.4	0.0	0.0	0.0	67.8	0.0	0.0	1.7	0.8	0.0	18.7	0.0	9.2	0.0	257.8	10.5	0.0	0.0	0.0	0.3	0.2	2.2	0.0	1.8	23.8	0.2	1.7	1.7	69.2	0.0	0.1	0.1	18.2	2.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.1	0.0	0.0	2.4	0.0	0.0	0.0	4.5	0.0	0.0	4.5	0.0	0.3	1.0	2.1	1.6	1.5	1.3	1.0	1.6	1.5	3.1	1.3	3.0	5.8	0.5	550.8	33.2	0.0	2.4	0.0	1.4	10.3	27.9	0.0	17.1	58.0	65.4	0.5	11.7	0.0	0.0	18.1	16.5	18.1	169.7	31.1	0.0	38.5	0.0	3.4	6.2	3.9	0.0	2.3	31.5	6.8	41.5	0.0	0.0	366.2	0.0	0.0	0.7	0.0	6.5	25.9	0.0	0.1	25.7	14.6	0.5	0.9	779.6
PLG		ENSG00000122194	Plasminogen	P00747	6	160702238-160753315	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis, Tissue remodeling"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	11	"liver: 269.9"	"Cell type enriched"	"Detected in some"	7	"Hepatocytes: 1391.0"	"Cancer enriched"	"Detected in some"	84	"liver cancer: 180.7"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEL: 1.2;HL-60: 3.6;RH-30: 4.0;U-698: 2.0;U-937: 1.6"									"CAB000668, CAB016678, HPA021602, HPA048823"	Supported				"Secreted to blood"	NA	NA	140000000000	41000000000			"CAB000668: , CAB016678: AB_1621208, HPA021602: AB_1855453, HPA048823: AB_2680532"		"unprognostic (1.70e-1)"		"unprognostic (2.16e-3)"	"unprognostic (2.44e-1)"		"unprognostic (8.54e-3)"	"unprognostic (1.41e-1)"		"unprognostic (1.76e-3)"	"unprognostic (6.28e-2)"	"unprognostic (7.25e-2)"	"prognostic favorable (4.22e-4)"	"unprognostic (3.97e-3)"	"unprognostic (5.21e-2)"		"unprognostic (2.33e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.0	269.9	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0		0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.5	0.0	3.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.4	0.0	0.0	0.3	0.2	0.9	0.0	0.0	0.4	4.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	1.0	0.0	2.0	0.0	1.6	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	2.2	0.0	0.0	0.0	0.6	28.1	2.7	0.0	1.8	0.0	0.0	16.6	0.0	0.1	0.0	0.0	23.3	0.0	0.0	0.0	0.0	1.1	1391.0	0.1	0.0	0.0	26.4	26.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	203.6	0.0	0.0	0.0	0.4	0.0	0.0	0.0	4.9	0.0	0.0
PNLIP	PL	ENSG00000175535	"Pancreatic lipase"	P16233	10	116545931-116567855	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	1895	"pancreas: 3207.8"	"Cell type enriched"	"Detected in some"	4	"Exocrine glandular cells: 3478.1"	"Cancer enriched"	"Detected in some"	4854	"pancreatic cancer: 2731.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"EFO-21: 3.1;HDLM-2: 2.8;U-2 OS: 4.6;U-251 MG: 1.1;U-266/84: 1.5"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"HPA062430, HPA062494"	Enhanced				"Secreted to digestive system"	NA	NA		13000000			"HPA062430: AB_2684761, HPA062494: AB_2684782"											"unprognostic (2.05e-2)"	"unprognostic (4.46e-2)"						0.2	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.2	0.1	0.1	0.0	0.1	0.4	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	1.6	3207.8	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.4	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.1	0.0	0.0	2.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	1.1	0.0	1.5	0.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2	0.5	0.0	0.0	0.0	3478.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	25.2	0.0	0.0	826.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PROC		ENSG00000115718	"Protein C, inactivator of coagulation factors Va and VIIIa"	P04070	2	127418427-127429246	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"liver: 137.5"	"Cell type enriched"	"Detected in many"	4	"Hepatocytes: 348.7"	"Cancer enriched"	"Detected in many"	22	"liver cancer: 118.3"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	9	"plasmacytoid DC: 29.2"	"Lineage enriched"	"Detected in many"	9	"dendritic cells: 29.2"	"Cell line enriched"	"Detected in some"	16	"Hep G2: 58.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA005550, CAB016721, CAB016792"	Supported				"Secreted to blood"	NA	NA		6400000000			"CAB016721: , CAB016792: , HPA005550: AB_1079687"	"unprognostic (2.46e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.58e-1)"	"unprognostic (6.64e-2)"	"unprognostic (3.13e-2)"	"unprognostic (4.90e-3)"	"unprognostic (2.63e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.29e-1)"	"unprognostic (3.74e-3)"	"unprognostic (2.56e-2)"	"unprognostic (8.12e-3)"	"unprognostic (2.01e-2)"	"unprognostic (1.71e-1)"	"unprognostic (4.60e-3)"	"unprognostic (8.06e-2)"	0.0	0.0	0.4	0.1	0.1	0.2	0.0	0.1	0.2	0.1	0.2	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.6	0.0	0.4	0.2	4.2	137.5	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.4	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.5	0.0	0.1	0.0	0.6	0.0	0.0	0.7	0.0	0.0	0.1	0.1	0.0	0.4	29.2	3.1	0.0	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.6	0.0	0.3	0.0	0.1	3.7	0.0	0.1	0.0	0.0	0.0	0.0	2.8	58.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.6	0.1	0.9	0.2	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	3.1	0.0	0.0	29.2	0.0	0.1	0.4	0.1	0.1	0.2	0.4	0.2	0.1	0.1	0.4	0.0	0.0	0.0	4.3	0.6	0.7	0.0	0.3	40.8	1.4	0.0	0.0	0.0	0.0	5.0	0.4	0.0	0.0	2.6	0.0	0.2	0.0	0.2	0.0	0.0	348.7	3.9	0.0	9.9	9.8	4.5	0.0	0.0	1.7	0.0	0.0	8.1	0.0	1.2	8.7	0.0	78.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	2.5	1.5	0.1
PROS1	PROS	ENSG00000184500	"Protein S"	P07225	3	93873033-93974066	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis"		"Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 114.6"	"Cell type enhanced"	"Detected in many"	13	"Hepatocytes: 266.4"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in many"	6	"pons and medulla: 24.2"	"Cell type enhanced"	"Detected in single"		"neutrophil: 1.9"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"ASC diff: 42.8;ASC TERT1: 31.9;HSkMC: 28.9;hTERT-RPE1: 24.2;SK-MEL-30: 46.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007724, HPA023974, CAB032610"	Approved				"Secreted to blood"	NA	NA	22500000000	3400000000			"CAB032610: AB_2237647, HPA007724: AB_1079688, HPA023974: AB_1855738"	"unprognostic (2.00e-2)"	"unprognostic (2.81e-2)"	"unprognostic (9.21e-2)"	"unprognostic (8.03e-3)"	"unprognostic (3.35e-2)"	"unprognostic (2.41e-1)"	"unprognostic (6.48e-2)"	"unprognostic (3.07e-1)"	"unprognostic (5.18e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.91e-1)"	"unprognostic (1.10e-1)"	"prognostic unfavorable (8.35e-4)"	"unprognostic (4.90e-2)"	"unprognostic (1.05e-2)"	"prognostic unfavorable (4.42e-5)"	16.0	3.9	2.5	3.8	3.8	0.1	15.5	0.8	2.8	7.4	8.0	4.1	2.8	3.9	7.6	9.5	10.9	8.5	11.3	30.2	4.0	3.1	17.6	114.6	17.3	13.7	4.3	1.8	23.9	2.7	10.1	6.2	10.2	24.2	6.8	8.5	9.3	5.6	4.3	5.6	8.5	6.5	8.3	4.8	8.8	4.9	5.5	2.2	0.1	10.6	6.9	3.3	8.0	9.5	0.0	0.8	1.9	0.8	0.1	0.4	6.8	0.3	2.4	2.5	10.3	42.8	31.9	0.8	1.5	3.5	0.8	3.1	6.1	0.9	0.2	9.3	2.3	7.8	0.1	0.8	0.6	1.1	0.1	2.7	16.6	1.1	17.0	3.6	0.6	0.8	28.9	0.6	1.8	0.6	24.2	3.5	2.1	11.5	0.2	16.6	0.2	0.1	0.0	2.0	1.5	2.4	0.3	2.0	0.0	9.0	0.0	3.8	7.0	1.8	0.0	46.2	0.8	0.1	8.1	3.0	6.8	1.5	3.7	0.8	0.0	0.1	0.0	21.2	10.6	9.9	0.0	0.8	0.7	0.1	0.6	0.0	0.0	0.0	0.0	0.8	0.0	0.4	0.0	1.9	0.1	0.2	0.0	0.2	6.8	2.5	3.8	0.8	2.8	4.0	3.1	4.3	1.8	24.2	2.2	59.6	29.8	3.7	2.9	13.2	0.6	40.3	12.7	76.3	12.5	1.8	9.8	0.6	3.3	5.6	2.3	47.0	2.6	0.0	4.0	0.6	62.0	4.7	29.0	266.4	9.9	1.6	15.1	69.3	24.7	4.0	26.4	7.7	18.6	1.0	14.6	22.0	3.9	7.0	34.6	36.2	7.8	12.9	26.2	0.2	0.5	29.1	1.4	4.5	13.3	2.0
PRSS1	TRY1	ENSG00000204983	"Serine protease 1"	P07477	7	142749468-142753076	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	Digestion	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	1708	"pancreas: 3057.4"	"Cell type enriched"	"Detected in some"	17	"Exocrine glandular cells: 49265.4"	"Cancer enriched"	"Detected in many"	224	"pancreatic cancer: 1920.3"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 1.7"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"EFO-21: 2.7;OE19: 10.1;RPMI-8226: 5.4;U-2 OS: 3.2;U-266/84: 1.9"									"CAB025487, CAB025538, HPA062452, HPA063471"	Enhanced		Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to digestive system"	NA	NA		26000000000	Vesicles	"Endoplasmic reticulum"	"CAB025487: , CAB025538: , HPA062452: AB_2684768, HPA063471: AB_2685017"	"unprognostic (6.55e-5)"	"unprognostic (5.28e-1)"	"unprognostic (7.58e-2)"	"prognostic unfavorable (6.41e-6)"				"unprognostic (8.26e-2)"		"prognostic favorable (7.05e-4)"	"unprognostic (1.35e-1)"			"unprognostic (3.93e-2)"	"unprognostic (1.96e-1)"	"prognostic favorable (4.91e-4)"	"unprognostic (3.12e-1)"	0.4	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.1	0.1	0.0	0.1	0.4	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	1.6	3057.4	0.0	0.1	0.1	0.1	0.2	0.0	0.1	0.4	0.2	0.1	0.0	0.4	0.1	0.1	0.1	0.5	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	1.0	0.0	1.7	0.0	0.0	0.9	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	10.1	0.0	0.0	0.0	5.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	1.1	0.0	1.9	0.4	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	1.0	0.9	0.0	0.0	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	58.1	0.0	0.0	0.0	0.0	49265.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	208.2	0.0	0.5	2827.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1
REN		ENSG00000143839	Renin	P00797	1	204154819-204190324	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Aspartyl protease, Hydrolase, Protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"kidney: 63.6"	"Group enriched"	"Detected in some"	5	"Early spermatids: 6.1;Late spermatids: 19.3"	"Cancer enriched"	"Detected in many"	8	"renal cancer: 39.4"	"Region enriched"	"Detected in single"	12	"basal ganglia: 1.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 2.4;BJ: 4.9;HMC-1: 6.5;RT4: 1.8;SK-BR-3: 4.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA005131	Approved				"Secreted to blood"	NA	NA	692000				"HPA005131: AB_1079174"	"unprognostic (4.45e-2)"	"unprognostic (3.35e-1)"	"unprognostic (1.62e-1)"	"unprognostic (8.58e-2)"		"unprognostic (2.89e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.13e-1)"	"unprognostic (7.20e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.57e-1)"	"prognostic unfavorable (6.45e-5)"	"unprognostic (1.22e-1)"	"unprognostic (1.70e-1)"	"unprognostic (4.98e-2)"	"unprognostic (6.49e-2)"	0.4	0.3	0.0	0.0	1.2	0.0	0.5	0.0	0.0	3.1	0.2	0.0	0.8	0.1	4.4	13.5	0.1	0.3	0.0	0.6	0.0	0.0	63.6	0.4	0.3	0.0	0.0	0.0	11.6	0.0	0.0	0.4	14.4	0.0	0.3	0.1	0.4	0.3	0.5	0.0	0.0	0.1	1.0	0.0	0.0	0.0	2.0	0.0	0.0	1.1	0.0	0.2	4.4	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	2.4	0.0	0.0	0.0	0.3	0.0	0.0	4.9	1.0	0.0	0.0	0.1	0.6	0.0	0.3	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.3	0.0	6.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.2	0.6	0.0	0.0	0.0	0.3	0.7	0.0	0.0	0.0	0.0	1.8	0.2	0.1	0.0	4.6	0.2	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.8	0.0	0.2	0.0	0.0	0.0	0.0	1.8	0.0	0.1	0.0	1.2	6.1	0.0	0.0	0.0	1.0	0.2	0.1	0.7	0.0	0.0	0.4	0.0	0.0	0.0	0.0	19.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.3	0.4	0.0	0.1	0.0	0.0	0.2	0.2	0.0	0.9	0.0	0.0	2.7
SERPINC1	"AT3, ATIII, MGC22579"	ENSG00000117601	"Serpin family C member 1"	P01008	1	173903804-173917378	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Heparin-binding, Protease inhibitor, Serine protease inhibitor"	"Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	203	"liver: 450.5"	"Cell type enriched"	"Detected in some"	54	"Hepatocytes: 2236.3"	"Cancer enriched"	"Detected in some"	871	"liver cancer: 1504.0"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"eosinophil: 2.2"	"Lineage enhanced"	"Detected in single"		"granulocytes: 2.2"	"Cell line enriched"	"Detected in some"	35	"Hep G2: 42.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA001816, CAB016790, HPA024007"	Supported				"Secreted to blood"	NA	NA		210000000000			"CAB016790: , HPA001816: AB_1079926, HPA024007: AB_1856732"	"unprognostic (1.28e-2)"	"unprognostic (2.22e-1)"	"unprognostic (3.83e-2)"	"unprognostic (5.98e-2)"	"unprognostic (6.91e-2)"	"unprognostic (1.93e-2)"	"prognostic favorable (3.40e-5)"	"unprognostic (1.75e-2)"	"unprognostic (8.67e-2)"	"unprognostic (3.48e-2)"	"unprognostic (4.74e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.36e-2)"	"unprognostic (5.28e-3)"	"unprognostic (5.80e-2)"	"unprognostic (6.35e-2)"	"unprognostic (8.21e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	450.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	42.6	0.0	0.8	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.1	0.5	0.0	0.0	0.0	2.2	0.5	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	14.0	0.0	0.0	0.0	0.1	38.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.0	2236.3	0.2	0.0	0.0	37.4	41.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.2	0.0	0.3	0.2	0.0	0.0	0.1
SERPIND1	"D22S673, HC-II, HC2, HCF2, HLS2"	ENSG00000099937	"Serpin family D member 1"	P05546	22	20773879-20787720	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Chemotaxis, Hemostasis"	"Heparin-binding, Protease inhibitor, Serine protease inhibitor"	"Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	47	"liver: 170.8"	"Cell type enriched"	"Detected in some"	10	"Hepatocytes: 223.1"	"Cancer enriched"	"Detected in many"	80	"liver cancer: 334.4"	"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	10	"Hep G2: 64.2"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"CAB008639, HPA055767"	Supported		Approved	Vesicles	"Secreted to blood"	NA	NA		94000000000	Vesicles		"CAB008639: AB_1618010, HPA055767: AB_2682912"	"unprognostic (1.68e-1)"	"unprognostic (8.27e-2)"	"unprognostic (4.40e-2)"	"prognostic favorable (4.09e-4)"	"unprognostic (5.42e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.12e-3)"	"unprognostic (1.56e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.21e-2)"	"unprognostic (2.88e-1)"	"unprognostic (3.94e-9)"	"unprognostic (2.01e-1)"	"unprognostic (4.66e-2)"	"unprognostic (8.36e-3)"	"unprognostic (1.46e-1)"	0.0	0.0	0.0	0.0	2.3	0.0	0.2	0.6	0.9	0.3	0.0	1.4	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	170.8	0.3	0.0	0.0	0.7	0.3	0.0	3.6	0.1	0.2	2.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.4	0.0	0.1	0.1	0.5	0.0	0.1	0.0	0.0	0.0	0.1	1.9	2.7	0.7	0.4	1.3	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	64.2	0.0	0.2	0.1	0.0	0.0	0.5	0.0	0.0	6.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.7	5.2	0.0	0.2	0.0	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	4.4	0.0	0.4	0.0	1.0	0.2	1.7	0.4	0.5	0.6	0.1	1.9	0.9	0.7	0.7	1.3	0.2	2.7	0.7	0.1	0.0	2.3	0.6	0.9	0.0	0.0	0.0	0.7	2.6	0.5	0.0	13.7	0.0	0.0	0.0	0.0	0.8	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.3	0.0	0.0	0.7	0.0	1.1	223.1	0.1	0.0	0.0	4.9	2.9	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
SERPINE1	"PAI, PAI1, PLANH1"	ENSG00000106366	"Serpin family E member 1"	P05121	7	101127089-101139266	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 253.6"	"Cell type enhanced"	"Detected in many"	22	"Pancreatic endocrine cells: 138.9;Syncytiotrophoblasts: 545.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	20	"NK-cell: 10.8"	"Lineage enriched"	"Detected in single"	20	"NK-cells: 10.8"	"Cell line enhanced"	"Detected in many"		"BJ: 142.8;HUVEC TERT2: 165.7;LHCN-M2: 160.0;TIME: 409.8;U-138 MG: 195.1;U-251 MG: 171.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA050039, CAB068501"	Uncertain		Approved	Cytosol	"Secreted to blood"	No	No	142000000	14000000	Cytosol		"CAB068501: AB_1642775, HPA050039: AB_2680997"	"unprognostic (5.02e-2)"	"prognostic unfavorable (5.01e-4)"	"prognostic unfavorable (2.82e-4)"	"unprognostic (2.10e-2)"	"unprognostic (9.04e-3)"	"prognostic unfavorable (2.84e-5)"	"unprognostic (6.80e-3)"	"prognostic unfavorable (4.41e-6)"	"unprognostic (2.33e-1)"	"unprognostic (1.45e-1)"	"unprognostic (2.88e-3)"	"unprognostic (1.58e-1)"	"prognostic unfavorable (5.88e-8)"	"prognostic unfavorable (3.27e-6)"	"unprognostic (1.05e-1)"	"unprognostic (4.33e-2)"	"prognostic unfavorable (5.51e-4)"	45.5	14.0	1.1	16.7	1.8	0.1	11.4	0.5	1.5	13.3	7.0	3.4	3.3	1.2	6.6	14.4	6.8	9.3	69.6	29.2	1.5	0.6	7.8	65.3	56.3	3.3	4.1	1.8	19.7	24.7	1.4	2.6	253.6	5.9	7.6	0.9	2.3	2.4	6.2	12.4	4.1	2.3	13.5	4.1	5.8	6.6	8.6	2.2	0.6	11.3	3.7	2.8	71.7	18.1	0.2	0.4	0.5	0.2	10.8	0.3	1.0	3.0	2.6	0.0	0.2	32.7	65.2	3.7	142.8	27.0	72.1	63.0	0.3	0.2	0.1	34.2	45.4	99.7	0.7	0.0	11.0	74.4	0.1	0.0	0.0	0.2	2.4	65.8	0.0	0.1	25.5	4.4	110.5	58.1	39.1	165.7	0.0	0.2	0.1	160.0	0.0	0.0	0.0	0.7	0.0	1.7	0.0	0.2	0.1	0.2	1.2	0.0	0.0	11.7	3.2	0.3	18.0	0.1	0.4	409.8	195.1	8.5	66.4	171.5	0.0	0.1	0.1	48.7	0.0	1.8	0.5	0.2	0.0	0.1	0.1	0.0	0.1	0.0	0.3	0.3	0.2	0.0	0.1	0.2	10.8	0.0	0.4	0.0	1.0	1.1	1.8	0.5	1.5	1.5	0.6	4.1	1.8	5.9	2.2	0.0	11.4	0.0	30.0	35.5	0.4	1.9	7.6	8.1	7.9	5.2	0.0	34.4	0.0	22.9	0.0	53.9	0.0	0.0	3.8	35.1	24.7	5.4	10.3	90.0	15.2	0.0	5.1	60.2	4.7	0.4	16.4	7.5	6.8	1.8	0.0	0.3	138.9	0.0	11.3	0.0	0.2	38.8	16.5	0.0	0.0	21.7	545.0	0.7	0.0	5.9
TEK	"CD202b, TIE-2, TIE2, VMCM, VMCM1"	ENSG00000120156	"TEK receptor tyrosine kinase"	Q02763	9	27109141-27230175	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Glaucoma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	8	"Endothelial cells: 58.3;Ito cells: 110.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 2.2"	"Lineage enhanced"	"Detected in single"		"granulocytes: 2.2"	"Group enriched"	"Detected in some"	4	"HUVEC TERT2: 36.5;NTERA-2: 18.2;TIME: 39.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010359, HPA073265"	Approved		Supported	"Plasma membrane,Centriolar satellite"	"Secreted to blood"	NA	NA	7750000	8300000	"Plasma membrane"	"Centriolar satellite"	"CAB010359: AB_2203226, HPA073265: AB_2686592"	"unprognostic (2.24e-1)"	"unprognostic (1.74e-1)"	"unprognostic (5.55e-2)"	"unprognostic (1.83e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.26e-3)"	"prognostic favorable (2.31e-5)"	"unprognostic (7.48e-2)"	"unprognostic (1.72e-2)"	"unprognostic (1.41e-1)"	"unprognostic (5.58e-2)"	"unprognostic (2.72e-1)"	"prognostic favorable (7.81e-4)"	"unprognostic (7.50e-3)"	"unprognostic (6.87e-3)"	"unprognostic (1.83e-1)"	"unprognostic (5.24e-3)"	28.6	7.8	8.1	4.6	5.9	0.4	17.9	3.4	5.4	10.8	4.7	4.6	3.4	3.2	14.5	5.3	6.7	5.9	9.1	13.0	7.1	6.1	25.4	8.7	27.8	2.9	6.9	3.4	6.1	4.5	3.5	4.0	36.3	6.9	5.4	4.7	12.4	3.4	5.5	7.8	3.0	5.3	10.6	5.3	23.4	4.0	3.7	3.5	0.3	9.7	8.4	2.4	6.4	12.4	0.0	0.1	2.2	0.6	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.2	2.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	1.0	0.0	0.7	0.0	0.0	0.7	0.0	0.9	0.3	0.0	36.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	18.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	7.8	0.0	0.0	39.6	0.0	0.2	3.6	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	8.1	5.9	3.4	5.4	7.1	6.1	6.9	3.4	6.9	3.5	3.0	2.2	0.0	0.0	1.3	0.0	7.8	0.0	0.0	1.2	1.8	0.0	0.4	0.0	0.0	0.6	58.3	0.0	0.0	0.0	1.5	2.4	0.2	0.0	0.8	0.2	0.0	0.0	110.5	10.4	0.4	0.6	0.9	0.0	0.0	0.0	0.0	0.7	0.0	0.4	0.0	0.2	0.0	0.4	0.0	0.2	1.1	1.1	0.0	0.0	0.0
TFPI	"EPI, LACI, TFI, TFPI1"	ENSG00000003436	"Tissue factor pathway inhibitor"	P10646	2	187464230-187565760	"Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Protease inhibitor, Serine protease inhibitor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 98.2;placenta: 192.3"	"Cell type enhanced"	"Detected in many"	13	"Extravillous trophoblasts: 1654.1;Ito cells: 765.5;Syncytiotrophoblasts: 735.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 5.5;plasmacytoid DC: 5.1"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HHSteC: 56.4;HUVEC TERT2: 106.1;LHCN-M2: 65.0;TIME: 63.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"HPA005575, CAB020842"	Supported				"Secreted to blood"	NA	NA		95000000			"CAB020842: , HPA005575: AB_1080290"	"unprognostic (8.75e-2)"	"prognostic unfavorable (2.02e-4)"	"unprognostic (7.95e-2)"	"unprognostic (4.99e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.48e-1)"	"unprognostic (3.05e-1)"	"unprognostic (5.63e-2)"	"unprognostic (3.86e-3)"	"unprognostic (9.22e-2)"	"unprognostic (2.43e-2)"	"unprognostic (2.72e-2)"	"unprognostic (7.05e-2)"	"unprognostic (3.39e-3)"	"unprognostic (4.05e-2)"	"unprognostic (4.49e-2)"	"unprognostic (5.81e-2)"	52.8	5.0	1.3	5.2	2.2	1.6	18.5	1.9	2.4	22.8	32.1	0.3	7.2	12.8	13.3	14.8	25.9	12.5	15.0	14.0	1.2	1.1	35.6	98.2	89.7	40.2	2.4	1.0	17.3	7.7	0.9	4.9	192.3	2.3	18.2	6.9	3.8	6.0	3.8	15.8	6.6	37.0	13.6	5.4	16.5	7.7	13.7	1.6	3.4	22.6	10.4	4.0	30.0	14.7	1.5	5.1	5.5	0.6	1.0	0.6	4.9	5.1	3.6	4.1	0.1	32.9	39.4	0.0	9.3	22.2	6.1	9.4	3.3	27.6	0.0	3.7	7.2	11.0	0.3	1.2	0.4	15.9	0.2	1.0	1.6	11.1	28.0	56.4	0.1	0.0	18.0	0.7	32.8	8.8	13.6	106.1	0.0	4.1	0.1	65.0	4.8	0.6	0.1	2.6	0.0	9.0	0.0	5.8	0.0	10.3	0.2	0.0	0.0	7.6	0.2	0.4	12.7	0.1	0.0	63.5	4.4	4.1	8.6	1.8	0.0	0.1	0.0	35.4	0.0	5.0	5.5	0.6	0.5	0.5	0.3	0.2	0.9	0.4	0.2	0.5	1.5	0.5	0.6	2.6	1.0	0.3	5.1	0.2	4.9	1.3	2.2	1.9	2.4	1.2	1.1	2.4	1.0	2.3	1.6	32.8	262.9	24.4	2.5	18.4	0.7	8.4	191.1	58.9	112.6	36.6	0.0	45.9	11.6	114.4	16.0	204.3	1.7	23.3	242.7	1654.1	163.0	4.2	12.8	338.6	44.3	1.6	101.1	765.5	77.7	9.8	159.0	19.5	25.3	57.7	1.2	31.4	108.2	2.9	65.7	100.4	1.1	213.4	163.5	1.1	0.4	16.2	735.3	15.4	1.3	6.0
TNF	"DIF, TNF-alpha, TNFA, TNFSF2"	ENSG00000232810	"Tumor necrosis factor"	P01375	6	31575567-31578336	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 14.6;lymphoid tissue: 28.0"	"Cell type enhanced"	"Detected in many"	10	"Hofbauer cells: 32.8;Macrophages: 42.1;T-cells: 34.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 10.8"	"Group enriched"	"Detected in many"	5	"granulocytes: 3.5;monocytes: 10.8;T-cells: 6.6"	"Group enriched"	"Detected in some"	5	"HDLM-2: 10.2;HMC-1: 9.8;NB-4: 29.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB078469	Supported				"Secreted to blood"	NA	NA	10100				"CAB078469: AB_908070"	"unprognostic (1.93e-1)"	"unprognostic (1.07e-2)"	"unprognostic (3.85e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.92e-1)"	"unprognostic (2.19e-2)"	"unprognostic (1.67e-1)"	"unprognostic (3.46e-1)"	"unprognostic (1.19e-2)"	"unprognostic (1.94e-1)"	"unprognostic (3.07e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.46e-2)"	"unprognostic (1.82e-1)"	"unprognostic (9.85e-3)"	"unprognostic (1.09e-1)"	"unprognostic (2.04e-1)"	2.3	1.2	0.6	15.6	1.0	14.6	1.2	0.4	1.8	1.7	1.3	3.7	0.3	1.3	1.1	0.4	1.5	0.9	2.3	2.0	0.5	0.3	2.6	1.9	9.5	8.0	0.8	0.0	0.6	0.7	0.5	0.5	3.2	2.0	0.7	0.7	0.4	2.2	0.8	0.4	2.7	4.1	0.7	1.0	28.0	1.0	0.4	0.5	2.1	0.6	5.3	14.7	1.2	0.4	1.3	1.2	3.5	10.8	0.5	6.6	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.2	0.0	0.0	0.0	0.0	10.2	0.0	1.9	0.0	0.0	0.0	0.8	9.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.6	0.0	0.0	0.0	1.8	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.3	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	1.7	0.0	4.1	6.5	6.6	1.3	3.1	2.4	1.2	1.3	0.9	1.0	3.5	0.5	10.8	0.7	2.2	2.1	0.6	1.0	0.4	1.8	0.5	0.3	0.8	0.0	2.0	0.5	0.0	4.0	13.4	0.2	7.4	0.1	2.0	5.1	1.4	2.3	0.0	2.0	0.3	0.0	6.7	0.1	2.8	0.0	0.0	2.9	1.5	2.1	0.9	11.6	0.0	32.8	0.0	0.0	1.3	8.7	0.0	0.3	42.1	5.0	1.0	0.1	0.1	10.2	0.0	0.0	0.0	0.1	0.0	2.3	0.0	0.0	3.6	0.9	34.1	0.0	0.3
TNFRSF1A	"CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60"	ENSG00000067182	"TNF receptor superfamily member 1A"	P19438	12	6328757-6342114	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Apoptosis, Host-virus interaction"	Receptor	"Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 86.5"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004102, CAB010309"	Approved				"Secreted to blood"	NA	NA		170000			"CAB010309: AB_2206639, HPA004102: AB_1846232"	"unprognostic (2.19e-2)"	"unprognostic (3.76e-2)"	"unprognostic (8.14e-2)"	"prognostic favorable (8.22e-4)"	"unprognostic (3.07e-2)"	"prognostic unfavorable (3.68e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.41e-3)"	"unprognostic (1.00e-1)"	"unprognostic (8.05e-2)"	"unprognostic (4.78e-2)"	"unprognostic (1.54e-2)"	"prognostic unfavorable (2.70e-7)"	"unprognostic (1.43e-2)"	"unprognostic (2.92e-2)"	"unprognostic (5.14e-3)"	"unprognostic (1.74e-1)"	55.1	43.9	16.8	28.9	16.8	13.7	40.6	7.2	15.6	40.3	41.5	14.1	22.6	39.2	38.2	27.5	39.4	34.2	37.1	26.8	14.0	7.5	49.3	61.6	40.9	37.2	19.2	6.4	59.5	21.4	20.3	19.9	45.3	18.3	37.0	23.0	31.1	25.7	22.2	34.2	30.9	81.7	38.8	25.1	43.6	28.2	21.8	15.7	31.6	42.7	25.4	22.3	49.1	58.5	0.0	20.8	86.5	27.1	1.8	11.6	15.9	7.4	57.8	8.1	11.5	56.0	57.3	15.3	15.9	27.5	21.4	18.6	6.9	29.7	0.6	5.5	34.3	17.1	20.8	2.5	18.6	14.8	0.1	4.8	4.1	16.0	15.3	49.7	19.3	13.0	59.0	18.7	17.7	26.1	49.7	26.0	8.0	6.2	5.7	24.5	10.6	6.1	18.2	19.7	27.7	16.9	5.3	12.9	5.7	16.5	13.5	0.0	0.4	22.5	11.8	11.8	21.7	3.2	21.1	28.3	16.8	14.4	12.6	14.7	0.0	1.8	2.4	20.1	18.0	20.8	2.2	27.1	15.0	11.6	21.8	11.1	0.0	4.9	9.5	20.8	0.0	4.5	6.6	86.5	1.8	17.5	6.0	4.8	15.9	16.8	16.8	7.2	15.6	14.0	7.5	19.2	6.4	18.3	15.7	47.6	42.8	9.0	92.6	109.3	0.1	8.4	63.7	10.7	42.1	26.2	0.0	53.2	13.3	86.6	0.6	80.7	166.1	23.3	104.3	104.8	112.3	113.8	7.0	128.2	148.0	0.0	32.3	138.1	133.7	3.3	94.6	103.1	67.4	101.0	44.9	16.3	93.0	210.5	61.9	94.3	0.3	122.9	122.4	0.5	1.1	117.7	124.3	45.7	42.3	123.4
TNFSF11	"CD254, ODF, OPGL, RANKL, TRANCE"	ENSG00000120659	"TNF superfamily member 11"	O14788	13	42562736-42608013	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Differentiation	"Cytokine, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Osteopetrosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 14.3;lymphoid tissue: 19.8"	"Cell type enhanced"	"Detected in some"	22	"Ductal cells: 3.3;Early spermatids: 5.8;Late spermatids: 14.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	8	"NK-cell: 14.3"	"Lineage enriched"	"Detected in many"	8	"NK-cells: 14.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 1.8;HSkMC: 5.4;NTERA-2: 7.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB009193, HPA045142"	Enhanced				"Secreted to blood"	NA	NA	17200				"CAB009193: , HPA045142: AB_2679231"	"unprognostic (3.97e-4)"	"unprognostic (1.40e-1)"	"unprognostic (9.01e-3)"	"unprognostic (3.81e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.09e-2)"	"unprognostic (7.70e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.25e-3)"	"unprognostic (1.00e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.94e-5)"	"unprognostic (1.87e-1)"	"unprognostic (9.67e-2)"	"unprognostic (5.46e-2)"	"unprognostic (7.74e-2)"	0.5	0.2	0.2	19.5	0.2	0.0	4.6	0.1	0.2	0.8	0.8	0.1	2.4	0.2	0.2	0.1	3.7	0.2	1.3	0.3	0.1	0.7	0.6	5.3	0.4	19.8	0.1	0.1	0.1	0.6	0.0	0.3	0.3	0.4	0.5	2.2	0.1	1.6	1.0	0.2	0.5	6.0	0.1	0.1	0.8	0.3	3.3	0.1	2.8	0.4	0.1	5.2	2.3	0.7	0.0	0.1	1.8	0.0	14.3	0.1	0.1	0.0	0.3	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.8	0.0	0.0	0.1	0.2	0.0	0.2	0.0	0.1	0.0	0.1	0.5	0.0	0.6	0.0	0.1	5.4	0.5	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	7.5	0.0	0.1	0.0	0.2	0.0	0.0	0.1	0.1	0.2	0.0	0.0	0.0	0.5	0.0	0.7	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	14.3	0.0	0.0	0.0	0.1	0.2	0.2	0.1	0.2	0.1	0.7	0.1	0.1	0.4	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.4	2.5	0.0	0.0	0.0	0.0	0.0	0.0	3.3	5.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.2	0.0	0.0	14.2	0.0	0.0	0.0	0.0	0.3	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.3	0.0	0.0	0.0	0.0
TNFSF13B	"BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20"	ENSG00000102524	"TNF superfamily member 13b"	Q9Y275	13	108251240-108308484	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 76.5;lymphoid tissue: 39.6"	"Cell type enhanced"	"Detected in many"	23	"Hofbauer cells: 88.9;Kupffer cells: 144.9;Macrophages: 141.3;monocytes: 457.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 76.5"	"Group enriched"	"Detected in many"	10	"dendritic cells: 31.0;granulocytes: 76.5;monocytes: 53.7"	"Cell line enriched"	"Detected in some"	7	"U-937: 61.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB009188, HPA030526"	Enhanced		Supported	"Vesicles,Plasma membrane,Focal adhesion sites"	"Secreted to blood"	NA	NA	393000	530000	"Plasma membrane"	"Vesicles, Focal adhesion sites"	"CAB009188: , HPA030526: "	"unprognostic (6.48e-2)"	"unprognostic (3.05e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.61e-2)"	"unprognostic (7.99e-2)"	"unprognostic (8.19e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.21e-1)"	"prognostic unfavorable (2.53e-11)"	"unprognostic (1.23e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.25e-1)"	7.2	8.2	3.0	18.5	8.2	13.2	3.4	1.4	5.2	1.6	4.2	2.1	1.0	7.8	1.2	6.5	3.5	2.9	9.4	9.4	5.7	2.9	3.1	5.0	13.2	39.6	7.2	2.6	2.9	2.7	0.5	2.1	6.4	5.7	3.7	6.4	2.6	5.4	1.8	1.6	1.6	6.8	3.5	11.6	23.5	3.4	1.0	4.9	7.2	5.1	1.7	12.7	8.5	3.8	1.0	31.0	76.5	53.7	0.6	5.3	20.8	0.0	0.1	0.0	0.0	0.2	0.3	0.0	0.1	0.3	0.2	0.8	0.0	0.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.2	0.0	0.3	0.1	0.0	0.1	3.6	0.1	0.7	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.0	0.0	1.9	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.1	0.5	0.1	0.0	0.0	0.1	0.1	0.0	8.1	0.0	0.1	0.0	0.0	0.1	3.8	0.1	0.0	3.9	61.0	0.6	1.2	53.7	14.4	0.8	39.8	5.3	0.6	3.5	0.7	31.0	1.0	1.7	0.5	76.5	0.6	31.7	11.5	2.8	20.8	3.0	8.2	1.4	5.2	5.7	2.9	7.2	2.6	5.7	4.9	14.9	17.5	3.7	0.7	6.4	0.3	0.5	12.7	2.7	5.7	5.2	0.0	0.5	1.7	2.0	1.0	1.3	0.5	0.0	29.2	0.9	13.3	1.6	4.7	1.5	88.9	0.0	1.2	4.9	144.9	0.2	4.9	141.3	8.5	457.1	0.2	0.4	1.9	0.0	1.8	1.0	0.0	6.5	5.0	0.1	0.1	4.1	0.9	6.2	1.2	1.3
VEGFA	"VEGF, VEGF-A, VPF"	ENSG00000112715	"Vascular endothelial growth factor A"	P15692	6	43770184-43786487	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Alveolar cells type 1: 324.6;Muller glia cells: 340.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 1.2;eosinophil: 1.9"	"Group enriched"	"Detected in many"	9	"granulocytes: 1.9;monocytes: 1.2"	"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 65.7;U-87 MG: 103.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005429, CAB039240, HPA069116, CAB069907"	Supported				"Secreted to blood"	NA	NA	562000				"CAB005429: AB_2212984, CAB039240: , CAB069907: AB_10001947, HPA069116: AB_2686089"	"unprognostic (1.12e-1)"	"prognostic unfavorable (4.50e-4)"	"unprognostic (2.42e-2)"	"prognostic unfavorable (2.10e-4)"	"unprognostic (4.35e-2)"	"unprognostic (1.49e-1)"	"prognostic unfavorable (2.34e-5)"	"unprognostic (5.10e-2)"	"unprognostic (5.27e-3)"	"unprognostic (2.30e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.00e-2)"	"prognostic unfavorable (1.76e-5)"	"unprognostic (2.20e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.43e-1)"	"prognostic favorable (2.73e-4)"	35.0	17.5	16.6	11.4	20.1	12.8	39.5	6.5	32.3	11.8	25.9	8.7	15.0	16.0	54.1	9.4	19.4	10.4	27.5	57.0	13.4	5.4	25.8	58.6	30.0	2.9	15.8	3.7	16.4	25.1	20.6	7.3	16.7	19.8	40.5	7.2	24.4	15.1	23.8	52.9	11.9	26.3	19.2	35.1	19.0	20.5	4.5	15.4	0.3	87.9	19.6	13.6	47.5	15.7	0.0	0.1	1.9	1.2	0.0	0.0	0.0	11.8	2.1	2.0	11.6	3.5	5.5	13.7	7.3	13.0	4.8	9.6	6.8	1.6	3.9	5.9	4.4	50.2	4.9	5.4	14.7	8.6	4.2	1.7	2.9	2.8	4.5	36.9	3.2	6.6	9.7	29.3	47.4	47.2	65.7	1.2	3.3	5.5	19.7	17.6	4.9	0.3	4.4	1.2	34.8	3.3	0.3	1.9	9.3	18.7	10.0	3.6	7.6	10.5	7.2	25.2	2.7	2.8	11.9	1.7	20.2	5.4	29.1	11.9	11.2	6.6	7.6	103.7	7.5	7.0	0.0	1.2	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	16.6	20.1	6.5	32.3	13.4	5.4	15.8	3.7	19.8	15.4	324.6	89.9	11.2	34.6	62.6	31.5	146.9	81.5	4.0	93.3	21.0	29.5	1.1	1.7	39.1	0.0	22.8	60.6	23.3	35.0	3.1	45.9	128.0	107.6	99.1	13.4	170.0	26.2	18.4	22.8	0.0	1.7	44.4	27.0	11.8	42.9	340.3	70.3	34.8	3.2	15.2	37.5	0.0	52.8	0.9	0.9	68.4	6.6	6.9	40.0	115.1
VEGFB	"VEGFL, VRF"	ENSG00000173511	"Vascular endothelial growth factor B"	P49765	11	64234538-64238793	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Cardiomyocytes: 177.8;Peritubular cells: 102.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	9	"plasmacytoid DC: 31.7"	"Lineage enriched"	"Detected in many"	9	"dendritic cells: 31.7"	"Cell line enhanced"	"Detected in all"		"U-266/70: 53.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Secreted to blood"	NA	NA	186000					"unprognostic (4.88e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.33e-2)"	"unprognostic (3.55e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.27e-1)"	"unprognostic (5.38e-2)"	"unprognostic (2.45e-1)"	"unprognostic (4.68e-1)"	"unprognostic (5.01e-3)"	"unprognostic (2.35e-3)"	"unprognostic (1.08e-2)"	"unprognostic (1.67e-2)"	"unprognostic (8.08e-3)"	"unprognostic (2.00e-1)"	"unprognostic (4.15e-2)"	"unprognostic (4.31e-3)"	98.5	23.4	25.9	15.3	22.7	5.2	77.1	9.1	21.6	21.4	27.6	16.6	31.3	15.3	21.7	21.2	19.4	13.8	26.2	56.9	20.4	23.1	16.8	8.1	19.1	22.5	25.0	15.4	23.3	43.0	15.6	22.3	13.4	15.5	27.1	5.9	32.2	29.5	34.5	94.0	18.4	15.4	29.9	14.9	18.1	17.4	12.7	14.1	10.3	22.9	26.9	11.8	28.8	33.8	3.3	31.7	0.6	0.1	0.4	1.8	0.4	9.0	12.5	5.2	17.5	26.5	19.1	7.1	8.5	14.4	7.1	8.2	6.7	20.0	11.3	16.5	7.7	16.6	12.3	7.3	6.2	1.3	11.0	6.7	9.8	16.0	6.2	26.1	2.8	11.8	21.5	6.2	10.1	6.1	17.1	9.2	11.8	10.5	19.8	10.5	15.1	14.6	7.1	4.4	6.2	11.0	18.9	12.8	27.6	5.5	9.7	7.9	26.1	6.8	25.2	32.9	4.2	16.8	3.2	8.1	30.8	19.6	14.0	5.1	53.9	25.5	8.4	28.8	3.2	16.3	0.4	0.1	0.6	1.1	0.0	0.9	3.3	0.8	1.0	0.5	2.7	1.1	1.8	0.0	0.4	0.0	31.7	0.4	0.4	25.9	22.7	9.1	21.6	20.4	23.1	25.0	15.4	15.5	14.1	17.9	31.2	13.7	6.1	11.3	45.9	177.8	7.6	6.7	6.8	14.0	31.4	8.1	33.2	10.0	1.1	14.7	15.1	0.0	11.1	13.1	16.9	10.1	18.4	11.9	43.1	62.0	51.2	14.1	19.1	3.2	56.4	23.8	33.7	26.2	12.0	67.9	15.7	5.8	102.6	21.4	29.5	6.5	20.6	0.3	1.2	12.2	7.4	10.1	10.2	6.4
VWF	F8VWF	ENSG00000110799	"Von Willebrand factor"	P04275	12	5948874-6124770	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Cell adhesion, Hemostasis"		"Cancer-related genes, Disease mutation, FDA approved drug targets, von Willebrand disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 91.7"	"Cell type enhanced"	"Detected in many"	24	"Cardiomyocytes: 99.1;Endothelial cells: 414.7;Ito cells: 229.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.3"	"Lineage enhanced"	"Detected in single"		"granulocytes: 1.3"	"Cell line enriched"	"Detected in some"	57	"HUVEC TERT2: 113.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB001694, HPA001815, HPA002082, CAB072874, CAB072875"	Supported				"Secreted to blood"	NA	NA	28300000000	6400000000			"CAB001694: , CAB072874: AB_2665726, CAB072875: AB_2665727, HPA001815: AB_611880, HPA002082: AB_1080575"	"unprognostic (3.66e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.46e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.91e-3)"	"unprognostic (7.09e-2)"	"unprognostic (4.63e-1)"	"unprognostic (5.63e-2)"	"unprognostic (3.92e-2)"	"unprognostic (4.69e-1)"	"unprognostic (1.12e-1)"	"unprognostic (2.98e-2)"	"prognostic unfavorable (2.31e-4)"	"unprognostic (1.55e-1)"	"unprognostic (3.12e-1)"	"unprognostic (2.73e-3)"	91.7	3.1	6.1	9.7	8.1	0.8	41.5	3.7	8.6	19.7	13.9	7.3	6.8	6.6	21.5	16.7	14.4	15.1	15.3	38.7	7.4	5.0	4.6	1.5	41.2	9.9	9.4	7.1	13.6	5.8	17.7	2.6	36.4	10.2	18.7	5.1	26.3	7.2	10.5	28.9	8.1	11.8	22.1	7.4	19.0	9.6	12.7	5.9	1.8	18.6	13.2	6.5	18.9	35.0	0.0	0.0	1.3	0.3	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	113.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	1.8	6.1	8.1	3.7	8.6	7.4	5.0	9.4	7.1	10.2	5.9	11.9	41.6	0.0	0.4	6.0	0.0	99.1	2.5	1.4	2.3	10.4	0.0	0.8	0.0	0.3	5.0	414.7	0.0	0.0	0.0	0.7	3.3	0.7	5.7	1.5	0.4	0.0	0.0	229.6	2.1	10.0	5.5	0.8	5.0	0.0	0.0	0.5	0.0	0.0	0.7	0.0	0.8	0.0	3.3	1.8	3.4	3.8	0.8	2.2	0.0	1.6
